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ABSTRACT
DEFINING THE NATURE OF CD8+ T CELL RESPONSES IN LYMPHOID
TISSUES OF HIV ELITE CONTROLLERS
Son N. Nguyen
Michael R. Betts and James A. Hoxie
Acquired Immunodeficiency Syndrome (AIDS) is an immunodeficiency caused by
infection with Human Immunodeficiency Virus (HIV). Since its first documentation in
1981, the AIDS pandemic has claimed the lives of 32 million people worldwide. The
introduction of antiretroviral therapy drugs (ART) and combined therapy in 1995 has
transformed HIV infections from a “death-sentence” into a manageable and often nonfatal chronic condition. Still, no cure is available. While without ART most HIV-infected
individuals (>99%) progress to AIDS, a subset of infected individuals (<1%), known as
elite controllers (ECs), can spontaneously control viremia and maintain undetectable
plasma viral load for many years. Effector functions of CD8+ T cells have been strongly
correlated with the EC status. However, while this correlation has been established
primarily in blood, HIV mainly replicates in lymphoid tissues (LTs) such as lymph nodes
(LNs) and gut-associated lymphoid tissue (GALT), where CD8+ T cell-mediated immune
responses are not well defined. Therefore, this study aims to investigate CD8+ T cell
responses in LTs, specifically LNs, of HIV-infected individuals and to define mechanisms
of viral control in LNs of ECs. In order to achieve this goal, we obtained LNs and blood
samples from HIV- donors, ECs, ART-treated individuals (ARTs), and viremic individuals
who are not on ART, hereafter termed chronic progressors (CPs). Using an integrative
vii

single-cell approach, we identified that most HIV-specific CD8+ T cells in LNs of HIVinfected individuals, especially in ECs, were tissue-resident memory T cells (TRM). While
CD8+ T cells in LNs of ECs could potently suppress viral replication, they surprisingly did
not display strong cytolytic activities. Instead, these cells were more poised for trafficking
into B cell follicles (BCFs), downregulated expression of inhibitory receptors, and
concurrently produced multiple cytokines upon stimulation with HIV antigens, which
could be functionally linked to efficient protein translation capacity. Together, these
results suggest that CD8+ T cells in LTs controls HIV replication through non-cytolytic
mechanisms, instead of cytotoxic mechanisms like CD8+ T cells in blood. In conclusion,
this dissertation highlights the tissue compartmentalization of CD8+ T cells’ effector
functions in anti-HIV immunity. Furthermore, the induction of TRM and CD8+ T cellmediated non-cytolytic mechanisms should be pursued as therapeutic strategies aiming
to establish durable control of HIV.
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CHAPTER 1: INTRODUCTION
1.1 A brief history on the discovery of HIV as the causing agent of AIDS
The term Acquired Immunodeficiency Syndrome (AIDS) was first coined in 1982 by the
United States Center for Disease Control (CDC) to describe a previously undescribed
condition that was “ at least moderately predictive of a defect in cell mediated immunity,
occurring in a person with no known case for diminished resistance to that disease”
(Centers for Disease, 1982b). The first cases of AIDS were documented in 1981 in
communities of homosexual men in Los Angeles and New York (Centers for Disease,
1981; Hymes et al., 1981). These previously healthy men experienced aggressive
Kaposi’s sarcoma and in some cases infection with Pneumocystis carinii (Centers for
Disease, 1981). Between 1981 and 1982 alone, 593 cases of AIDS (with 243 deaths)
were reported to the CDC (Centers for Disease, 1982b). Among these cases, 75% were
of homosexual or bisexual males and most of them (80%) occurred in major
metropolitan areas in the United States (Centers for Disease, 1982b). Risk factors of the
disease were blood transfusion, sexual interactions, and intravenous drug administration
(Ammann et al., 1983; Centers for Disease, 1982a; Curran et al., 1984; Marmor et al.,
1982). AIDS patients all showed immunologic abnormalities including
hypergammaglobulinemia, increased CD8+ T cell counts, and decreased CD4+ T cell
counts, suggesting that the etiology of this disease likely involved an sexuallytransmitted or blood-born infectious agent targeting the immune system, more
specifically CD4+ T cells (Stahl, Friedman-Kien, Dubin, Marmor, & Zolla-Pazner, 1982;
Stahl, Friedman-Kien, & Zolla-Pazner, 1983). In May 1983, American (led by Robert
Gallo) and French (led by Luc Montagnier) scientists simultaneously isolated a new
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retrovirus from AIDS patients, indicating that a retrovirus could be linked to the etiology
of AIDS (Barre-Sinoussi et al., 1983; Gallo et al., 1983; Gelmann et al., 1983). In 1984,
multiple studies found the presence of this new retrovirus and antibodies targeting it in
90-100% of pre-AIDS and AIDS patients, confirming the etiological relationship between
the virus and AIDS (Gallo et al., 1984; Levy et al., 1984; Marx, 1984; Popovic,
Sarngadharan, Read, & Gallo, 1984; Sarngadharan, Popovic, Bruch, Schupbach, &
Gallo, 1984; Schupbach et al., 1984). Initially, the American researchers termed this
retrovirus HTLV-III, standing for human T-cell leukemia virus (HTLV)-III, because it
appeared to be closely related to previously described HTLVs, especially HTLV-I (Gallo
et al., 1984; Gallo et al., 1983; Gelmann et al., 1983). In contrast, the French scientists
found that the isolated retrovirus was distinct from both HTLV-I and II and independently
named it lymphadenopathy-associated virus or LAV (Barre-Sinoussi et al., 1983;
Montagnier et al., 1984). This finding was corroborated by the independent isolation of a
LAV-resembling retrovirus, termed AIDS-associated retrovirus or ARV, from AIDS
patients in San Francisco, California (Levy et al., 1984). Subsequent analyses indicated
that HTLV-III/LAV/ARV was morphologically and genetically more homologous to visna
virus, a pathogenic nononcogenic sheep lentivirus, and other lentiviruses than to HTLV-I
and HTLV-II (Gonda et al., 1986; Gonda, Wong-Staal, Gallo, Clements, & Gilden, 1985;
Gonda, Wong-Staal, Gallo, Clements, Narayan, et al., 1985). In 1986, the virus was
renamed as human immunodeficiency virus, or HIV (Case, 1986).
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1.2 Biology of HIV pathogenesis
Origin of HIV
HIV belongs to the family Retroviridae and the genus Lentivirus. Two forms of HIV have
been described: HIV-1 and HIV-2. HIV-1 is made up of four distinct genetic groups: M,
O, N, and P. Group M (major) was the first one to be discovered and it is responsible for
the AIDS pandemic (Sharp & Hahn, 2011).(Sharp & Hahn, 2011). This group can be
further divided into subtypes, or clades, including A, B, C, D, F, G, H, J, and K, which are
closely related in sequence but have been proposed to have different pathogenesis
properties and global distribution (Taylor, Sobieszczyk, McCutchan, & Hammer, 2008).
Group O (outlier) was isolated from two Cameroon individuals who were living in
Belgium in 1990 (De Leys et al., 1990). Group O accounts for approximately 1% of all
HIV-1 infections (Mourez, Simon, & Plantier, 2013). Group N (non-M, non-O) was
discovered in 1998 in Cameroon and has been reported in only 15 cases (Mourez et al.,
2013; Simon et al., 1998). Group P was identified in 2009 from a Cameroonian woman
living in France and there have been only two cases of confirmed infection from this
group (Plantier et al., 2009; Vallari et al., 2011). While infections with group M are found
worldwide, infections with non-M are largely restricted to Africa (Mourez et al., 2013).
The different groups of HIV originated from independent transmission events of lentivirus
from other primate species into humans. Lentivirus infecting non-human primate species
are termed Simian immunodeficiency virus (SIV). SIV has been co-evolving with primate
species for at least as long as 32000 years (Worobey et al., 2010). With a long history of
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co-evolution between SIVs and non-human primate species, these viruses are not
pathogenic in their natural hosts. Key features that distinguish non-pathogenic SIV
infections in natural hosts from pathogenic infections in non-natural hosts include, but
are not limited to, lack of chronic immune activation, CD4+ T cell depletion, microbial
translocation, and perinatal transmission (Chahroudi, Bosinger, Vanderford, Paiardini, &
Silvestri, 2012; Klatt, Silvestri, & Hirsch, 2012). SIV infections have been found only in
African monkeys and apes, suggesting that these viruses emerged in Africa after the
divergence between African and Asian Old World monkeys (Sharp & Hahn, 2011).
Throughout history, several cross-species transmission events of SIV have occurred,
generating new strains of virus. For example, SIVcpz is the result of a recombination
event when two SIVs, SIVrcm and SIVgsn/SIVmus/SIVmon, crossed over from Red-capped
mangabey and Mona monkey, respectively, into chimpanzees (Bailes et al., 2003).
Sequentially, the transmission of SIVcpz to humans generated HIV-1, specifically group M
and N (Gao et al., 1999; Hahn, Shaw, De Cock, & Sharp, 2000; Sharp & Hahn, 2011).
Meanwhile, group O and P are thought to derive from SIVgor (gorilla), which was the
product of SIVcpz crossing from chimpanzees into gorillas (D'Arc et al., 2015; Sharp &
Hahn, 2011). The transmission events of SIVcpz into humans have been estimated to
date back to the beginning of the 20th century, between 1915 and 1941 (Korber et al.,
2000; Worobey et al., 2008). How these cross-species transmission into humans exactly
occurred is not known. Most likely, these events occurred via the exchange of blood
and/or bodily fluids, in the context of extensive physical encounters between west central
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Africans and ape species or in the context of bushmeat consumption (Sharp & Hahn,
2011).
Similar to HIV-1, HIV-2 is the result of an independent cross-species transmission. It was
first identified in 1985 and isolated in 1986 from infected individuals in West Africa (Barin
et al., 1985; Clavel et al., 1986). Studies revealed that HIV-2 originated from SIVsmm
(sooty mangabey) (Chen et al., 1996; Gao et al., 1992; Hirsch, Olmsted, Murphey-Corb,
Purcell, & Johnson, 1989). The original transmission event was dated back to be around
1940 in Guinea-Bissau (Lemey et al., 2003). Genetically, HIV-1 and HIV-2 shares
approximately 55% similarity at the nucleotide level (Motomura, Chen, & Hu, 2008).
Nonetheless, the two viruses differ in pathogenicity and burden on public health.
Compared to HIV-1, HIV-2 infection appears to be less pathogenic in humans, evident
by the lower viral loads, the lower rate of transmission, and the lower frequency of
progression to AIDS (Esbjornsson et al., 2019; Rowland-Jones & Whittle, 2007).
Consequentially, HIV-2 has not caused a pandemic like HIV-1 (De Cock et al., 1993).
Instead, HIV-2 has been looked upon as a model for protective immunity to HIV-1
(Esbjornsson et al., 2019; Rowland-Jones & Whittle, 2007).
In this dissertation, HIV is used to specifically refer to HIV-1 unless otherwise specified.

HIV life cycle
The life cycle of HIV is made up of several steps: attachment and entry, reverse
transcription, integration, gene expression, viral assembly, budding, and maturation.

5

The binding of HIV to target cells is mediated by proteins on the viral membrane and
molecules on the host cell membrane. This attachment promotes the engagement of HIV
Env(elope) and its primary receptor, CD4, on the host cell (Maddon et al., 1986;
McDougal et al., 1986; Sattentau & Weiss, 1988). The interaction between Env and CD4
is the first required step for infection to occur. Env is a glycosylated protein made up
trimers of gp120 and gp41 heterodimers. Upon the binding of gp120 to CD4, Env
undergoes conformational changes, allowing for coreceptor engagement to occur. The
major coreceptors of HIV are chemokine receptors CCR5 and CXCR4 (Alkhatib et al.,
1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996;
Feng, Broder, Kennedy, & Berger, 1996). Once coreceptor engagement occurs, Env
undergoes further rearrangements, exposing the fusion peptide of gp41. Due to its
hydrophobic nature, the fusion peptide on each Env trimer can insert itself into the host
cell membrane, permitting the formation of the six-helix bundle (Melikyan, 2008). The
fusion of viral membrane and host cell membrane is the last step in the entry process,
leading to the transport of viral materials into the host cell cytoplasm (Wilen, Tilton, &
Doms, 2012).
The next step in the viral life cycle is reverse transcription, which converts the viral (+)
single-stranded RNA into DNA. The viral reverse transcriptase (RT) is generated via the
proteolytic cleavage of the Gag-Pol polyprotein by the viral protease (Hu & Hughes,
2012). HIV RT is a heterodimer of two subunits: p66 and p51 (di Marzo Veronese et al.,
1986; Lightfoote et al., 1986). The process begins with the generation of a (-) DNA
strand at the 5’ end of the HIV RNA genome. This (-) DNA strand is transferred to the 3’
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end, allowing for continuous DNA synthesis. After the generation of (-) DNA strand, the
(+) strand can be generated using the (-) strand as the template. The final product of
reverse transcription is the double-stranded DNA version of the HIV genome (Hu &
Hughes, 2012). Reverse transcription is a key driver of HIV diversity. HIV-encoded RT
does not have a proofreading function, which results in the introduction of mutations. In
vitro experiments have indicated that HIV RT can introduce mutations at a rate of
between 5.9 x 10-4 and 5.3 x 10-5 mutations/base pair/replication cycle (Rezende &
Prasad, 2004; Svarovskaia, Cheslock, Zhang, Hu, & Pathak, 2003). In addition to the
infidelity of HIV RT, the family of host proteins known as APOBEC is another major
contributor of mutations generated during reverse transcription (Hu & Hughes, 2012). In
fact, 98% of mutations generated during the HIV life cycle are caused by APOBEC
proteins (Smyth & Negroni, 2016). APOBECs, the most well-known being APOBEC3G,
are cytidine deaminases. These enzymes are incorporated into newly made HIV virions.
Upon the generation of the (-) DNA strand during reverse transcription, APOBECs
convert up to 10% of Cs on this strand into Us (Malim & Bieniasz, 2012). As the result,
these C-to-U conversions will lead to G-to-A hypermutations in the RNA genome of the
next round of virion production.
Once reverse transcription is completed, the newly synthesized HIV DNA genome is
ready for integration into the host genome. The main orchestrator of this process is the
virus-encoded enzyme integrase. Similar to RT, integrase is an enzyme generated from
the cleavage of the Gag-Pol polyprotein. Viral DNA, viral proteins, including integrase,
and host proteins form the pre-integration complex. This complex localizes to the nuclear
7

membrane and is transported into the nucleus through pore proteins. The first step of
integration involves 3’ end processing when two nucleotides are removed by integrase.
In the second step, this enzyme facilitates the attack of 3’ ends of viral DNA strands on a
pair of phosphodiester bonds on opposite host DNA strands, creating the integration
immediate. To complete the integration process, the 5’ end overhangs on the viral DNA
strands are removed, the single-strand gaps are filled, and the 5’ ends of the viral DNA
are ligated to the host DNA (Craigie & Bushman, 2012). Though HIV integration can
occur at any location in the host genome, this process preferentially occurs in actively
transcribed genomic regions (A. R. Schroder et al., 2002).
The integrated HIV provirus now serves as a template for the production of new virions.
Viral gene expression is regulated by two viral proteins, Tat and Rev (Karn & Stoltzfus,
2012). These two proteins are among the first viral proteins produced after infection.
Transcription is initiated by the recruitment of the host transcription factor NF-κB to the
HIV long terminal repeat (LTR) region. As transcription generates transactivationresponsive region (TAR) RNA, Tat and the elongation factor P-TEFb are recruited,
promoting transcription elongation of viral genes. Viral transcription occurs in two waves.
Completely spliced mRNAs encoding Tat, Rev, and Nef, are generated first, followed by
incompletely spliced mRNAs, encoding Env and accessory proteins Vif, Vpr, and Vpu,
and full-length unspliced mRNAs, encoding the viral RNA genome as well as the GagPol polyprotein (Karn & Stoltzfus, 2012). These two waves differ based on their
dependency on Rev. While the first wave is Rev-independent, the second one is Revdependent. The binding of Rev to the Rev-responsive element on nascent viral mRNAs
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allows the proper transport of these intron-containing mRNAs to the cytoplasm (Karn &
Stoltzfus, 2012).
Upon translation of viral mRNAs in the cytoplasm, viral proteins, cellular tRNA,
molecules required to initiate cDNA synthesis, and two copies of full-length viral RNA
genome are packaged into each new virion, which buds out from the host cell using the
host ESCRT pathway (Sundquist & Krausslich, 2012) . After budding, virions undergo a
multi-steps maturation process where the viral protease cleaves Gag-Pol polyprotein,
generating fully processed MA (matrix), CA (capsid), NC (nucleocapsid), p6, PR
(protease), RT, and integrase (Sundquist & Krausslich, 2012). This maturation process
results in infectious virions that are ready for the next round of infection.

HIV pathogenesis
As mentioned in the previous section, HIV infection requires the expression of CD4 and
a co-receptor, either CCR5 or CXCR4. Since these molecules are mainly expressed by
CD4+ T cells, dendritic cells, and monocytes/macrophages, these cells are possible
cellular targets of HIV. Between the two cell subsets, HIV has a preference for infecting
CD4+ T cells and more specifically HIV-specific memory CD4+ T cells (Douek et al.,
2002; Klatzmann et al., 1984; Schnittman et al., 1990).
The acquisition of HIV occurs primarily through the mucosa or blood. Upon transmission,
the virus can replicate locally at the site of entry prior to disseminating systemically.
While a large number of virions can be transmitted, most infections are established by
one or two genetically unique transmitted-founder virus (Keele et al., 2008). In the case
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of mucosal transmission, HIV virions are initially captured by epithelial dendritic cells.
Subsequently, these cells can transport infectious HIV virions to permissive CCR5+ CD4+
T cells, which are abundant in the lamina propria of mucosal tissues (Xu, Wang, &
Veazey, 2013). Alternatively, free HIV virions can cross from the mucosal epithelium to
the lamina propria via paracellular passage or transcytosis (Gonzalez, Aguilar-Jimenez,
Su, & Rugeles, 2019). Initial replication of HIV in mucosal CCR5+ CD4+ T cells establish
a source of virus and infected cells, which ultimately spread through other sites in the
body via lymphatic and blood circulation systems (Xu et al., 2013). In the case of
intravenous transmission, HIV disseminate throughout the entire body as soon as it
enters the bloodstream, which allows the concurrent establishment of infection at
multiple sites.
Early replication of HIV cannot be reliably detected by clinical tests on blood samples.
This window of time is known as the eclipse phase and can last up to 10 days (Konrad,
Taylor, Conway, Ogilvie, & Coombs, 2017). Between two and four weeks post-infection,
HIV replicates vigorously throughout the body, causing high levels of viremia that peak
at 107 copies of viral RNA (vRNA) per mL blood or more (Coffin & Swanstrom, 2013;
Robb et al., 2016). Infected individuals commonly experience symptoms associated with
other viral infections such as fever, sore throat, fatigue, weight loss, and myalgia (T.
Schacker, Collier, Hughes, Shea, & Corey, 1996). This period is considered as the acute
phase of infection. During this phase, the HIV reservoir is established and the immune
response against HIV is initiated. At the end of the acute phase, the level of viremia is
reduced to the set point level of approximately 104 copies of vRNA per mL blood (Robb
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et al., 2016). Once the viral set point is established four weeks post-infection, the
infection enters the chronic phase where viremia persists stably for many years. During
the chronic phase, the virus and host undergo a co-evolution battle in which the host
immune system attempts to control/clear the virus while the virus continuously mutates
in order to escape the pressure exerted by the host immune system (Bonsignori et al.,
2017; Goulder & Watkins, 2004). Unless ART is initiated, the host ultimately loses out to
the virus and progresses to AIDS within 2-10 years (Giesecke, Scalia-Tomba,
Hakansson, Karlsson, & Lidman, 1990).
The first major hallmark of HIV pathogenesis is the progressive loss of CD4+ T cells. In
fact, the nadir CD4+ T cell count is strongly correlated with disease progression and was
previously used to determine the initiation of ART (Miller et al., 1999). During the acute
phase of infection, CD4+ T cells are heavily depleted, especially in the gut mucosa
(Guadalupe et al., 2003; Veazey et al., 1998). This depletion is likely caused by multiple
mechanisms including but not limited to the cytopathic effect of viral replication, the
pyroptotic death of the bystander cells, and the cytotoxic activity of CD8+ T cells (Doitsh
et al., 2014; Okoye & Picker, 2013).The population of CD4+ T cells lost during the acute
phase of infection can initially be replenished by the differentiation of central-memory
CD4+ T cells (TCM) into effector-memory cells (TEM). However, during the chronic phase
of infection, this replenishment fails over time as the homeostatic quality of TCM gradually
deteriorates. On one hand, inflammation caused by ongoing viral replication induces
fibrosis in gut and lymphoid tissues (Deeks, Tracy, & Douek, 2013; J. Estes et al., 2008;
J. D. Estes et al., 2007). Such architectural change limits the access of CD4+ TCM and
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naïve CD4+ T cells (TN) to key factors required for their maintenance such as IL-7 (Zeng
et al., 2011). Consequently, the pool of CD4+ TCM and TN ultimately fails to repopulate in
order to sufficiently replenish the loss of TEM. On the other hand, intrinsic dysfunction of
CD4+ T cells also contributes to their progressive loss. Evidently, HIV-specific CD4+ T
cells exhibit a profile of immune exhaustion, in which they upregulate several inhibitory
receptors such as PD-1, TIM-3, and CTLA-4 (Morou, Palmer, & Kaufmann, 2014). In
addition, CD4+ T cells from HIV-infected individuals display impaired proliferative
capacity and an abnormal cytokine profile (Cayota, Vuillier, Scott-Algara, Feuillie, &
Dighiero, 1992).
ART initiation can stop the loss and allow the recovery of CD4+ T cells (Ho et al., 1995;
Wei et al., 1995). However, reconstitution of CD4+ T cells is not completely universal as
20% of ART-treated individuals do not experience a rise in CD4+ T cell count even in the
presence of full viral suppression (Piketty et al., 1998). The degree of CD4+ T cell
recovery have been linked to several factors. Older age, coinfection with hepatitis C
virus, and a low CD4 nadir contribute toward immunological nonresponsiveness (Wilson
& Sereti, 2013). High levels of IL-6 and soluble CD14 have also been associated with
poor CD4+ T cell recovery upon ART initiation (Hernandez-Walias et al., 2020). In
contrast, a high pre-treatment viral load has been linked to better CD4+ T cell recovery
during the first three months post-treatment (C. J. Smith et al., 2004). Early initiation of
ART (< 4 months after the estimated time of HIV infection) is another factor liked to
enhanced recovery of CD4+ T cell count (Le et al., 2013; Stirrup et al., 2018).
Mechanistically, this correlation is likely due to the reduction in immune activation and
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inflammation, which in turn mitigates the extend of gut and lymphoid fibrosis (Deleage,
Schuetz, et al., 2016; T. W. Schacker et al., 2005; Schuetz et al., 2014). Not only
allowing a recovery of CD4+ T cell count early ART treatment also permits recovery in
CD4+ T cell functionality. In fact, cytokine production (IFNγ) and proliferative capacity of
HIV-specific CD4+ T cells is preserved when ART is initiated during the acute phase of
infection (Ndhlovu et al., 2019).
The second hallmark is chronic inflammation. Acute HIV infection is highly inflammatory
as evident by an elevation in the frequencies of activated immune cells and in the
production of proinflammatory cytokines (IL-6, TNF, IP-10, and type 1 interferons)
(Deeks et al., 2013; Stacey et al., 2009). Immune activation creates a favorable
environment for HIV replication, as productive infection predominantly occurs in
activated memory CD4+ T cells (Blankson, Persaud, & Siliciano, 2002; Brenchley et al.,
2004; Stevenson, Stanwick, Dempsey, & Lamonica, 1990). Consequentially, as
discussed above, CD4+ T cells are heavily depleted during acute infection (Douek,
Picker, & Koup, 2003). After the acute phase, inflammation is not resolved but reaches a
steady-state level and persists throughout the chronic phase (Klatt, Chomont, Douek, &
Deeks, 2013). Chronic immune activation is often monitored by the frequencies of
activated T cells expressing CD38 and HLA-DR and the plasma levels of
proinflammatory biomarkers such as IL-6, lipopolysaccharide, soluble CD14, soluble
CD163, and IDO (Klatt, Chomont, et al., 2013). This steady-state level of inflammation is
predictive of the rate of CD4+ T cell decline, plasma viral RNA level, and disease
progression (Deeks et al., 2004; Klatt, Chomont, et al., 2013).
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Microbial translocation is a key driver of chronic inflammation in HIV infection (Klatt,
Funderburg, & Brenchley, 2013; Sandler & Douek, 2012). The phenomenon occurs as
the integrity of the gut mucosal barrier is damaged, allowing microbes and microbial
products, which are restricted to the gut lumen during homeostasis, to enter the lamina
propria and gain access to the bloodstream (Sandler & Douek, 2012). In fact, HIVinfected individuals and SIV-infected rhesus macaques have an increased plasma level
of lipopolysaccharide, an indication of microbial translocation. The circulation of
lipopolysaccharide triggers the secretion of soluble CD4 by activated
monocytes/macrophages, which contributes to the systemic immune activation. In
addition, an elevation in plasma level of lipopolysaccharide is correlated with increased
T cell activation and IFNα production (Brenchley et al., 2006). Microbial translocation
happens early during infection, as early as 8-14 days post-infection in SIV-infected
rhesus macaques (Ericsen et al., 2016; J. D. Estes et al., 2010). The cause of microbial
translation involves the disruption of the gut epithelium and potentially the loss of gut IL17-producing CD4+ T cells (Klatt, Funderburg, et al., 2013; Sandler & Douek, 2012).
During acute HIV infection, a large amount of gut epithelial cells undergo apoptosis,
resulting in a loss of tight junction formation and an increase in barrier permeability to
microbes (Epple et al., 2010; J. D. Estes et al., 2010). In addition, as previously
discussed, CCR5+ CD4+ T cells in the gut are heavily depleted during HIV infection.
Since these cells are crucial in maintaining gut homeostasis via IL-17 and IL-22
secretion, their loss compromises the antimicrobial immunity in the gut (Bettelli, Korn,
Oukka, & Kuchroo, 2008; Klatt, Estes, et al., 2012). In fact, depletion of gut IL-17-
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producing CD4+ T cells is positively correlated with plasma viremia (Cecchinato et al.,
2008). Other mechanisms such as decreased clearance of bacterial products from the
gut by phagocytic cells can also contribute to the microbial translocation observed in HIV
infection (J. D. Estes et al., 2010; Sandler & Douek, 2012).
The levels of immune activation and microbial translocation are significantly reduced
upon ART initiation. However, they are still higher than in HIV-uninfected individuals
(Brenchley et al., 2006; Hunt et al., 2008). This is true even when ART is started early
during acute infection (Deleage, Schuetz, et al., 2016; Hunt, Lee, & Siedner, 2016;
Ponte et al., 2016; Sereti et al., 2017). Chronic inflammation can drive HIV persistence
under ART as evident by the positive association between the level of T cell activation
and the level of cell-associated HIV DNA or RNA (Hatano et al., 2013; Yukl et al., 2010).
Mechanistically, this correlation can be due the continuous generation of target cells and
progressive immune dysfunction (Klatt, Chomont, et al., 2013). In return, HIV
persistence, combined with the replication of co-infecting pathogens such as
cytomegalovirus (CMV) and Epstein-Barr virus (EBV), can drive further inflammation,
generating a positive feedback loop that makes inflammation-associated conditions,
such as cardiovascular diseases, major comorbidities in ART-treated individuals (Deeks
et al., 2013; Lerner, Eisinger, & Fauci, 2019).
Another hallmark of HIV pathogenesis is the establishment of persisting viral reservoirs.
As a retrovirus, HIV integrates its genome into the host’s genome upon infection.
Consequently, the virus persists for the life of the infected cells as well as their daughter
cells upon cellular replication and division. These cellular viral reservoirs present a major
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obstacle for curing individuals of HIV. Despite the effectiveness of ART in keeping
plasma viremia below detectable levels by clinical standards (<40 copies/mL), HIV can
rebound as quickly as 1-6 weeks of treatment interruption (Colby et al., 2018).
Furthermore, it has been estimated to take approximately 73.4 years of continuous ART
treatment to fully eradicate all HIV reservoirs in an individual (Siliciano et al., 2003). This
estimation rules out the feasibility of using ART as the sole cure agent.
The seeding of viral reservoirs occurs very early during the acute phase of infection. In
rhesus macaques, SIV reservoirs are seeded within 2-5 days following intrarectal or
intravenous infection, which precedes the onset of plasma viremia (Okoye et al., 2018;
Whitney et al., 2014). In humans, the initiation of ART as early as during Fiebig I, the
clinical stage when HIV RNA is first detectable in plasma (Fiebig et al., 2003), cannot
prevent viral rebound upon therapy cessation, indicating that reservoirs are seeded
within the first two weeks of infection (Colby et al., 2018). However, limiting the size and
changing the cellular composition of HIV reservoirs with early ART treatment can
sometimes result in long-term virologic remission. In fact, ART initiation on day 4-5 but
not day 6-12 after SIV infection reduces the size of viral reservoirs and prevents viral
rebound after treatment interruption with up to 9 months of follow-up (Okoye et al.,
2018). Similarly, some HIV-infected individuals who receive ART during the acute phase
of infection (between Fiebig I and V) experience virologic remission for a median of 89
months (Saez-Cirion et al., 2013). In these individuals, the cellular composition of virusharboring cells shift from longer-lived CD4+ TCM to shorter-lived transitional memory (TTM)
cells (Saez-Cirion et al., 2013).
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HIV reservoirs are found to be distributed throughout the body. In rhesus macaques,
most SIV vRNA+ cells in the body are actually located in lymphoid tissues, such as the
gut and lymph nodes (LNs). In contrast, only 0.2% of vRNA+ cells are found in the blood
(J. D. Estes et al., 2017). In humans, lymphoid tissues have been shown to be critical
sites of HIV reservoirs during the chronic phase of infection (Pantaleo et al., 1991;
Pantaleo et al., 1993; Pantaleo et al., 1994). Viral reservoir in tissues will be discussed in
detail in section 1.7.

1.3 HIV elite controllers (ECs)
Identification of ECs
While the majority (99%) of HIV-infected individuals progress to AIDS in the absence of
ART, a rare subset of infected individuals can achieve spontaneous and durable control
of HIV replication. Multiple terms have been used to described these individuals
including long-term non progressors (LNTPs), viremic controllers, and elite controllers
(ECs) (Deeks & Walker, 2007). LNTPs is the broadest term used to describe HIVinfected individuals who maintain a normal amount of CD4+ T cells count and do not
show any clinical progression towards AIDS regardless of viral loads. These individuals
make up approximately 5%-15% of all infected individuals (Cao, Qin, Zhang, Safrit, &
Ho, 1995; Deeks & Walker, 2007; Munoz et al., 1995; Pantaleo et al., 1995; Sheppard,
Lang, Ascher, Vittinghoff, & Winkelstein, 1993). Once methods for measuring viral load
became available in the mid 1990s, this criteria was used to define HIV non-progressors,
now known as viremic controllers and ECs. While viremic controllers maintain a viral
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load of 50-2000 copies/mL and are present at a prevalence of 2%-4% of all infected
individuals, ECs <50 copies/mL and <1% (Deeks & Walker, 2007; Hubert et al., 2000;
Okulicz et al., 2009). Using ultrasensitive assays, on average 2.3 (0.2-14) copies of HIV
RNA/mL are detected in the plasma of ECs (Pereyra et al., 2009).
Earliest documented cases of ECs were the Sydney Blood Bank Cohort. In 1991, six
individuals in New South Wales, Australia were identified to have remained clinically
asymptomatic despite acquiring HIV via blood transfusions in the mid 1980s from a
single common HIV-positive but asymptomatic donor (J. Learmont et al., 1992;
Zaunders, Dyer, & Churchill, 2011). The donor, a homosexual man, was first recruited to
the Sydney AIDS Prospective Study in 1984 when he was tested negative for HIV p-24
antigen but positive for anti-HIV antibodies (J. Learmont et al., 1992). The fact that this
donor had anti-HIV antibodies indicates that he had been infected with HIV despite the
lack of viremia. The six recipients had received blood transfusions from this donor
between 1982 and 1984 (J. Learmont et al., 1992). Though they were diagnosed with
HIV infection in follow-ups, these individuals maintained stable CD4+ T cell counts and
showed no signs of disease progression up to 7 to 10 years after infection (J. Learmont
et al., 1992). Notably, all seven individuals, including the donor, did not receive any
antiretroviral therapy (J. Learmont et al., 1992).

Determinants of ECs
What are determinants of ECs? Characterization of the HIV isolated from individuals in
the Sydney Blood Bank Cohort showed that these individuals were infected with an
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attenuated strain containing deletions in the nef and U3-LTR regions (Deacon et al.,
1995). Therefore, elite control of HIV replication was originally thought to be entirely due
to defective viral fitness. However, longitudinal follow-ups revealed that three out of the
six recipients as well as the donor eventually displayed a low amount of viremia, ranging
from 600 to 2500 copies/mL (J. C. Learmont et al., 1999; Zaunders et al., 2011).
Especially, the donor showed symptoms of HIV-associated dementia and a viral load in
cerebrospinal fluid of 750000 copies/mL in 1998, which was 14 years after the first
positive test for anti-HIV antibodies (Churchill et al., 2004; Zaunders et al., 2011). These
results suggested that the non-progression observed in the Sydney Blood Bank Cohort
was not simply caused by infections with unfit viruses as these viruses were replication
competent and ultimately caused disease. HIV isolated from other EC cohorts has been
shown to robustly replicate in vitro, generally lack genetic defects, and continuously
evolve, which together further argue against low viral fitness as the main determinant of
ECs (Blankson et al., 2007; Julg et al., 2010; Lamine et al., 2007; Mens et al., 2010;
Miura et al., 2008).
Currently, it is widely agreed that host factors, rather than viral factors, are mostly
responsible for the EC status. Genetic studies have shown that certain HLA class I
alleles such as B*5701 or B*27 are strongly enriched in EC populations (Bailey,
Williams, Siliciano, & Blankson, 2006; Lambotte et al., 2005; Migueles et al., 2000;
Pereyra et al., 2008). Conversely, certain alleles such as B*0702 and B*35 are more
associated with disease progression (Emu et al., 2008; International et al., 2010);
nevertheless this association is observed primarily in clade B and not in clade C infection
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(Kloverpris et al., 2014; Matthews et al., 2012). Mechanistically, the quality of immune
responses targeting epitopes presented by each HLA allele is likely responsible for the
association between these alleles and either elite control or disease progression
(Goulder & Walker, 2012; Kiepiela et al., 2007). However, the presence of “favorable”
HLA alleles does not guarantee the establishment of the EC status (Emu et al., 2008).
Vice versa, the presence of “unfavorable” does not preclude individuals from becoming
ECs (Bendenoun et al., 2018; Emu et al., 2008).
It has been proposed that CD4+ T cells from ECs are more resistant to HIV infection.
Intracellular restriction factors such as APOBEC3G, BST2/tetherin, and TRIM5α can
interfere with various stages in the HIV life cycle (Neil, Zang, & Bieniasz, 2008; Sheehy,
Gaddis, Choi, & Malim, 2002; Stremlau et al., 2004; Van Damme et al., 2008). However,
expression levels of these molecules were found to be no higher in ECs compared to
non-ECs (Abdel-Mohsen et al., 2013). Concurrently, CD4+ T cells from ECs are not more
resistant to HIV infection than CD4+ T cells from non-ECs (Julg et al., 2010; O'Connell,
Rabi, Siliciano, & Blankson, 2011; Saag & Deeks, 2010). These results argue that
effective immunity targeting infected cells rather than elevated intrinsic resistance to
infection is more likely the main mechanism maintaining the undetectable viral loads in
ECs.
Various aspects of innate and adaptive immunity against HIV in ECs have been
examined. Regarding innate immunity, natural killer (NK) cells have been suggested to
play a role in ECs. The epistatic interaction of the KIR3DS1 allele, an activating receptor
for NK cells, and the HLA-B Bw4-80IIe allele has been associated with delayed
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progression to AIDS (Martin et al., 2002). In vitro experiments have functionally
confirmed this association where compared to those not bearing the KIR3DS1 allele, NK
cells bearing the KIR3DS1 allele show superior ability to inhibit HIV replication in target
cells expressing HLA-B Bw4-80 (Alter et al., 2007). In addition, ECs have a higher
frequency of the CD11b+ CD57- CD161+ Siglec-7+ subpopulation of CD56dim CD16+ NK
cells in their blood compared to non-controllers. This specific subpopulation of NK cells
displays increased functionality compared to other subpopulations, as evident by a
higher frequency interferon γ (IFNγ)+ and CD107a+ cells (Pohlmeyer et al., 2019).
However, NK cells from ECs are phenotypically similar to NK cells from ART-treated
patients, implying that NK cells might not be directly responsible for viral control in ECs
(Barker, Martinson, Brooks, Landay, & Deeks, 2007). Therefore, it is unclear how
significantly NK cells contribute to the EC status. Another population of innate immune
cells that has been studied in ECs is plasmacytoid dendritic cells (pDCs). The quantity of
these cells is preserved in ECs but not in ARTs and CPs (Machmach et al., 2012). Also,
pDCs from ECs produce a higher amount of IFNα, which directly suppresses HIV
replication in vitro, and better induce apoptosis of infected-CD4+ T cells through the
expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) (Barblu et
al., 2012; Machmach et al., 2012). Nevertheless, the in vivo importance of these effector
functions exerted by pDCs remained to be examined. Though innate immunity possibly
play a role the control of HIV in ECs, its direct contribution is unclear. This is partially due
to the fact that the majority of studies on ECs have been carried out during the chronic
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phase of infection whereas innate immunity primarily exerts its function during the acute
phase of infection.
On the other hand, the contribution of adaptive immunity, including both humoral and
cell-mediated, to the EC status has been extensively investigated. Several lines of
evidence; including low titers of neutralizing antibodies as well as low degree of
sequence diversity, few N-linked glycosylation sites, and short variable loops in HIV env;
suggest that humoral immunity does not exert a strong pressure on viruses in ECs and
is not a key contributor to the EC status (Bailey, Lassen, et al., 2006; Deeks et al., 2006;
Pereyra et al., 2008).
In contrast, cell-mediated immunity has emerged as the clearest and most robust
correlate of the EC status. Despite being a major target of HIV infection, CD4+ T cells
from ECs are still highly functional. Indeed, HIV-specific CD4+ T cells are present at a
higher frequency in ECs than in non-controllers (Ferrando-Martinez et al., 2012). These
cells have low co-expression of inhibitory receptors, such as PD-1, TIGIT, and CTLA-4,
implying that they are not exhausted (Noyan, Nguyen, Betts, Sonnerborg, & Buggert,
2018). Consequentially, upon stimulation, HIV-specific CD4+ T cells can robustly
proliferate and are highly polyfunctional, evident by their production of multiple cytokines,
such as IL-2, TNF, IFNγ, and beta-chemokines (Emu et al., 2005; Harari, Petitpierre,
Vallelian, & Pantaleo, 2004; Rosenberg et al., 1997). These cytokines can either have a
direct effect by suppressing HIV replication or an indirect effect by boosting the CD8+ T
cell response. Though cytolytic activity is often ascribed to CD8+ T cells, a subset of
CD4+ T cells can exert this effector function (Soghoian & Streeck, 2010). In HIV-infected
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individuals, cytolytic CD4+ T cells are identified by their expression of CD57 (Johnson et
al., 2015). These cells are maintained in ECs but not in non-controllers (Phetsouphanh
et al., 2019). In addition, they emerge early during infection and are associated with a
lower viral set point (Johnson et al., 2015; Soghoian et al., 2012). However, the
importance of cytolytic CD4+ T cells in ECs has been called into question as these cells
are relatively absent from lymphoid tissues (LTs) of ECs (Buggert, Nguyen, McLane, et
al., 2018).
Similar to CD4+ T cells, multiple aspects of CD8+ T cell response have been correlated
with the ECs. These aspects are going to be discussed in more detailed in section 1.6.

1.4 CD8+ T cell subsets and their trafficking properties
CD8+ T cells were originally recognized as a distinct subset of T lymphocytes in 1975
(Cantor & Boyse, 1975; Kisielow et al., 1975; Shiku et al., 1975). At this point, it was
thought that all CD8+ T cells are homogenous and can recirculate between blood, nonlymphoid tissues, and lymphoid tissues. However, in the late 1990s and early 2000s,
phenotypic heterogeneity of CD8+ T cells began to be elucidated. In 1999, TCM and TEM
were described as distinct subsets of memory CD8+ T cells (Sallusto, Lenig, Forster,
Lipp, & Lanzavecchia, 1999). TCM preferentially home to secondary lymphoid organs
due to their high expression of CCR7 and CD62L. Meanwhile, TEM do not express CCR7
and CD62L, therefore preferentially home to inflamed peripheral tissues instead of
secondary lymphoid organs (Sallusto et al., 1999). In terms of functions, TEM can readily
produce a high amount of IFΝγ and carry out cytotoxic function upon activation while
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TCM preferentially produce IL-2, lack immediate cytotoxic function, but are highly
proliferative (Sallusto, Geginat, & Lanzavecchia, 2004; Sallusto et al., 1999). Similar to
TCM, stem-cell memory T cells (TSCM) are a rare subset of memory cells that have a long
life spans and high proliferative capacity (Gattinoni et al., 2011; Gattinoni, Speiser,
Lichterfeld, & Bonini, 2017). Upon stimulation, TCM (or T`SCM) can proliferate and
differentiate into TEM (Sallusto et al., 2004; Schmueck-Henneresse et al., 2015). This
observation leads to the classic model that TEM are the cells that surveil peripheral
tissues and respond immediately to an insult while TCM surveil lymphoid tissues and
serve as the reservoir that can resupply the TEM population during the course of a
response. This model was recently refined using the expression pattern of the fractalkine
receptor CX3CR1(Bottcher et al., 2015; Gerlach et al., 2016). According to this new
model, CX3CR1- memory T cells coincides with TCM while CX3CR1+ cells can be
subdivided into CX3CR1hi, which coincides with TEM, and CX3CR1int, which is termed
peripheral memory cells (Gerlach et al., 2016). It is the peripheral memory cells but not
TEM cells that surveil peripheral tissues.
Another subset of CD8+ T cells with distinct trafficking properties was described in 2001
and these cells are tissue-resident memory cells or TRM (Masopust, Vezys, Marzo, &
Lefrancois, 2001). Recent studies have clearly demonstrated the critical role of TRM in
anti-pathogen and anti-tumor immunity (Amsen, van Gisbergen, Hombrink, & van Lier,
2018; Muruganandah, Sathkumara, Navarro, & Kupz, 2018). Similar to TEM, these cells
also do not express CCR7. However, instead of recirculating in a similar pattern to TEM,
TRM persist in tissues for an extended period of time (Schenkel & Masopust, 2014).
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Tissue residency is largely established through the upregulation of CD69, which
downregulates the expression of the tissue-egress receptor sphingosine-1-phosphate
receptor 1 or S1PR1 (Bankovich, Shiow, & Cyster, 2010; Mackay, Braun, et al., 2015;
Skon et al., 2013). Under homeostasis, T cells exit LNs by following a gradient of
sphingosine-1-phosphate toward peripheral blood (Baeyens, Fang, Chen, & Schwab,
2015). Therefore, the downregulation of S1PR1 mediated by CD69 prevents cells from
leaving tissues and allows them to stay resident. Another molecule that has been
implicated in the mechanism of residency is CD103. This is an integrin (αΕ) that
interacts with E-cadherin to act as a tether for cell retention within a tissue. Its
expression appears to be more common on TRM in the epithelia than in other locations
(Topham & Reilly, 2018). Though CD69 and CD103 are canonical markers used to
identify TRM, these cells can be distinguished from other subsets by their unique
transcriptional program, including but not limited to the upregulation of transcription
factors such as TCF-1, Blimp-1, Hobit, and Runx3 (Behr, Chuwonpad, Stark, & van
Gisbergen, 2018).

1.5 Effector functions of CD8+ T Cells
Cytotoxicity
The first major effector function of CD8+ T cells is cytotoxicity. Though it was first
observed in the early 1920s by James Murphy through a series of experiments on the
rejection of allograft tumors, cytotoxicity was not ascribed to T cells, specifically CD8+ T
cells, until 1975 (Masopust, Vezys, Wherry, & Ahmed, 2007; Shiku et al., 1975). Since
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then, the exact mechanisms of how CD8+ T cells execute their cytotoxic functions have
been well worked-out. Upon the recognition of their cognate antigens that are presented
on MHC-class I molecules, CD8+ T cells undergo major cytoskeletal reorganization in
order to form an immunological synapse with their targets (Griffiths, Tsun, &
Stinchcombe, 2010). This formation of the immunological synapse allows the CD8+ T
cells to release lytic granules containing perforin and granzymes, which trigger apoptosis
in the target cells (Peters et al., 1991).
Perforin, also known as Perforin-1, was first isolated from lytic granules of CD8+ T cells
in the mid 1980s (Henkart, Millard, Reynolds, & Henkart, 1984; Podack, Young, & Cohn,
1985). It is a 67 kDa protein with structural homology to the complement component C9.
Upon release, perforin monomers can oligomerize on the membrane of target cells in a
Ca2+-dependent manner. This oligomerization results in the formation of pores on the
membrane of target cells in a similar fashion as the complement system (Lichtenheld et
al., 1988; Shinkai, Takio, & Okumura, 1988; Tschopp, Masson, & Stanley, 1986; Young,
Cohn, & Podack, 1986). The activity of perforin is highly independent on pH and Ca2+ as
it is only active at a neutral pH and an Ca2+ concentration of at least approximately
100μM (Young, Damiano, DiNome, Leong, & Cohn, 1987). Therefore, perforin is inactive
when it is stored in the acidic environment of secretory lysosomes, which prevents the
self-destruction of CD8+ T cells (Voskoboinik, Whisstock, & Trapani, 2015).
Granzymes, which are also known as granule-associated enzymes, are a family of 30-50
kDa serine proteases that are found in lytic granules of CD8+ T cells along with perforin
(Masson & Tschopp, 1987; Young, Leong, et al., 1986). Five granzymes are expressed

26

in humans (A, B, H, K, and M) and ten in mice (A, B, C, D, E, F, G, L, M, and N)
(Chowdhury & Lieberman, 2008). Among all the granzymes, granzyme B has been the
most well studied given its high abundance in both human and mouse CD8+ T cells as
well as its well-established function in cell-mediated cytotoxicity. Granzyme B is highly
expressed by late-differentiated cells, such as TEM and TEMRA (Takata & Takiguchi,
2006). Upon delivery to target cells, granzyme B triggers apoptosis by directly cleaving
the executor caspase, caspase-3 (Darmon, Nicholson, & Bleackley, 1995). In addition, it
can cleave caspase-8, PARP-1, BID, lamin B, ICAD, DNA-PK, and Nu-Ma, all of which
can lead to the death of target cells (Chowdhury & Lieberman, 2008).
Though the delivery of granzyme B, as well as other granzymes, to target cells is mainly
mediated by perforin, the specific mechanism of this process has been a topic of
controversy and extensive investigation. It is generally thought that granzymes enter the
cytosol of target cells through membrane pores created by perforin (Masson & Tschopp,
1985; Tschopp et al., 1986). In fact, the crystal structure of perforin and the threedimensional reconstruction of perforin pores suggest that the lumen of these pores is
130-300 Å, which is sufficient to allow the entrance of granzymes, including granzyme B,
into target cells (Law et al., 2010). Alternatively, as the two cytolytic molecules are taken
up together by target cells through endocytosis or macropinocytosis, perforin can pore
the endosomal membrane to trigger granzyme B delivery into the cytoplasm (Thiery et
al., 2011; Trapani et al., 2003). There is also evidence for perforin-independent
endocytosis of granzyme B (Froelich et al., 1996; Motyka et al., 2000). In fact, granzyme
B can autonomously cross the plasma membrane in the absence of perforin (Shi et al.,
1997). In addition, conflicting reports have indicated a controversial role of the mannose27

6-phosphate receptor in perforin-independent delivery of granzyme B into target cells
(Dressel et al., 2004; Motyka et al., 2000; Trapani et al., 2003).
Despite the debate on the exact mechanism of granzyme B delivery by perforin, there is
a strong consensus on the essence of both molecules in CD8+ T cell-mediated
cytotoxicity. Perforin deficiency in mice and humans both result in impaired immunity
against viral infection and tumors (Davis, Smyth, & Trapani, 2001; Kagi et al., 1994;
Stepp et al., 1999). In addition, though it can bind to and enter target cells, soluble
granzyme B cannot trigger apoptosis in the absence of perforin (Froelich et al., 1996; Shi
et al., 2005). On the other hand, granzyme B-deficient CD8+ T cells are less efficient in
inducing DNA fragmentation and apoptosis in allogenic target cells compared to wildtype cells (Davis et al., 2001; Heusel, Wesselschmidt, Shresta, Russell, & Ley, 1994).
These cells are also impaired in mediating graft versus host disease in mice (Graubert,
Russell, & Ley, 1996). In most circumstances, the cooperation between perforin and
granzyme B is required to achieve maximal killing efficiency.
In addition to perforin and granzyme B, lytic granules of CD8+ T cells contain other
proteins with cytotoxic activities. Granulysin is a pore-forming protein that belongs to the
saposin-like protein family. It is synthesized in the full length but inactive form of 15 kDa.
Proteolytic cleavage of the full length protein generates the active form of 9 kDa
granulysin (Dotiwala & Lieberman, 2019; Krensky & Clayberger, 2009). Though both
forms are found in cytoplasmic granules, only the 9 kDa active form of granulysin is
found in secretory lytic granules (Pena, Hanson, Carr, Goralski, & Krensky, 1997). The
insertion of granulysin into plasma membrane through charge interaction with membrane
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lipids leads to the release of cytochrome c, caspase-3 activation, and eventually
apoptosis in target cells (Anderson et al., 2003; Kaspar et al., 2001). Granulysin has
been shown to be important in anti-microbial immunity. Upon delivery to infected cells by
perforin, granulysin can deliver granzymes into intracellular parasites such as T.cruzi, T.
gondii, L. major, and P. vivax, and intracellular bacteria such as E. coli,
L.monocytogenes, and S. aureus, causing the generation of superoxide in these
microbes and their death (Dotiwala & Lieberman, 2019; Dotiwala et al., 2016; Junqueira
et al., 2018; Krensky & Clayberger, 2009; Walch et al., 2014). Different from perforin,
which has a preference for cholesterol-rich plasma membrane of mammalian cells,
granulysin has a preference for cholesterol-poor plasma membrane, which is typically
found in bacteria and parasites (Barman et al., 2006). Therefore, granulysin is generally
thought to be less important than perforin when it comes to targeting virally infected and
cancerous mammalian cells. However, there are precedents for the involvement of
granulysin in these forms of immunity. Granulysin is capable of inducing lysis of YAC-1
tumor cells in vitro, as measured by 51Cr-release (Pena et al., 1997). This result has
been extended to multiple myeloma cell lines and primary tumors from B-CLL patients
(Aporta et al., 2014). The model of athymic “nude” mouse receiving human breast
adenocarcinoma or multiple myeloma xenografts has demonstrated a protective role of
granulysin in vivo (Al-Wasaby et al., 2015).
Other granzymes beside granzyme B can induce apoptosis in target cells. Granzyme A,
which along with granzyme B is the most abundant granzyme in human and mouse
CD8+ T cells, can trigger cell death in a caspase-independent manner. This granzyme is
distinctive from the others since it can homodimerize. It targets and destroys the SET
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complex, a protein complex that protects cells from DNA damage, which allows the
nuclear endonuclease NM23-H1 to generate single-strand DNA nicks (Chowdhury &
Lieberman, 2008; Lieberman, 2003). Granzyme K is also found in both human and
mouse CD8+ T cells, though at a much lower level (Bratke, Kuepper, Bade, Virchow, &
Luttmann, 2005). The mechanism of apoptosis induction by granzyme K is similar to that
of granzyme A. Though granzyme M can initiate apoptosis, there are conflicting reports
on whether the process is caspase dependent or independent (Chowdhury & Lieberman,
2008). The expression of this granzyme is originally thought to be restricted to innate
immune cells such as NK cells but has recently been shown to be expressed by CD8+ T
cells (de Koning et al., 2010; Sayers et al., 2001). Little is known about granzyme H
except the fact that it is highly homologous to granzyme B and induces apoptosis
independent of caspase-3 activation and of cytochrome c release. In addition, its role in
cell-mediated cytotoxicity is likely limited to NK cells, given its expression is not
detectable in CD8+ T cells (Chowdhury & Lieberman, 2008; Fellows, Gil-Parrado, Jenne,
& Kurschus, 2007; Sedelies et al., 2004).
The knock-out of perforin and/or granzyme B in mouse models resulted in major, but
incomplete, reduction in target cell killing, indicating the existence of an alternative
mechanism of CD8+ T cell-mediated cytotoxicity. Cell surface receptor-mediated
cytotoxicity is one such alternative mechanism. The main mediators of this mechanism
are Fas/FasL and the TNF-related apoptosis-inducing ligand (receptor) TRAILR/TRAIL
(Brincks, Katewa, Kucaba, Griffith, & Legge, 2008; Falschlehner, Schaefer, & Walczak,
2009; Lowin, Hahne, Mattmann, & Tschopp, 1994; Rouvier, Luciani, & Golstein, 1993).
The binding of the ligand (either FasL or TRAIL) on the surface of CD8+ T cells to its
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receptor (either Fas or TRAILR) on the surface of target cells recruits pro-caspase 8 to
the cytoplasmic domain of Fas, initiating the cleavage of pro-caspase 8 to active
caspase 8. Once activated, caspase 8 can cleave Bid, resulting in mitochondrial
membrane damage and the release of cytochrome C, which ultimately triggers apoptosis
in target cells. In contrast to perforin-mediated cytotoxicity, cell surface receptormediated cytotoxicity is Ca2+-independent (Rouvier et al., 1993).

Cytokine and chemokine secretion
In addition to cytotoxicity, cytokine secretion is another important effector function of
CD8+ T cells. This effector function can either exert direct antimicrobial activities or
regulate adaptive immune responses. Early studies on alloreactive CD8+ T cell clones
showed that these cells could secrete cytokines such as IFNγ, TNF and IL-2, similar to
TH1 CD4+ T cells (Fong & Mosmann, 1990). In addition, the ability of CD8+ T cells to
concurrently produce multiple cytokines, which is also known as polyfunctionality, has
been correlated to control of viral infections such as HIV and EBV (Betts et al., 2006;
Lam et al., 2018)
IFNγ is the only member of type II IFN. Though various immune cell subsets can
produce IFNγ, CD4+ and CD8+ T cells are major producers of this cytokine during
adaptive immune responses (K. Schroder, Hertzog, Ravasi, & Hume, 2004). During the
initiation of an adaptive immune response, IFNγ produced by CD8+ T cells synergizes
with IL-12 produced by antigen presenting cells to polarize CD4+ T cells toward a TH1
profile via the activation of the transcription factor T-bet (Das, Sheridan, & Janeway,
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2001; Szabo et al., 2002; Teixeira et al., 2005). Besides its role in regulating adaptive
immune responses, IFNγ can directly inhibit viral replication (Wheelock, 1965).
TNF is another major cytokine that can be produced by CD8+ T cells. It can be
expressed in a transmembrane form as well as secreted in a soluble form after cleavage
by ADAM family metalloprotease. Both forms have been shown to be biologically active.
For example, while soluble TNF is critical for controlling primary Listeria infection,
transmembrane TNF is sufficient for controlling secondary infection (Mehta, Gracias, &
Croft, 2018). In addition to its direct antimicrobial effect, TNF can modulate immune
responses by signaling through its receptor TNFR1/2. Specifically, it can increase the
ability of CD8+ T cells to produce cytokine, proliferate, and survive during the priming
phase of immune responses. However, TNF signaling can induce apoptosis of effector
CD8+ T cells during the contraction phase (Mehta et al., 2018).
Though IL-2 produced by CD8+ T cells does not have a direct antiviral effect, it is an
important regulator of adaptive immune responses. Autocrine IL-2 aids CD8+ T cell
proliferation during the primary and secondary expansion. In addition, it is mainly
produced by less differentiated populations of CD8+ T cells such as central memory cells
(Wherry et al., 2003).
Beside the cytokines mentioned above, CD8+ T cells can secrete other interleukins. IL17-producing CD8+ T cells can concurrently produce other cytokines including IL-21, IL22, TNF, and IFNγ. These cells have been largely associated with inflammatory
diseases such as psoriasis, multiple sclerosis, and type-1 diabetes (Srenathan, Steel, &
Taams, 2016). The pathogenicity of IL-17+ CD8+ T cells have been attributed both to
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their cytotoxic capacity as well as their ability to attract inflammatory immune cells to
sites of inflammation (Ciric, El-behi, Cabrera, Zhang, & Rostami, 2009). IL-9 producing
CD8+ T cells have been shown be more potent than classical type-1 CD8+ T cells at
antitumor responses (Lu et al., 2014; Lu et al., 2012). IL-4, IL-5, and IL-10 producing
CD8+ T cells have also been identified. These cells can either enhance type-2 immune
responses, providing B cell help or suppressing type-1 immune responses (Le Gros &
Erard, 1994).
Similar to cytokines, chemokines are soluble molecules. However, their main function is
to direct traffic of immune cells. The ability of CD8+ T cells to secrete chemokines has
been demonstrated. One such family of chemokines are beta-chemokines, including
CCL3, CCL4, and CCL5. These molecules bind to their cognate receptor CCR5 to
recruit cells to sites of inflammation. Their production by CD8+ T cells have exhibited a
protective role in HIV infection (Cocchi et al., 1995). Another chemokine that is produced
by CD8+ T cells is CXCL10. In response to CD27/CD70 co-stimulation, CD8+ T cells
produce CXCL10 to recruit other primed CD8+ T cells within a LN to form a pool of CD8+
effector T cells (Peperzak et al., 2013).

1.6 CD8+ T cells in anti-HIV immunity
Shortly after the identification of HIV as the etiological agent of AIDS, HIV-specific CD8+
T cells were detected in HIV-seropositive individuals (B. D. Walker et al., 1987; C. M.
Walker, Moody, Stites, & Levy, 1986). These cells are detectable as early as day 3 postinfection (Ndhlovu, Kamya, et al., 2015). The emergence of virus-specific CD8+ T cells
temporally correlates with the drop in viral load, indicating that CD8+ T cells contribute to
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viral control (Borrow, Lewicki, Hahn, Shaw, & Oldstone, 1994; Demers et al., 2016; Koup
et al., 1994; Ndhlovu, Stampouloglou, et al., 2015). This concept was definitely
demonstrated in the rhesus macaque model where the depletion of CD8+ T cells in SIVinfected animals, both during acute and chronic phases of infection, resulted in a
complete loss of viral control (Fukazawa et al., 2015; Jin et al., 1999; Matano et al.,
1998; Schmitz et al., 1999). Even when the viral load is extremely low during ART, CD8+
T cells still actively antagonize viral replication as their removal results in an increase in
viremia (Cartwright et al., 2016). Genetic and virologic studies have also implicated an
important role of CD8+ T cells in controlling HIV. As mentioned in section 1.3, within the
EC population, there is an enrichment of specific HLA alleles such as HLA-B*5701 and
B*27, which implies the involvement of CD8+ T cells in viral control (Bailey, Williams, et
al., 2006; Lambotte et al., 2005; Migueles et al., 2000; Pereyra et al., 2008). Longitudinal
analyses of viral sequences reveal that HIV continuously mutates in order to escape
from the immune pressure exerted by CD8+ T cells (T. M. Allen et al., 2005; T. M. Allen
et al., 2000; Barouch et al., 2002; Borrow et al., 1997; N. A. Jones et al., 2004; Phillips et
al., 1991). Together, these findings argue that CD8+ T cells are an essential immune
subset for HIV control.
HIV-specific CD8+ T cells are detectable in all chronically infected individuals and they
can target all viral proteins (Betts et al., 2001). These cells have a skewed maturation
phenotype. They predominantly (70%) are CCR7- CD45RA-/CD45RO+ CD27+, which
reflects a TTM phenotype . This is in stark contrast with CMV-specific CD8+ T cells where
most cells are TEMRA (CCR7- CD45RA+/CD45RO- CD27-) (Appay et al., 2000;
Champagne et al., 2001). With a TTM phenotype, HIV-specific CD8+ T cells are capable
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of producing antiviral cytokines such as IFNγ, TNF, and MIP-1β but are impaired in their
cytolytic function, typified by a low frequency of perforin+ cells and low ex vivo target
lysis capacity (Appay et al., 2000). However, this cytolytic capacity is dynamic
throughout the course of infection as it is high during the acute phase before collapsing
as the infection moves into the chronic phase (Demers et al., 2016; Roberts et al., 2016;
Trautmann et al., 2012). In addition to the low cytotoxicity, HIV-specific CD8+ T cells
have a low proliferative capacity upon activation (Appay et al., 2000). This diminished
proliferation is linked to immune exhaustion, a phenomenon caused by prolonged
antigen during chronic viral infections and cancers (McLane, Abdel-Hakeem, & Wherry,
2019). HIV-specific CD8+ T cells, indeed, exhibit a molecular profile of exhaustion
including the expression of multiple inhibitory receptors such as PD-1, TIGIT, 2B4, and
CD160; and a high expression level of the transcription factors Eomes and BATF but low
T-bet; (Buggert, Tauriainen, et al., 2014; Day et al., 2006; Quigley et al., 2010;
Tauriainen et al., 2017; Trautmann et al., 2006; J. Y. Zhang et al., 2007). Initiation of
ART does alleviate the exhaustion of CD8+ T cells but does not fully restore their
functionality (Jensen et al., 2015; Rutishauser et al., 2017; Trautmann et al., 2006;
Yamamoto et al., 2011). A complete preservation of CD8+ T cell functionality most likely
requires the initiation of ART as early as 2 days post-diagnosis during Fiebig I or II
(Ndhlovu et al., 2019).
Through the studies of ECs, several features of CD8+ T cell response have been
associated with effective HIV control. The targeting of specific epitopes has been linked
to different disease outcomes. Responses targeting a broad range of epitopes within
Env and accessory proteins are associated with higher viremia (Kiepiela et al., 2007;
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Pereyra et al., 2008). Meanwhile, Gag-specific responses, including their breadth, are
associated with lower viremia (Edwards et al., 2002; Kiepiela et al., 2007; Rolland et al.,
2008). Furthermore, CD8+ T cells from ECs largely target immunodominant B*5701- and
B*27-restricted Gag epitopes (Almeida et al., 2007; Migueles et al., 2000; Pereyra et al.,
2008). Mutations of these epitopes reduce viral fitness while still maintaining a high level
of antigen-specific CD8+ T cell-responses (Bailey, Williams, et al., 2006; Martinez-Picado
et al., 2006; Miura et al., 2009; Schneidewind et al., 2007). This is potentially due to the
flexible binding grooves of the protective HLA alleles, which allows them to better
tolerate mutations in the binding epitopes (Goulder & Walker, 2012).
Cellular functionality of CD8+ T cells appears to be preserved in ECs. HIV-specific CD8+
T cells exhibit a higher proliferation capacity that is positively correlated with the
expression of HLA-DR (Saez-Cirion et al., 2007). In addition, these cells are primed for
survival and are resistant to apoptosis (Yan et al., 2013). Preservation of functionality
allows CD8+ T cells from ECs to exhibit superior viral inhibition capacity (Saez-Cirion et
al., 2007; Shasha et al., 2016). This viral inhibition capacity is contact-dependent, is
stable over time, strongly correlates with the magnitude of Gag-specific response, and is
cross-reactive with other human lentiviruses (Saez-Cirion et al., 2007; Saez-Cirion et al.,
2009).
The ability of CD8+ T cells to inhibit HIV replication in ECs has been attributed to the
enhancement of effector functions. Cytotoxic capacity of CD8+ T cells is elevated in ECs.
Specifically, HIV-specific CD8+ T cells from ECs quickly express a high level of perforin
and granzyme B upon ex vivo stimulation (6 hours) and this enhanced cytotoxic potential
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is associated with an increase in T-bet expression (Hersperger et al., 2011; Hersperger
et al., 2010). The high level of perforin expression by these cells is also coupled to a
high level of cellular proliferation after 6 days of stimulation (Migueles et al., 2002) . In
addition, efficient delivery of granzyme B is required for the elimination of HIV-infected
cells associated with the EC status (Migueles et al., 2008). These phenomena have
been extended to the rhesus macaque model (Mendoza et al., 2013).
Beside cytotoxicity, cytokine production is another effector function that is augmented in
EC CD8+ T cells. Upon stimulation with HIV peptides, HIV-specific CD8+ T cells from
ECs exhibit polyfunctionality as they can concurrently upregulate the expression of the
degranulation marker CD107a and produce multiple cytokines including IFNγ, TNF, and
MIP-1β (Betts et al., 2006; Ferre et al., 2009). MIP-1β (also known as CCL4) and other
beta-chemokines such as CCL3 and CCL5 are antiviral as they interfere with viral entry
by binding to CCR5, a key co-receptor of HIV (Cocchi et al., 1995). TNF has also been
shown to inhibit HIV replication in macrophages (Lane et al., 1999). The production of
the cellular antiviral factor (CAF) is also higher in ECs (Blackbourn et al., 1996; Killian,
Johnson, Teque, Fujimura, & Levy, 2011). CAF was first described in 1986 when it was
observed that CD8+ T cells can suppress HIV replication without killing infected cells in
vitro (C. M. Walker et al., 1986). However, though certain characteristics of this factor
have been described, its exact identity remains elusive (Levy, 2003).

1.7 Lymphoid tissues in immunity and in HIV infection
Lymphoid tissues (LTs) are organized structures that support immune responses. There
are primary and secondary LTs. Primary LTs are bone marrow and thymus where
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lymphocytes are generated and mature prior to entering circulation. Secondary LTs are
sites of immunosurveillance where adaptive immune responses are induced. These
secondary LTs include but are not limited to LNs, tonsils, spleen, and Peyer’s patches.
In the context of this dissertation, LNs are the main focus of investigation and discussion
as the representative secondary lymphoid tissue.

Cellular architecture of lymph nodes
LNs are organized into two main regions: the medulla and the cortex (von Andrian &
Mempel, 2003). The medulla is made up of lymph-draining sinuses that are divided by
medullary cords. This area contains mostly antibody-secreting plasma cells,
macrophages, and memory T cells (von Andrian & Mempel, 2003). The cortex area is
subdivided into the parcortex (or T cell zone, TCZ) and the B cell follicles (BCF). The
paracortex is the induction site of cellular adaptive immunity, the BCFs of humoral
adaptive immunity. The paracortex is segmented into paracortical cords by cortical
sinuses. Each paracortical cord stretches from below BCFs toward the medulla and
ultimately merge into medullary cords. Besides T cells, the paracortex contains a large
number of dendritic cells (von Andrian & Mempel, 2003). On the other hand, BCFs
contain mainly B cells, follicular CD4+ T cells (either helper or regulatory), and follicular
CD8+ T cells. Upon the induction of humoral immune response, BCFs become germinal
centers where B cells undergo somatic hypermutation and affinity maturation as they go
through rounds of proliferation and selection in areas known as the dark zone and the
light zone (C. D. Allen, Okada, & Cyster, 2007; De Silva & Klein, 2015).
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In addition to the hematopoietic cells, LNs are architecturally supported by a network of
endothelial and non-endothelial stromal cells (Chang & Turley, 2015). Endothelial cells in
LNs include lymphatic endothelial cells and vascular endothelial cells. High endothelial
venules are structures that contain most vascular endothelial cells in LNs. These
structures are found at the center of paracortical cords, which allows lymphocytes in
blood to enter LNs. Non-endothelial stromal cells, such as lymphoid tissue organizer
cells, are largely responsible for the formation of LNs. These cells also differentiate into
other stromal populations in LNs such as follicular dendritic cells (FDC), fibroblastic
reticular cells (FRC), and marginal reticular cells (MRCs) (Chang & Turley, 2015). MRCs
are primarily found beneath the subcapsular sinus where they constitutively produce
CXCL13 (Chang & Turley, 2015). FRCs are a heterogenous group of cells that densely
populates the TCZ. These cells are critical for the maintenance of high endothelial
venule integrity, recruitment of T cells via the secretion of CCL19 and CCL21, and the
homeostatic maintenance of these cells via the production of IL-7 (Brown & Turley,
2015; Link et al., 2007). FDCs are mainly found in BCFs. These cells are important for
the formation of germinal centers through their efficient capture and retention of
antigens, promotion of B cell survival by the secretion of BAFF and APRIL, and B cell
and follicular helper T fells (TFH) trafficking to BCFs via the production of CXCL13
(Chang & Turley, 2015).
All cellular subsets present in LNs, both hematopoietic and stromal, coordinate with
each other in order to successfully induce an adaptive immune response.
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Lymph nodes as sites of adaptive immune priming
LNs, as well as other LTs, are connected by a system of lymphatic vessels. These
vessels collect fluid that drains from tissues, known as lymph, pass it through the
network of hundreds of LNs distributed throughout the body, and ultimately channel it
back to the blood. As lymph passes through LNs, it is surveilled by the different cell
subsets in those LNs. If antigens and the immune cells that can recognize them are
present in a specific LN, their interaction will result in the induction of an adaptive
immune response.
Lymph enters a LN through an afferent lymphatic vessel. The fluid travels through the
subcapsular sinus, trabecular sinuses, medullary sinuses, and eventually exits via an
efferent lymphatic vessel. As lymph travels through a LN, its content is sampled for the
presence of microorganisms and debris by FRCs, macrophages, and dendritic cells that
are present in intranodal lymph channels (von Andrian & Mempel, 2003). As these cells
take up antigenic content present in lymph, they can process them and present to B cells
and T cells. Antigen presentation to B cells is often performed by subcapsular sinus
macrophages and FDCs (Phan, Gray, & Cyster, 2009). Meanwhile, antigen presentation
to T cells is mainly executed by dendritic cells, both resident and migratory ones. Naïve
T cells (both CD4+ and CD8+) will be activated upon their interaction with antigen
presenting cells, presenting the cognate antigens for their T cell receptor. Upon
activation, these antigen-specific effector T cells will proliferate prior to exiting LNs via
efferent lymphatic vessels along a gradient of the chemokine sphingosine-1-phosphate,
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or S1P (Cyster & Schwab, 2012). As these cells enter circulation, they can traffic to sites
of inflammation to execute effector functions during the course of an immune response.

Lymph nodes as sites of HIV reservoirs
Since HIV mainly targets CD4+ T cells and LNs contain a large number of these cells, it
is rational to postulate that LNs are critical sites of HIV infection. In fact, this concept was
recognized very early on as AIDS patients presented with signs of lymphadenopathy
(Goudsmit, Tersmette, Kabel, Miedema, & Melief, 1983; Harris et al., 1983). After the
identification of HIV as the etiological agent of AIDS, it was observed that major HIV
reservoirs are found in LTs, such as LNs (Pantaleo et al., 1991). In addition, HIV
replication remains active in these tissues even during the clinically latent stage of the
disease when minimal replication activity is observed in blood (Pantaleo et al., 1993).
Full body quantification of SIV-infected rhesus macaques also reveals that over 99% of
SIV-RNA+ cells are found in LTs, such as gut and LNs (J. D. Estes et al., 2017).
HIV viremia in the periphery is quickly suppressed to undetectable levels upon ART
initiation. However, in LNs, even when ART is started as early as Fiebig I, viral RNA is
still detectable (Colby et al., 2018; J. D. Estes et al., 2017; Wong et al., 1997). Studies in
the rhesus macaque model have indicated that even when infection is well-controlled,
productive SIV infection still occurs in LNs (Fukazawa et al., 2015). Furthermore, viral
reservoirs are seeded in LNs extremely early, by 3-5 days and as quickly as 3 hours
post-infection (Okoye et al., 2018; Whitney et al., 2014; Whitney et al., 2018).
Consequently, initiation of ART in these SIV-infected macaques as soon as 6 days post41

infection still does not prevent viral rebound post-treatment interruption (Okoye et al.,
2018; Whitney et al., 2014).
Virus persistence in LNs is driven largely by TFH. These cells are highly permissive to
infection, being the most frequent HIV-DNA+ and RNA+ cells after ART initiation; and
they produce the highest amount of virions upon activation (Banga et al., 2016; Kohler et
al., 2016; Perreau et al., 2013). In rhesus macaques that naturally control SIV infection,
productive infection is restricted almost exclusively to TFH (Fukazawa et al., 2015). This
persistence of HIV in TFH is largely due to the localization of these cells to BCFs, which
are considered to be immunologically privileged (Bronnimann, Skinner, & Connick,
2018). CD8+ T cells, though capable, are largely restricted from trafficking into BCFs
(Connick et al., 2014; Connick et al., 2007; Folkvord, Anderson, Arya, MaWhinney, &
Connick, 2003; Folkvord, Armon, & Connick, 2005). As a result, infected TFH do not
experience the same level of immune pressure compared to infected non-TFH. In fact,
when CD8+ T cells are depleted from EC rhesus macaques, productive SIV infection is
redistributed to non-TFH and upon CD8+ T cell recovery, the restriction of productive
infection to TFH is restored (Fukazawa et al., 2015). Besides TFH, another driver of viral
persistence in BCFs is FDCs as free HIV virions can remain infectious for months to
years when retained on these cells (Heesters et al., 2015; Heesters, Myers, & Carroll,
2014; B. A. Smith et al., 2001).
How viral reservoirs in LNs are maintained under ART is still a matter of debate. On one
hand, it has been argued that they are maintained by ongoing viral replication. This
concept is supported by the evolution of viral sequences observed in LNs during ART
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(Lorenzo-Redondo et al., 2016). In addition, lower concentrations of ART measured in
LNs compared to blood can potentially allow HIV to replicate and infect new cells
(Fletcher et al., 2014). On the other hand, multiple studies have found no signs of viral
evolution in LNs, arguing against the concept of ongoing replication during ART. These
studies suggest that viral reservoirs in LNs are maintained by cellular proliferation of
cells that are infected prior to ART initiation (McManus et al., 2019). There is also
evidence for the contribution of both ongoing viral replication and cellular proliferation in
maintaining viral reservoirs in LTs (Boritz et al., 2016). Irrespective of the exact
mechanism of persistence, HIV reservoirs in LNs (and other LTs and NLTs) present a
major hurdle for a cure strategy to overcome.

1.8 Objectives
As laid out in the sections above, a cure for HIV remains unavailable. Typically, there are
two types of HIV cure in discussion: functional cure and sterilizing cure. While a
functional cure primarily aims to suppress viral replication and inhibit disease
progression in the absence of ART, a sterilizing cure aims to completely eradicate HIV
from the body. The successful development of a cure strategy most likely will involve the
identification of immune mechanisms required to effectively control the replication of HIV
reservoirs, in the case of a functional cure, or to eliminate these reservoirs, in the case of
a sterilizing cure. Though a sterilizing cure might be the ultimate goal, a functional cure
is more attainable. Over the past four decades, a robust body of literature has supported
the essential role of CD8+ T cells in controlling HIV replication, especially in ECs,
individuals who autonomously maintain an undetectable viral load in the absence of
43

ART. In fact, the presence of these cells is required for the maintenance of the EC status
in the rhesus macaque model of infection (Fukazawa et al., 2015). Furthermore, specific
aspects of CD8+ T cell functions, such as cytotoxicity, proliferation, and polyfunctionality,
have been strongly correlated with the EC status. It is worth emphasizing that these
correlates were established in the peripheral blood. However, as discussed in section
1.7, most of HIV viral reservoirs are located in tissues, mainly in LTs, and not the blood.
Though it has historically been reasonable to assume that T cells in blood accurately
represent T cells in tissues, the identification of T cell subsets with different trafficking
properties, including TRM, has challenged this assumption. On one hand, a large number
of T cells in tissues are TRM (Farber, Yudanin, & Restifo, 2014; Thome et al., 2014).
Since these cells, by definition, stay resident in a tissue, they are not found in the blood.
One the other hand, different microenvironmental stimuli can affect T cell functions. As a
result, the functional properties of T cells in tissues might not be accurately represented
by T cells in blood.
With these notions in mind, the overarching goal of this dissertation is to define the
identity of CD8+ T cells that are involved in maintaining HIV control in LTs of ECs, with a
focus on LNs. Specifically, this project aims to determine, first, if TRM are involved in antiHIV immunity in LNs and, second, which properties of LN CD8+ T cells are linked to the
effective immune-mediated control of HIV replication in ECs. The results from this study
will hopefully be insightful for the future development of a HIV cure strategy.
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CHAPTER 2: LYMPHOID TISSUES OF HIV ELITE CONTROLLERS
HABOR A LARGE FREQUENCY OF TISSUE-RESIDENT MEMORY
CD8+ T CELLS
This chapter is presented as a re-print (with permission) of the article titled “Identification and
characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue” by
Buggert M, Nguyen S, Salgado-Montes de Oca G, Bengsch B, Darko S, Ransier A, Roberts ER,
Del Alcazar D, Brody IB, Vella LA, Beura L, Wijeyesinghe S, Herati RS, Del Rio Estrada PM,
Ablanedo-Terrazas Y, Kuri-Cervantes L, Sada Japp A, Manne S, Vartanian S, Huffman A,
Sandberg JK, Gostick E, Nadolski G, Silvestri G, Canaday DH, Price DA, Petrovas C, Su LF,
Vahedi G, Dori Y, Frank I, Itkin MG, Wherry EJ, Deeks SG, Naji A, Reyes-Terán G, Masopust D,
Douek DC, Betts MR. Science Immunology. 2018 Jun 1, 3(24), eaar4526.
doi:10.1126/sciimmunol.aar4526

2.1 Introduction
It is well established that CD8+ T cells are required for effective immune control of HIV.
The contemporary literature is also replete with studies describing the qualitative
characteristics of effective HIV-specific CD8+ T cell responses. For example, allotype
restriction, antigen sensitivity and specificity, clonotype distribution, cytolytic activity,
polyfunctionality, proliferative reserve, and response magnitude have all been
associated with differential rates of disease progression (Migueles & Connors, 2015).
However, most of these correlates are based on data acquired from peripheral blood,
despite the fact that HIV replicates primarily in lymphoid tissues (LTs).
HIV seeds, replicates, and persists in LTs (J. D. Estes, 2013). It is therefore important to
develop an anatomically consistent view of immunosurveillance, especially in light of the
fact that follicular helper T cells (TFH) facilitate viral replication and harbor much of the
viral reservoir (Banga et al., 2016; Folkvord et al., 2005; Perreau et al., 2013). The
45

efficacy of live-attenuated SIV vaccines can be predicted from the magnitude of virusspecific T cell responses in LTs (Fukazawa et al., 2012). In addition, CD8+ T cell
depletion is associated with a rapid redistribution of productive SIV infection to non-TFH
in EC macaques, suggesting active viral suppression by CD8+ T cells in LTs (Fukazawa
et al., 2015). However, very little is known about the antiviral properties of HIV/SIVspecific CD8+ T cells that reside in LTs.
Gowans and colleagues have demonstrated that lymphocytes recirculate between
tissues and blood through lymph via the thoracic and lymphatic ducts (Gowans, 1959).
More recent studies of human blood have categorized memory CD8+ T cells broadly into
two circulating subsets based on their tissue homing properties. Central memory T cells
(TCM) express lymphoid homing receptors (CCR7 and CD62L) and recirculate between
blood, LTs, and lymph, while effector memory T cells (TEM) lack CCR7 and CD62L and
recirculate between blood, non-lymphoid tissues (NLTs), and lymph to survey visceral
organs and body surfaces (Sallusto et al., 1999). Recently, a new subset known as
resident memory T cells (TRM), that reside within NLTs, has been identified (Gebhardt et
al., 2009; Masopust et al., 2010; Masopust et al., 2001; Wakim, Waithman, van Rooijen,
Heath, & Carbone, 2008). Most TRM constitutively express CD69 (Masopust, Vezys,
Wherry, Barber, & Ahmed, 2006), which downregulates the sphingosine-1-phosphate
receptor 1 (S1PR1) (Shiow et al., 2006), thereby preventing tissue egress. NLTs are
seeded with TRM soon after immune priming (Masopust et al., 2010), establishing a frontline tissue defense that can eliminate pathogens largely without the involvement of
circulating T cells (Mackay, Wynne-Jones, et al., 2015). Importantly, TRM have distinct
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functional, phenotypic, and transcriptomic profiles attuned to their compartmentalized
state (Mackay et al., 2013).
TRM have been identified in murine LTs (Schenkel, Fraser, & Masopust, 2014), where
they are relatively sparse compared with circulating T cells (Steinert et al., 2015). CD8+
TRM have also been observed in human LTs (Sathaliyawala et al., 2013; Thome et al.,
2014; Woon et al., 2016). The notion that TRM may exist in LTs could transform our
understanding of CD8+ T cell-mediated control of HIV infection. In line with this
possibility, the frequency of HIV-specific CD8+ T cells is generally higher in lymph nodes
(LNs) compared with matched peripheral blood samples (Altfeld et al., 2002; Connick et
al., 2007), despite the fact that most circulating HIV-specific CD8+ T cells lack classical
lymphoid homing characteristics (Buggert, Tauriainen, et al., 2014; Champagne et al.,
2001). Moreover, CD8+ T cells accumulate in HIV-infected LTs (Lederman & Margolis,
2008) and respond poorly to S1PR1-mediated signals (J. C. Mudd et al., 2013).
However, it remains unclear if HIV-specific CD8+ T cells with a TRM phenotype exist in
HIV-infected LTs. To resolve this issue, we conducted a detailed assessment of CD8+ T
cells in the peripheral blood and LTs of healthy and HIV+ subjects. Our data show that
TRM most often dominate the HIV-specific CD8+ T cell response in LTs, and identify a link
between increased magnitudes of HIV-specific CD8+ TRM and effective immune control of
HIV.
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2.2 Results
HIV+ LNs harbor an abundance of CD69+ CD8+ T cells
CD69 has often been considered as a marker of early T cell activation (Chattopadhyay &
Roederer, 2010). We examined CD69 expression on LN CD8+ T cells from HIV+ and
HIV– subjects (Table 2.1). Irrespective of adherence to antiretroviral therapy (ART),
higher frequencies of LN CD69+ CD8+ T cells and CCR7- (TEM) cells were present in HIV+
compared with HIV– subjects (Fig 2.1A and 2.2A). In HIV+ subjects, higher frequencies
of CD8+ T cells expressed CD69 in LNs compared with blood (Fig 2.1B). A strong
association was also detected between the frequency of memory CD8+ T cells and the
frequency of CD69+ CD8+ T cells in LNs (Fig 2.1C and 2.2B). Moreover, LN CD69+
CD8+ T cells from HIV+ subjects were biased towards a TEM phenotype (Fig 2.1D and
2.2B).
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Table 2.1 Clinical data of subjects included in the study
HIV-

HIV+ acute
(Fiebig IV-VI)

HIV+ chronic
ART-

HIV+ chronic
ART+

HIV elite
controllers

Number of
individuals

47

8

35

19

9

Sites of
collection

University of
Pennsylvania,
Case Western
Reserve
University
Blood (n=11),
spleen (n=8),
tonsil (n=7),
iliac LN (n=6),
mesenteric LN
(n=6), hepatic
LN (n=2),
matched blood
and TDL (n=7)
N/A

INER-CIENI

University of
Pennsylvania,
INER-CIENI

University of
Pennsylvania,
INER-CIENI

UCSF, INERCIENI

Matched blood
and cervical LN
(n=8)

Matched blood
and cervical
LN (n=33),
matched blood
and iliac LN
(n=1), matched
blood and
TDL (n=1)

Matched blood
and cervical
LN (n=11),
matched blood
and TDL (n=8)

Matched blood
and inguinal
LN (n=8),
matched blood
and cervical
LN (n=1)

23 (21-27)

29 (23-33)

29(28-39)

49 (39-63)

CD4 count
(cells/mL)

N/A

306 (238-370)

348 (248-497)

382 (367-811)

835(643-1111)

Viral load
(copies/mL)

0

<40 (<40-<40)

N/A

75,043
(22,429203,904)
4.90 (4.465.32)

<40 (<40230,948)

Log viral
load

1,996,027
(1,297,4614,421,034)
6 (6.11-6.63)

<1.6 (<1.65.36)

<1.6 (<1.6<1.6)

Types of
tissues

Age

To determine if LN CD8+ T cells express CD69 as a consequence of activation, we
stained blood and LT CD8+ T cells for canonical activation markers. Of note, CD69+
CD8+ T cells expressed lower levels of multiple activation markers compared to in vitro
stimulated T cells (Fig. 2.3). In addition, we obtained samples from HIV+ subjects in the
acute/early stages of infection (Fiebig IV-VI), a time when early cycling (Ki-67+) CD8+ T
cells are prevalent in blood (Ndhlovu, Kamya, et al., 2015). Substantially higher
frequencies of LN CD8+ T cells expressed Ki-67 in acutely infected HIV+ compared with
HIV– subjects (Fig 2.1E). These LN Ki-67+ CD8+ T cells also showed evidence of HIV
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specificity (Fig. 2.4A), as demonstrated previously in blood (Ndhlovu, Kamya, et al.,
2015; Takata et al., 2017). However, only a minority of LN CD69+ CD8+ T cells
expressed Ki-67 (Fig 2.1F and 2.4B).
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Figure 2.1. CD69 is not coupled to an early immune activation signature in HIVinfected LNs. (A) Frequency of CD69 expression on total LN CD8+ T cells from
HIV+ and HIV− subjects. Red indicates ART− and orange indicates ART+ in the
HIV+ scatter plot group. (B) Frequency of CD69 expression on total blood (top) and LN
(bottom) CD8+ T cells. Matched samples from one subject are shown in the
representative flow cytometry plots. Lines connect matched samples across all subjects
in the graph. (C) Correlation between the frequency of memory (non-CCR7hi nonCD45RO−) CD8+ T cells and CD69 expression on total blood (top) and LN (bottom)
CD8+ T cells. Blue: HIV− subjects: red: HIV+ ART− subjects; orange
HIV+ ART+ subjects. (D) Frequency of CCR7− CD69+ memory CD8+ T cells in HIV− (blue)
and HIV+ (red: ART−; orange: ART+) subjects. (E) Co-expression pattern of Ki-67 and
CD69 in/on total LN CD8+ T cells from an HIV− subject (left) and an HIV+ ART− subject
(right) with acute infection (Fiebig V). (F) Frequency of Ki-67–/+ CD69+ CD8+ T cells in
LNs from HIV+ subjects with acute infection (n = 7). (G) Expression intensity of CD69,
ICOS, Ki-67, and CD38 in multidimensional viSNE space. viSNE plots were derived
using 27576 cells (n = 17 subjects) and the markers shown in Fig. 2.1I. (H) The same
viSNE display with sub-populations colored using the PhenoGraph implementation of
Cytofkit (top). Distribution of CD69 expression over all 14 sub-populations derived using
PhenoGraph (bottom). (I) Hierarchical clustering of expression intensity (z-score) for all
assessed markers within the different sub-populations derived using PhenoGraph.
Median and IQR are shown for all scatter/bar plots. **P < 0.01; ***P < 0.001.
Conventional (fluorescence) flow cytometry was used for all stains in (A-F) and mass
cytometry (CYTOF) was used in (G-I).

In addition, we utilized mass cytometry to assess the expression of multiple activation
markers on LN CD8+ T cells in HIV+ subjects with chronic disease (Fig 2.1G). Fourteen
CD8+ T cell clusters were identified algorithmically in t-distributed stochastic neighbor
embedding (tSNE) space, where one cluster (#4) displayed high co-expression of
several activation markers (CD38, Ki-67, ICOS), but not CD69 (Fig 2.1H). In contrast,
CD69 expression intensity was high on unique clusters (#7, #8) with elevated levels of
CD38, but also dissociated with CD38 expression in other dominant CD69 clusters (#2,
#3) (Fig 2.1H). Furthermore, some naïve-like clusters (#10, #14) demonstrated low
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CD69 intensity (Fig. 2.1I), but these clusters also expressed low to high intensity of BCL6, CD95 and CXCR5 (#10) as well as CXCR3 and CCR6 (#14), suggestive of memory
stem T cell (TSCM)-like features (Gattinoni et al., 2011; Im et al., 2016). Hierarchical
clustering confirmed that CD69 expression was more closely related to PD-1, CD95, and
CXCR3 expression than CD38, Ki-67, and ICOS expression (Fig 2.1I). Collectively,
these data indicate that high levels of CD69 expression on memory CD8+ T cells in HIVinfected LTs cannot be explained by an increased early/cycling immune activation
profile.

Figure 2.2. Maturation of LN CD8+ T cells. (A) Flow cytometry and frequency of LN
naïve (CCR7+CD45RO-/CD45RA-), TCM (CCR7+CD45RO+/CD45RA-), TEM (CCR7CD45RO+/CD45RA-) and Teff (CCR7-CD45RO-/CD45RA+) CD8+ T cells between HIVand HIV+ subjects. Red indicate ART- and orange ART+ in the HIV+ group. (B)
Correlation between the frequency of LN naïve, TCM, TEM or TEff CD69 expression on
total CD8+ T cells. Blue marks HIV- subjects, red HIV+ART-, and orange HIV+ ART+
subjects. *P < 0.05, **P < 0.01 and ***P < 0.001.
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Figure 2.3. Expression of immune activation markers by LT CD8+ T cells.
Frequency of different immune activation markers on CD69- (white) and CD69+ (black)
CD8+ T cells in blood (n = 12) and LTs (Iliac LN: n = 6; Mes LN: n = 6; Tonsil: n = 6,
Spleen: n = 6); all data points are derived from HIV– subjects. Anti-CD3-CD28 stimulated
blood memory CD8+ T cells (red) were used as a positive control (n = 4). Median and
IQR are shown for all bar plots.

Figure 2.4. Cycling CD8 T cells in acute HIV-infected LNs. (A) Flow cytometry plots
of negative background (mock) and a CD8+ HIV-tetramer+ response in an acute HIVinfected LN sample. (B) Frequency of Ki-67+ CD8+ T cells that are CD69+ or CD69-.
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LN CD69+ CD8+ T cells display characteristics of TRM
To determine if human LT CD69+ CD8+ T cells have a transcriptional signature
resembling TRM, we sorted mesenteric LN (MesLN) memory CD69– and CD69+ CD8+ T
cells (Fig 2.5A) and performed RNA sequencing (RNA-seq) analysis. We identified a
core signature of genes that were either upregulated or downregulated in LN memory
CD69– and CD69+ CD8+ T cells (fold change > 2; P < 0.05), where particular genes that
are downregulated in NLT TRM, such as S1pr1, Klf3, and Sell (Pan et al., 2017), were
also poorly expressed in LN memory CD69+ CD8+ T cells (Fig 2.6A). Of note, Znf683
(Hobit), previously associated with murine TRM formation (Mackay et al., 2016), was
downregulated in LN memory CD69+ CD8+ T cells. Gene-set enrichment analysis
(GSEA) revealed that genes linked with human lung CD69+ CD103+ CD8+ T cells
(Hombrink et al., 2016a) were also enriched in LN CD69+ CD8+ T cells (Fig 2.5B).
Ingenuity pathway analysis further demonstrated that the major differences between
CD69– and CD69+ CD8+ T cells included cell-mediated immune responses and cell
trafficking (Fig 2.6B). In addition, many genes typically associated with TRM and TCM/TEM
(Appay et al., 2007; Mackay et al., 2013) were upregulated (Itgae, Rgs1, Rgs2, Xcl1,
Tbx21, Ifng) or downregulated (Fam65b, Klf2, Rasgrp2, S1pr1, Sell, Ccr7, Lef1, Tcf7,
Cxcr3, Cxcr4) in CD69+ CD8+ T cells (Fig 2.6C). Most of these genes followed the
patterns observed in splenic CD69+ CD8+ T cells and TCM (CD69– CD62L+) isolated from
P14 T cell receptor (TCR)-transgenic mice (Fig 2.6C). We further conducted Assay for
Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq) to
map potential differences in open chromatin regions (OCRs) between LN memory
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CD69– and CD69+ CD8+ T cells. OCRs adjacent to genes known to be involved in the
establishment of residency and immune responses displayed marked differences
between these two subsets of LN memory CD8+ T cells (Fig 2.6D). For example, several
OCRs were present next to Ifng, Xcl1, and Xcl2 primarily in CD69+ CD8+ T cells (Fig
2.6E), suggesting a readiness to upregulate these effector functions (Hombrink et al.,
2016b; Mackay et al., 2013). Prdm1 (encoding Blimp-1), recently associated with TRM
formation (Mackay et al., 2016), were also enriched for OCRs in CD69+ CD8+ T cells
(Fig 2.5C). In contrast, CD69– CD8+ T cells were more likely to have multiple OCRs
adjacent to genes associated with trafficking, including Klf2 and S1pr1 (Fig 2.6F), and
the Znf683 locus (Fig 2.5C). We further inferred transcription factor occupancy in
regulatory elements by motif analysis and found that RUNX, AP-1 and ETS families
belonged to the most enriched motifs in CD69+ CD8+ T cells, while CD69- CD8+ T cells
showed enriched motifs belonging to the PAX, TCF and KLF families, demonstrating that
unique transcription factor families are likely cooperatively responsible for regulating
resident and recirculating T cell states (Fig 2.6G).
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Figure 2.5. RNA-seq, ATAC-seq and CCR7 analysis of LN TRM (A) Gating strategy for
RNA- and ATACseq sort to get a pure mesLN memory CD69- and CD69+ CD8+ T cell
population. (B) Normalized enrichment score (NES) of down- and upregulated gene sets
from lung TRMs (CD69+CD103+) (Hombrink et al., 2016) in mesLN CD69+ compared to
CD69- memory CD8+ T cells. (C) ATAC-seq tracks for the Znf683 (Hobit) locus. (D)
CD69 frequency on sorted CD69+ CD8+ T cells after 9 days in culture with CCL19/21 or
without. Both conditions contained also rhIL-7. (E) MFI of CD69 on CCR7+ and CCR7CD69+ CD8+ T cells after 9 days in culture with rhIL-7. (F) Expression of resident and
effector molecules on CCR7+ and CCR7-CD69+ CD8+ T cells. *P < 0.05, **P < 0.01 and
***P < 0.001.
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Figure 2.6. CD69+ CD8+ T cells display functional and transcriptional TRM
signatures in LTs. (A) RNA-seq heat-map showing differentially expressed genes (fold
change > 2; P < 0.05) between human MesLN memory CD69− and CD69+ CD8+ T
cells. (B) Ingenuity pathway analysis based on all differentially expressed genes (P <
0.05) between CD69− and CD69+ CD8+ T cells in the RNA-seq dataset. The top
pathways involved in the “physiological system development and function” arm are
shown in the table. (C) Differential expression patterns of TRM-related and TCM/EM-related
genes between human LN memory CD69− and CD69+ CD8+ T cells (top) and between
splenic CD69− and CD69+ CD8+ T cells from P14 TCR-transgenic mice
(bottom). (D) ATAC-seq volcano plot showing open chromatin regions adjacent to
specific genes. Green marks ATAC-seq peaks that are differentially enriched (fold
change > 2; P < 0.05) in human hepatic LN memory CD69− and CD69+ CD8+ T
cells. (E) ATAC-seq tracks from human LN memory CD69− (red) and CD69+ (blue)
CD8+ T cells. (F) Enriched ATAC-seq de novo motifs for CD69+ (left) and CD69− (right)
CD8+ T cells (G) Human memory CD69− and CD69+ CD8+ T cells from spleen, tonsil,
and hepatic LNs (n = 2 each) were assessed over time for CD69 expression in the
presence or absence of rhIL-7. Lines represent mean ± SD. Conventional flow cytometry
was used for all stains in this figure.

To further support the concept that CD69+ CD8+ T cells are enriched for TRM in vivo, we
performed a variety of functional experiments. We sorted human LT memory CD69– and
CD69+ CD8+ T cells, and found that CD69 was stably expressed on the surface of TRM
for up to 9 days (Fig 2.6H). Classical TRM express low levels of CCR7 and CD62L
(Schenkel & Masopust, 2014). We found no evidence that supplementation with CCR7
ligands (CCL19 or CCL21) influenced CD69 downregulation on LT memory CD69+ CD8+
T cells (Fig 2.5D). However, CD69 was downregulated significantly on CCR7+ CD69+
CD8+ T cells after 9 days in culture (Fig 2.5E), and markers associated with residency
and effector functions were predominantly expressed by CCR7– CD69+ CD8+ T cells ex
vivo (Fig 2.5F). Altogether, these data show that LT CD69+ CD8+ T cells show enriched
phenotypic, transcriptional, epigenetic and functional traits of tissue residency.
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The majority of HIV-specific CD8+ T cells in LTs are CD69+
The observation that memory CCR7–CD69+ CD8+ T cells are expanded in HIV-infected
LNs (Fig 2.1) led us to postulate that HIV-specific cells are TRM. In contrast to matched
blood, most LN HIV-specific CD8+ T cells expressed CD69 (Fig 2.7A and 2.8). To
confirm that HIV-specific CD69+ CD8+ T cells do not leave LTs, we collected thoracic
duct lymph (TDL) from HIV+ subjects. Akin to our previous findings, we detected only
very low levels of CD69 on bulk and HIV-specific CD8+ T cells in TDL (Fig 2.7A). Of
note, CD69 expression on HIV-specific CD8+ T cells was unaffected by ART status (Fig
2.7A), indicating that antigen load is not necessarily a determinant of CD69 expression,
in contrast to classical immune activation markers in blood (Buggert, Frederiksen, et al.,
2014; Evans et al., 1998).
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Figure 2.7. Majority of HIV-specific CD8+ T cells display a TRM phenotype in LNs.
(A) Flow cytometry plots of on memory CD8+ T cells showing CD69 expression on
matched HIV-tetramer+ cells in blood and LNs (left), and matched HIV-tetramer+ cells in
blood and TDL (middle). Frequency of CD69 expression on HIV-tetramer+ cells in blood
(n = 13 subjects), ART− LNs (n = 4 subjects), ART+ LNs (n = 4 subjects), and TDL (n = 7
subjects) (right). (B) Distribution of LN HIV-tetramer+ (spec) CD69+ CD8+ T cells among
the naïve (CD45RO− CCR7+), TCM (CD45RO+ CCR7+), TEM (CD45RO+ CCR7−), and
effector (TEFF; CD45RO− CCR7−) compartments. (C) CD69 and CD103 expression
profiles for blood (blue), LN (red: ART−; orange: ART+), and TDL (yellow) HIV-specific
CD8+ T cells. (D) Representative flow cytometry plots showing memory CMVtetramer+ (left) and HIV-tetramer+ (right) CD8+ T cell frequencies in blood (top) and LNs
(bottom) from the same subject. (E) Frequency of CD69 and CD103 expression on LN
CMV-NV9-specific and HIV-FK10-specific CD8+ T cells in the same subjects with
detectable tetramer+ responses to both viruses. Each color represents a matched
subject and a matched tetramer+ response. (F) Representative flow cytometry plots
showing CD69 expression on Perforin+ Granzyme B (GzmB)+ HIV-specific CD8+ T cells
in LNs (left). Frequency of CD69–/+ cells among Perforin+ (n = 20 responses) and
GzmB+ (n = 16 responses) HIV-specific CD8+ T cells in ART+ and ART− LNs
(right). (G) Flow plots showing CXCR5 and CD69 co-expression on blood, LN, and TDL
memory CD8+ T cells in HIV+ subjects (matched for blood and LNs, but not for TDL).
Frequency of CXCR5 expression on memory CD8+ T cells in blood, LNs (red: ART−;
orange: ART+), and TDL. (H) Frequency of CD69 expression on blood, LN, and TDL
CXCR5+ memory CD8+ T cells in HIV+ subjects. (I) Frequency of CCR7 expression on
LN CD69+ CXCR5+ memory CD8+ T cells in HIV+ subjects. Bar plots are based on all
subjects in Fig. 2.6A. (J) Representative flow cytometry plots showing CXCR5 and CD69
co-expression on blood, LN, and TDL HIV-tetramer+ CD8+ T cells (matched for blood and
LNs, but not for TDL). (K) Frequency of CD69 expression on blood (n = 18 responses),
LN (n = 21 responses), and TDL (n = 10 responses) HIV-specific CXCR5+ CD8+ T
cells. (L) Frequency of CCR7 expression on LN (n = 21 responses) HIV-specific
CD69+ CXCR5+ CD8+ T cells. (M) Frequency of CD69+ CXCR5+ cells among LN CMVspecific and HIV-specific CD8+ T cells in subjects with detectable tetramer+ responses to
both viruses. Each dot represents a single tetramer+ response in all scatter plots. Each
color represents a matched subject and a matched tetramer+ response. *P < 0.05, **P <
0.01; ***P < 0.001. Conventional flow cytometry was used for all stains in this figure.
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In line with our previous findings, most HIV-specific CD69+ CD8+ T cells (median =
84.1%) did not express CCR7 (Fig 2.7B). Moreover, HIV-specific CD8+ T cells in LNs
demonstrated a predominant CD69+ CD103+ or CD69+ CD103– profile, in contrast to
HIV-specific CD8+ T cells in blood and TDL (Fig 2.7C). We further examined
cytomegalovirus (CMV)-specific CD8+ T cells for markers of residency, because CMV
does not replicate primarily in LTs (Jarvis & Nelson, 2007; Myerson, Hackman, Nelson,
Ward, & McDougall, 1984). In subjects with detectable CMV-specific and HIV-specific
CD8+ T cell responses, we consistently found that HIV-specific CD8+ T cells were
present in blood and LNs, while CMV-specific CD8+ T cells were always more prevalent
in blood compared with LNs (Fig 2.7D) (Ellefsen et al., 2002). HIV-specific CD8+ T cells
also expressed higher levels of CD69 and CD103 than CMV-specific CD8+ T cells in LNs
(Fig 2.7E). In addition, HIV-specific CD69+ CD8+ T cells were more likely to express
cytolytic proteins (perforin and/or Granzyme B) than HIV-specific CD69– CD8+ T cells
(Fig 2.7F).
Virus-specific CXCR5+ follicular CD8+ T cells have recently been shown to play a key
role in immune protection against chronic viral infections (Adnan et al., 2016; Im et al.,
2016; Leong et al., 2016; Li et al., 2016; Mylvaganam et al., 2017). However, it is unclear
if human CXCR5+ CD8+ T cells exhibit TRM properties akin to TFH (J. Y. Lee et al., 2015).
In HIV+ subjects, we observed higher frequencies of CXCR5+ CD8+ T cells in LNs
compared with blood and TDL (Fig 2.7G). The majority of CXCR5+ CD8+ T cells in LNs
co-expressed CD69 and lacked CCR7 (Fig 2.7H and I). Similarly, we found very low
levels of HIV-specific CXCR5+ CD8+ T cells in peripheral blood and TDL compared with
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LTs (Fig 2.7J), likely because the majority of LT HIV-specific CXCR5+ CD8+ T cells
displayed a residency phenotype, including high levels of CD69 (Fig 2.7K) and low
levels of CCR7 (Fig 2.7L). In addition, we found that LT HIV-specific CD8+ T cells more
commonly expressed a CD69+ CXCR5+ phenotype compared with LT CMV-specific
CD8+ T cells (Fig 2.7M). These data suggest that HIV-specific CXCR5+ are TRM and
induced due to preferential localization of HIV in B cell follicles.

Figure 2.8. tSNE analysis of LN and blood HIV-specific CD8+ T cells. tSNE plot
based on total LN and blood CD8+ T cells from one HIV+ donor. Clustering is based on
CCR7, CD45RO, CD69, CD103 and CXCR5 expression. LN/CD69+ CD8+ T cells
generate a unique memory cluster (green), while blood/CD69- cells generate an opposite
positioned memory cluster (red). The HIV-specific CD8+ T cells from LN and blood are
largely encompassed to either the green or red cluster respectively.
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HIV-specific CD8 TRM are enriched in LNs of ECs and are transcriptionally
distinct
Recent work has shown that LT CD8+ T cells suppress viral replication in SIV elite
controller rhesus macaques (Fukazawa et al., 2015). In human ECs, we found that the
majority of LN HIV-specific CD8+ T cells displayed a TRM phenotype (Fig 2.9A). Human
ECs also displayed higher LN/blood ratios of HIV-specific CD8+ T cells (Fig 2.9B), and
higher frequencies of HIV-tetramer+ CD69+ CD8+ T cells (Fig 2.9C), compared with other
HIV+ subjects. In HLA-B*5701+ ECs, we found that TRM selectively targeted
immunodominant HLA-B*5701-restricted epitopes, rather than immunodominant nonHLA-B*5701-restricted epitopes (Fig 2.9D).

Figure 2.9. ECs exhibit high frequencies of CD69+ HIV-specific CD8+ T cells in LNs.
(A) Representative flow cytometry plots of memory CD8+ T cells showing CD69
expression on HIV-tetramer+ cells in matched blood and LN samples from an HIV elite
controller (EC). (B) Relative distribution of HIV-specific CD8+ T cells in blood and LNs
from ECs (black) and other HIV+ subjects. (C) Magnitude of LN HIV
tetramer+ CD69+ CD8+ T cell responses in ECs and other HIV+ subject. (D) Magnitude of
LN HIV-tetramer+ CD69+ CD8+ T cell responses specific for immunodominant HLAB*5701-restricted and non-HLA-B*5701-restricted epitopes in ECs. Data points were
only included where both HLA-B*5701+ and HLA-B*5701− tetramers were tested to avoid
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analysis biases. Each dot represents a single tetramer+ response in all scatter plots.
Red: ART−; Orange: ART+. *P < 0.05; **P < 0.01.

We next index-sorted HLA-B*2705–restricted and/or HLA-B*5701– restricted Gagspecific CD8+ T cells from LNs and blood of two ECs and conducted single-cell RNA-seq
(scRNAseq) (Fig 2.10A). HIV-specific CD8+ T cells from LN and blood clustered
differentially in the single-cell space (Fig 2.10B). Immune-related pathways, including
interferon signatures, were higher in blood, whereas pathways related to maintenance of
cell location were higher in LNs, suggesting that both immunological and trafficking
properties distinguish the LN response from blood (Fig 2.10C). We next compared blood
versus LN CD69− HIV-specific CD8+ T cells and found that specific cytolytic genes and
pathways involved in lymphocyte degranulation were higher in blood (Fig 2.10D).
Cytolytic differences at the transcript level were not seen between blood and LN CD69+
HIV-specific CD8+ T cells (Fig 2.10F). Last, to assess whether residency was associated
with any specific functional gene signatures, we compared CD69− versus CD69+ HIVspecific CD8+ T cells in LNs (Fig 2.11). LN CD69+ HIV-specific CD8+ T cells were
enriched for cytolytic and effector-differentiated genes (Fig 2.11) and gene set
signatures (Fig 2.12), whereas LN CD69− HIV-specific CD8+ T cells demonstrated a lessdifferentiated phenotype instead (Fig 2.11 and 2.12). Together, these findings support
the concept that HIV-specific TRM represent the frontline effector defense in LTs.
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Figure 2.10. Index sorting strategy and scRNAseq analysis. (A) Gating strategy for
index sorting of LN and blood HIV-specific CD8+ T cells and purity of index-sorted HIVspecific CD8+ T cells. Memory cells were gated as non-CCR7hi non-CD95- to include
stem-cell memory T cells (TSCMs). (B) tSNE plot of single HIV-specific CD8+ T cells from
LN (blue) and blood (red) from ECs (n=2). The plot is based on the top 200 significant
genes differentially expressed between groups in the scRNAseq data set. (C) Significant
GSEAs of gene sets involved in immunological reactions and trafficking from LN versus
blood HIV-specific CD8+ T cells. (D) Violin plots and GSEAs for genes and gene sets
involved in cytolytic T cell responses from LN CD69- and blood HIV-specific CD8+ T cells.
(E) Leukocyte degranulation GSEA between LN CD69+ and blood HIV-specific CD8+ T
cells.
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Figure 2.11. LN HIV-specific CD69+ and CD69- are transcriptionally distinct. Singlecell RNA-seq (scRNAseq) was conducted on CD69+ and CD69− index sorted HLAB*2705-restricted and/or HLA-B*5701-restricted Gag-specific CD8+ T cells from LNs of
two ECs. The heat-map (left) illustrates the single-cell gene expression variability of
differentially expressed genes (P < 0.01) and violin plots (right) immune-related genes
differentially expressed between CD69+ and CD69− single HIV-specific CD8+ T
cells. *P < 0.05; **P < 0.01
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Figure 2.11. Gene set enrichment analysis (GSEA) between CD69+ and CD69- CD8+
T cells using the Gene Ontology (GO) and Immunological Signature database. The
size of circles indicates the number of genes in each gene set found to be enriched in a
subset. The color of the circles indicates the statistical significance of the enrichment.
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2.3 Discussion
TRM provide constant immunosurveillance and early protection against secondary
challenge in NLTs. Here, we show that CD8+ T cells with a TRM phenotype also
accumulate in LTs and dominate the LT CD8+ T cell response against HIV. Our key
findings were: (i) CD69+ CD8+ T cells are highly expanded in HIV-infected LNs; (ii) LT
CD69+ CD8+ T cells are largely not recently activated and instead bear transcriptional
and epigenetic signatures of TRM cells distinct from non-resident T cells in LTs; (iii) LT
CD69+ TRM do not recirculate to the blood via the thoracic duct; and (iv) LT CD69+ TRM
most often dominate the HIV-specific CD8+ T cell response in LNs. Moreover, we found
high magnitudes of LT HIV-specific TRM in ECs and demonstrate that CD69 expression
is closely linked to the distribution of HIV-specific clonotypes between LN and blood.
Collectively, these data advance our current understanding of immunosurveillance in
LTs and define that ongoing CD8+ T cell-mediated immunity against HIV in LTs is in part
mediated by TRM.
Previous studies have identified bona fide LT CD8+ TRM in mice (Schenkel et al., 2014),
but generally at low levels (Steinert et al., 2015), especially compared with the
frequencies of human LT CD69+ CD8+ T cells recently described by Farber and
colleagues (Sathaliyawala et al., 2013; Thome et al., 2014). These human studies have
generated some debate as CD69 expression may be triggered by brain death-induced
immune activation (Floerchinger et al., 2012). Our data show that high frequencies of
non-cycling CD69+ CD8+ T cells are indeed generally present in multiple human LTs,
and further show that LN CD69+ CD8+ T cells share many of the core transcriptomic
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signatures of NLT TRM (Hombrink et al., 2016b; Mackay et al., 2013; Pan et al., 2017). A
recent study confirmed that human spleen and lung CD69+ CD8+ T cells share several
prototypical genes of TRM (Kumar et al., 2017); however, this study was done on a bloodfiltering lymphoid organ (spleen) from brain-dead organ donors whereas our study solely
focused on LNs from alive subjects. As such, the genes that are differentially expressed
between CD69- and CD69+ CD8+ T cells are not entirely similar between our and the
data set derived from spleen (Kumar et al., 2017). Notably, similar to other studies in the
human TRM field, we do not find an association between residency in human LTs and the
murine TRM-associated transcription factor Hobit (Hombrink et al., 2016b; Pallett et al.,
2017). We also report the epigenetic structure of human LT CD8+ TRM; clear epigenetic
differences were apparent between the proximal regulatory regions of many genes in
CD8+ TRM versus non-TRM, including genes associated with cellular motility, migration,
adhesion, and function. Here, we indeed found OCRs for Blimp-1 that were more readily
detected, suggesting a potential role in TRM development (Mackay et al., 2016). These
results strongly support the notion that LT CD69+ cells are enriched for TRM.
Our data indicate that CD69 can be expressed on CCR7+ cells, including naïve-like cells,
whereas CD69+CCR7- cells usually represent bona fide TRM in both NLTs and LTs in
mice. We cannot formally exclude the possibility that CCR7+CD69+ could modulate
CD69 to exit LTs. Likewise, it remains unclear whether also CD103+CD69-CCR7+ CD8+
T cells originate from CD8+ TRM in LTs that modulate expression of CD69 and CCR7, or
if these cells represent a recirculating CD8+ T cell memory population transiently
observed both in LT and efferent lymph. Indeed, previous studies in KAEDE mice have
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identified CD103+CD69-CCR7+ migrating CD4+ T cells in both draining lymph nodes and
blood originating from the skin after photo-activation that share the same phenotype we
observed in both LT and TDL CD8+ T cells (Bromley, Yan, Tomura, Kanagawa, & Luster,
2013). One possible mechanism by which T cells can downregulate CD69 is through
extensive cycling, leading to increased KLF2 and S1PR1 expression (Rivera, Proia, &
Olivera, 2008). This concept aligns with our acute SIV infection data, which show that
CD69+ CD8+ T cell frequencies decline dramatically in LTs when antigen-specific T cells
reach a cycling plateau, however then accumulate progressively as LT SIV-specific
CD8+ T cells no longer cycle. It remains unclear whether these kinetic changes reflect
homeostatic expansion of the original population or the conversion of recirculating cells
into TRM. However, if all LT CD8+ TRM were free to transiently modulate CD69 and
equally recirculate, it would be difficult to explain the observed clonotypic disequilibrium
between LNs and blood in subjects with prominent HIV-specific CD8+ CD69+ responses.
Importantly, clonotypic disequilibrium has also been observed in LTs with high levels of
CD4+ TRM, such as in Peyer’s patches (Ugur, Schulz, Menon, Krueger, & Pabst, 2014).
Coupled with the lack of CD69+ cells in the thoracic duct and extensive expansion of
CD69+CCR7- cells in HIV infection, these data suggest that HIV-specific CD8+ T cells,
which mostly bear the CD69+CCR7- phenotype, become resident as a consequence of
local antigen exposure in LTs.
In light of the fact that CD8+ TRM are abundant in all human LTs, it seems plausible that
these cells serve as regional sentinels that scan all antigen-presenting cells originating
from areas that drain to their respective LNs. CD8+ TRM may therefore acquire unique
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population-level specificities as a function of pathogen exposure history within different
LNs. There are estimated to be at least 600 distinct LNs/LTs in the human body (Goroll,
May, & Mulley, 1987), without necessarily including ectopic/tertiary lymphoid structures
at mucosal sites (Ruddle, 2016) that can number in the thousands in the large intestine
alone (Langman & Rowland, 1986). HIV replicates actively in all of these tissues.
Accordingly, HIV-specific CD8+ T cell responses must be deployed to all LT sites at all
times to maintain overall control of viremia in HIV+ subjects. It should be noted in this
context that we only compared the clonal distribution of HIV-specific CD8+ T cells
between peripheral blood and a single LT site. In previous studies of peripheral blood,
we showed that individual CD8+ T cell clonotypes specific for the same viral antigen can
have distinct functional and phenotypic properties (Price et al., 2005). The observation
that residency status directly influences the anatomical distribution of HIV-specific CD8+
T cell clonotypes therefore has far-reaching implications for our understanding of
protective immune responses against HIV. First, our data indicate that HIV-specific CD8+
T cells in blood do not necessarily parallel HIV-specific CD8+ T cells in LTs. Second,
there may be distinct HIV-specific CD8+ TRM populations between different LTs, which
could impart differential immune pressure on viral replication at each site. Third, it
becomes clear that we need to develop a comprehensive understanding of the functional
abilities and potential deficiencies of LT HIV-specific TRM, because these cells exist in
continuous proximity to HIV-infected CD4+ T cells and likely spearhead the cellular
immune response against HIV. This view is supported by the observation that ECs
maintain high levels of HIV-specific TRM, despite low levels of viral replication in LTs.
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In summary, our data indicate that CD8+ TRM likely play a central role in
immunosurveillance against HIV. Further studies are now warranted to examine the
precise mechanisms through which LT CD8+ TRM control HIV replication, potentially
informing new approaches to the development of therapeutic vaccines and other
immunotherapeutic strategies designed to eliminate the viral reservoir in established HIV
infection.

2.4 Methods
Human samples
Lymph node (LN) biopsies, peripheral blood, and TDL were collected from individuals
classified as HIV– (n = 47), HIV+ chronic and naïve to ART (n = 35), HIV+ chronic on ART
(n = 19), HIV+ ECs (n = 9), and HIV+ acute/early seroconverters (Fiebig IV–VI; n = 8).
Recruitment occurred at four sites: INER-CIENI in Mexico City (HIV+ ART+/ART– blood
and matched cervical LNs); Case Western Reserve University (HIV– mesenteric LNs);
University of Pennsylvania (HIV– blood, spleen, iliac LNs, tonsils, and TDL; HIV+ blood,
iliac LNs, and TDL); and University of California, San Francisco (HIV+ EC inguinal LNs).
Subject grouping, tissue types, and clinical parameters are summarized in Table S1. All
participants enrolled in this study provided written informed consent as per protocols
approved by the INER-CIENI Ethics Committee and the Federal Commission for the
Protection against Sanitary Risk (COFEPRIS), and the Institutional Review Boards of the
University of Pennsylvania and Case Western Reserve University. HIV– LN and TDL
samples were obtained from following procedures/conditions: tonsils (non-enlarged
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tonsils from sleep apnea patients), mesenteric LNs (normal structures from patients
undergoing abdominal surgery), iliac LNs (normal structures from kidney transplant
donors), spleen (splenectomy due to trauma or surgical intervention), and TDL (patients
with chylopericardium and chylothorax due to trauma or idiopathic disease). Sample
sizes were based on the availability of biological samples rather than a pre-specified
effect size. Investigators were not blinded to group identity during the course of
experimentation.

Cells and tissues
Peripheral blood mononuclear cells (PBMCs) were purified from whole blood or
leukapheresis products using Ficoll-Hypaque density gradient centrifugation. Lymph
node mononuclear cells (LNMCs) and splenocytes were isolated using mechanical
disruption. PBMCs and LNMCs were cryopreserved and stored at –140°C.
TDL was accessed as described previously (G. Nadolski & Itkin, 2013; G. J. Nadolski &
Itkin, 2012). In short, a 25-gauge spinal needle was advanced into an inguinal LN under
ultra-sound guidance and an oil-based contrast agent (Ethiodol, Savage Laboratories)
was injected under fluoroscopic guidance at a rate of approximately 1 mL per
minute. After opacification of the cisterna chyli, access was gained via an anterior
transabdominal approach using a 21–22-gauge Chiba needle (Cook Medical Inc.). A
V18 control guide wire (Boston Scientific) was then advanced into the thoracic duct and
manipulated cephalad. Over the wire, a 60-cm 2.3F Rapid Transit microcatheter (Cordis
Corp.) was advanced further into the thoracic duct to aspirate TDL. Aspirated TDL was
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stored in heparin tubes and centrifuged over a Ficoll-Hypaque density gradient on the
same day to remove contrast agents. TDL samples were cryopreserved as described
above or used directly in flow cytometry experiments.

Conventional flow cytometry (FACS)
Human cryopreserved PBMCs, LNMCs, and TDL samples were thawed and rested in
RPMI-1640 media supplemented with 10% FBS, 1% L-glutamine, and 1%
penicillin/streptomycin for at least 1 hour. Cells were then washed with PBS and prestained for chemokine receptors and adhesion molecules at 37oC for 10 minutes. After
staining with LIVE/DEAD Aqua (Invitrogen) for 10 minutes, an optimized antibody
cocktail was added for a further 20 minutes to detect additional surface markers. Cells
were then washed with FACS buffer (PBS containing 0.1% sodium azide and 1% BSA),
fixed, and permeabilized using a Cytofix/Cytoperm Buffer Kit (BD Biosciences) or a
FoxP3 Transcription Factor Buffer Kit (eBioscience). An optimized antibody cocktail was
then added for 1 hour to detect intracellular markers. In the relevant experiments,
tetramers were added for 10 minutes at room temperature immediately before pre-stain.
Stained cells were fixed in PBS containing 1% paraformaldehyde (Sigma-Aldrich) and
stored at 4oC. All samples were acquired within 3 days using an LSRII (BD
Biosciences). Data were analyzed with FlowJo software (version 9.8.8 or higher,
TreeStar). The gating strategies are depicted in the relevant figures.
For sorting experiments, thawed and rested PBMCs and/or LNMCs or fresh splenocytes
were stained in 15-mL conical tubes following the procedure described above with
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higher concentrations of antibodies (i.e. not diluted 1:50 in FACS buffer). Cells were then
washed with PBS and suspended in RPMI-1640 media without phenol red. All sorting
experiments were carried out using a FACSAriaII (BD Biosciences).
The following antibodies were used for human FACS experiments: anti-CCR7 APC- Cy7
(clone G043H7, BioLegend), anti-CD49a PE-Cy7 (clone TS2/7, BioLegend), antiCXCR6 BV421 (clone K041E5, BioLegend), anti-CX3CR1 PE (clone 2A9-1, BioLegend),
anti-CCR5 BV650 (clone 3A9, BD Biosciences), anti-CXCR3 BV711 (clone G025H7,
BioLegend), anti-CD14 BV510 (clone M5E2, BioLegend), anti-CD19 BV510 (clone
HIB19, BioLegend), anti-CD3 AF700 or APC-R700 (clone UCHT1, BD Biosciences),
anti-CD3 (clone UCHT1, BioLegend), anti-CD4 PeCy5.5 (clone S3.5, Invitrogen), antiCD8a BV570, BV605, BV711, or BV785 (clone RPA-T8, BioLegend), anti-CD27 AF700,
BV650 or BV785 (clone O323, BioLegend), anti-CD45RO BV650 or PE-CF594 (clone
UCHL1, BD Biosciences), anti-CD45RA BV650, PE or PE-CF594 (clone HI100, BD
Biosciences), anti-CD69 BV421 or PE-Cy5 (clone FN50, BioLegend), anti-CD69 PE-Cy5
(clone TP1.55.3, Beckman Coulter), anti-CD103 BV605 or PE-Cy7 (clone Ber-ACT8,
BioLegend), anti-CD52 FITC (clone HI186, BioLegend), anti-CXCR5 AF488 or AF647
(clone RF8B2, BD Biosciences), anti-PD-1 BV421 or PE (clone EH12.2H7, BioLegend),
anti-HLA-DR BV605 or BV650 (clone G46-6, BD Biosciences), anti-CD38 APC or BV711
(clone HIT2, BioLegend), anti-CD25 PE (clone M-A251, BD Biosciences), anti-4-1BB
BV421 (clone 4B4-1, BioLegend), anti-OX40 APC (clone ACT35, BD Biosciences), antiICOS PE-EF610 (clone ISA-3, eBioscience), anti-PD-L1 BV785 (clone 10F.9G2,
BioLegend), anti-CD95 BB515 (clone DX2, BD Biosciences), anti-IFNγ Alexa700 (clone
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B27, Invitrogen), anti-TNF PE-Cy7 (clone MAb11, BD Biosciences), anti-perforin BV421
or PE-Cy7 (clone B-D48, BioLegend), anti-perforin PE- Cy7 (clone dG9, eBioscience),
anti-granzyme B Alexa700 (clone GB11, BD Biosciences), anti-T-bet PE (clone 4B10,
eBioscience), anti-T-bet PE-Dazzle 594 (clone 4B10, BioLegend), anti-Eomes AF647
(clone WD1928, eBioscience), and anti-Ki67 FITC (clone B56, BD Biosciences).
LIVE/DEAD Aqua (Invitrogen) was used to discriminate dead cells.

Tetramers
MHC class I tetramers conjugated to PE or BV421 were used to detect CD8+ T cells
specific for HIV-SLYNTVATL (SL9)/HLA-A*0201, HIV-ILKEPVHGV (IV9)/HLA-A*0201,
HIV-FLGKIWPSHK (FK10)/HLA-A*0201, HIV-TLNAWVKVV (TV9)/HLA-A*0201, HIVNLVPMVATV (NV9)/HLA-A*0201, HIV-RYPLTFGW (RW8)/HLA-A*2402, HIVKYKLKHIVW (KW9)/HLA-A*2402, HIV-GPGHKARVL (GL9)/HLA-B*0702, HIVHPRVSSEVHI (HI10)/HLA-B*0702, HIV-SPAIFQSSF (SM9)/HLA-B*0702, HIVKRWIILGLNK (KK10)/HLA-B*2705, HIV-KAFSPEVIPMF (KF11)/HLA-B*5701, HIVTSTLQEQIGW (TW10)/HLA-B*5701, HIV-ISPRTLNAW (ISW9)/B*5701, and HIVQASQEVKNW (QW9)/HLA-B*5701. All fluorochrome-conjugated peptide-HLAmonomers were received from the NIH Tetramer Core Facility at Emory University or as
gifts from Dr. David Price. All monomers were produced and tetramerized as previously
described (Price et al., 2005).
SIV-TTPESANL (Tat-TL8)/Mamu A*01 APC conjugated tetramers and SIV-CTPYDINQM
(Gag-CM9)/Mamu A*01 monomers were supplied by the NIH Tetramer Core Facility at
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Emory University. Gag-CM9 Mamu A*01-BV421 tetramers were prepared in our
laboratory as previously described (Price et al., 2005).

Kinetics of CD69 expression
Memory CD69– and CD69+ CD8+ T cells were isolated from LTs using a FACSAriaII
(BD Biosciences). Cells were then cultured for 9 days in 96-well plates in the presence
or absence of 10 ng/mL rhIL-7 (R&D Systems).

CCL19/21 stimulations
Memory CD69– and CD69+ CD8+ T cells were isolated from LTs using a FACSAriaII (BD
Biosciences). Cells were then cultured for up to 9 days in 96-well plates in the presence
or absence of 100 ng/mL rhCCL19 and 100 ng/mL rhCCL21 (R&D Systems).

Bulk RNA sequencing (RNA-seq)
Memory CD69– and CD69+ CD8+ T cells from MesLNs (250 cells per subset) were
sorted using a FACSAriaII (BD Biosciences) directly into lysis buffer provided with the
SMART-Seq v4 Ultra Low Input RNA Kit (Takara) and snap frozen. RNA-seq libraries
were prepared using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara) according to
manufacturer’s protocols. Briefly, 3’ SMART-Seq CDS (oligo-dt) Primers were hybridized
to the poly(A) tail of all the mRNA and reverse transcribed with the SMARTScribe RT
enzyme. cDNA was pre-amplified using SeqAmp DNA polymerase and frozen. Amplified
material was purified using Agencourt AMPure XP beads (Beckman) and cDNA quantity
was assessed on a Qubit 3.0 (Thermo) and fragment size was evaluated on a 2100
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BioAnalyzer (Agilent). The PCR products were next indexed using the Nextera XT DNA
Library Prep Kit (Illumina) according to manufacturer’s protocol. Briefly, products were
tagmented using the Amplicon tagment mix, containing Tn5 transposase, and indexed
using Nextera index 1 (i7) and index 2 (i5) primers. The libraries were again cleaned-up
with Agencourt AMPure XP beads, pooled, quantified and sequenced across 75 base
pairs (bp) using a paired-end strategy with a 150-cycle high output flow cell on a
NextSeq 550 (Illumina). Three biological replicates were sequenced per experiment.
Fastq files from three sequencing runs were concatenated and aligned using STAR
2.5.2a and hg38 to generate a final unique paired mapped read depth ranging from 8
million to 13.6 million reads per sample. The aligned files were normalized using Deseq2
(Love, Huber, & Anders, 2014).

Bulk RNAseq analysis
Differential expression analysis - Differentially expressed genes on normalized RNA-seq
counts between LN CD69– and CD69+ CD8+ T cells were assessed using a t-test (P <
0.05) with the R limma package (v3.28.21). Genes of interest were then submitted to
ingenuity pathway analysis (IPA, Qiagen Bioinformatics) to identify overrepresented
pathways and upstream predictors. Differentially expressed genes with a larger than 2fold difference between LN CD69– and CD69+ CD8+ T cells were visualized using the
Pheatmap package in R (v. 1.0.8).
Gene set enrichment analysis (GSEA) - Normalized RNA-seq counts from sorted LN
CD69– and CD69+ CD8+ T cells were subjected to GSEA (Subramanian et al., 2005)
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using Broad Institute software (http://www.broadinstitute.org/gsea/index.jsp). Gene
signatures from LN CD69– and CD69+ CD8+ T cells were compared with gene signatures
indicative of lung TRM programs (Hombrink et al., 2016b).

ATAC sequencing (ATAC-seq)
ATAC-seq was performed as described previously with minor modifications (Buenrostro,
Giresi, Zaba, Chang, & Greenleaf, 2013). Memory CD69– and CD69+ CD8+ T cells from
hepLNs (30,000–50,000 cells per subset) were sorted using a FACSAriaII (BD
Biosciences) directly into R10 media. Cells were pelleted, washed with PBS, and treated
with lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA630). Nuclear pellets were resuspended in a transposition reaction with Tn5 transposase
(Illumina) for 30 minutes to tag and fragment accessible chromatin, and the reaction was
incubated in a water bath at 37ºC. Tagmented DNA was purified using a MinElute
Reaction Cleanup Kit (Qiagen) and amplified using PCR. Libraries were then purified
using a QIAQuick PCR Purification Kit (Qiagen) and paired-end sequenced (38bp +
37bp) on a NextSeq 550 (Illumina). Two biological replicates were sequenced per
experiment.

Single-cell RNA sequencing
Single-cell clonotypic analysis was derived from a previously published method (63). In
brief, single HIV-tetramer+ cells were index sorted using a FACSAria II (BD Biosciences)
directly into 96-well microtiter plates containing lysis buffer. In total, 552 cells were
sorted, and full genome was sequenced from 221 cells. Cellular nucleic acids were
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recovered by processing the lysates with an RNEasy Plus Micro Kit (Qiagen) and then
binding to RNAClean (SPRI) beads (Beckman Coulter). ERCC RNA control (Ambion)
was diluted 1 in 107 from stock, and 10% by volume was added to the RNAClean beads
prior to purification. mRNA was then reverse transcribed from an anchored oligo-dT
primer that includes a universal priming site at the 5’ end. RT reactions also included a
template-switch oligonucleotide to allow the incorporation of the universal priming site at
cDNA 3’ ends. Whole transcriptome cDNA was then amplified by PCR for 22–24 cycles
using universal priming sites primers and Kapa HiFi Hot Start ReadyMix. After post-PCR
clean-up, amplified whole transcriptome cDNA was incorporated into barcoded Illumina
Nextera libraries and sequenced to a depth of about 2 million 150bp paired-end
reads/cell on a HiSeq 4000 (Illumina).

Single-cell RNAseq analysis
Data were initially filtered for quality. Paired-end sequencing reads were then trimmed to
remove adaptor sequences and low-quality basecalls using the utility Trimmomatic.
Reads were subsequently aligned using Bowtie against a genomic repeat element
database derived from RepeatMasker software to quantify and remove transcript reads
considered to be irrelevant for the analysis in hand (rRNA, rRNA, LINEs, SINEs, etc).
The remaining reads were aligned against the most recent human genome build, hg38,
using the splice-site aware aligner, STAR. As a bioinformatic measure of library quality,
the total frequency of reads that could be mapped to the transcriptome was determined,
and outliers were excluded from further analysis. Transcripts were then quantified and
normalized using the bioinformatics package, Cufflinks. In our experience, a small
81

number of libraries display low complexity and lack expression of highly expressed
housekeeping genes. In most systems, a set of housekeeping genes should be
expressed in every cell. We therefore use qPCR to identify viable samples expressing
two distinct housekeeping genes. Samples with low or no expression of these genes are
removed from Nextera library construction. To further ensure exclusion of data from
single cells for which library construction was unsuccessful, we determined diversity
(Shannon entropy and count of detected genes) using the R package, Vegan, and
discarded outliers.
For differential gene expression analysis of CD69- and CD69+ HIV-specific CD8+ T
cells, raw counts were normalized using the R package, SCnorm. The normalized data
was then transformed using z-transformation and analyzed for differential expression
using the R package, ROTS.
For gene set enrichment analysis (GSEA), normalized single cell RNAseq counts from
were subjected to GSEA using Broad Institute software
(http://www.broadinstitute.org/gsea/index.jsp).

General statistical analysis
Mann-Whitney or unpaired t-tests were used to compare differences between
unmatched groups, and Wilcoxon matched-pairs single rank or paired t-tests were used
to compare differences between matched samples. Spearman or Pearson tests were
used for correlation analyses. Non-parametric or parametric tests were conducted based
on normal distribution of the data points (Shapiro-Wilk normality test). All analyses were
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performed using R studio or Prism v7.0 (GraphPad). Cell ACCENSE (Automatic
Classification of Cellular Expression by Nonlinear Stochastic Embedding) analyses were
conducted to visualize phenotypic relationships within multivariate data sets (Shekhar,
Brodin, Davis, & Chakraborty, 2014).

83

CHAPTER 3: CD8+ T CELLS DISPLAY DISTINCT
TRANSCRIPTIONAL AND FUNCTIONAL SIGNATURES
ASSOCIATED WITH ELITE CONTROL OF HIV IN LYMPHOID
TISSUES
This chapter is presented as a reprint (with permission) of the article titled “Elite control of HIV is
associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells ”
by Nguyen S, Deleage C, Darko S, Ransier A, Truong D, Agarwal D, Sada Japp A, Wu VH, KuriCervantes L, Abdel-Mohsen M, Del Rio Estrada PM, Ablanedo-Terrazas Y, Gostick E, Price DA,
Hoxie JA, Naji A, Reyes-Terán G, Estes JD, Douek DC, Deeks SG, Buggert M, Betts MR.
Science Translational Medicine. 2019 Dec 18, 11(523), eaax4077.
doi:10.1126/scitranslmed.aax4077
Son Nguyen was directly involved with data collection and/or analysis of all experiments

3.1 Introduction
It is established that virus-specific CD8+ T cells are critical determinants of the EC
phenotype in humans and rhesus macaques (Deeks & Walker, 2007; Fukazawa et al.,
2015). In addition, HIV-specific CD8+ T cells in ECs are qualitatively distinct from HIVspecific CD8+ T cells in chronic progressors (CPs), typically displaying enhanced
polyfunctionality (Almeida et al., 2007; Betts et al., 2006), cytolytic activity (Hersperger et
al., 2010; Migueles et al., 2002; Migueles et al., 2008), and proliferative capacity
(McKinnon et al., 2012; Migueles et al., 2002), as well as a more differentiated memory
phenotype and a distinct immunodominance profile (Addo et al., 2007; Almeida et al.,
2007; Goulder et al., 1997; Migueles et al., 2000). These attributes have been
documented primarily among circulating lymphocytes, however, whereas HIV replication
occurs predominantly in lymphoid tissues (Pantaleo et al., 1991; Pantaleo et al., 1993;
Pantaleo et al., 1994; Perreau et al., 2013).
84

Lymphoid tissues are major reservoir sites for HIV. Recent studies have further
demonstrated that almost 99% of viral RNA (vRNA)+ cells in SIV-infected rhesus
macaques occur in lymphoid tissues (J. D. Estes et al., 2017), reinforcing the need to
understand anatomically colocalized mechanisms of immune control. It has long been
known that circulating CD8+ T cells are more cytolytic than CD8+ T cells in the lymphoid
tissues of donors infected with HIV (Andersson et al., 1999). Moreover, a state of
immune privilege exists in lymphoid tissues, which limits immunosurveillance by cytolytic
HIV-specific CD4+ and CD8+ T cells (Buggert, Nguyen, McLane, et al., 2018; Reuter et
al., 2017). In conjunction with the identification of distinct lymphoid tissue-resident
memory CD8+ T cell subsets (Buggert, Nguyen, Salgado-Montes de Oca, et al., 2018;
Kumar et al., 2017; Woon et al., 2016), these observations suggest that HIV-specific
CD8+ T cells limit viral replication in lymphoid tissues via effector mechanisms that differ
from those used by circulating HIV-specific CD8+ T cells (Buggert, Nguyen, SalgadoMontes de Oca, et al., 2018). It also seems reasonable to propose that non-cytolytic
suppression rather than cytolytic eradication dictates effective immune control of HIV,
given reports of ongoing viral evolution (Mens et al., 2010; O'Connell et al., 2010) and
the presence of replication-competent viral strains in ECs (Blankson et al., 2007).
However, this proposition remains unproven to date, because previous studies have not
defined the antiviral efficacy and functional characteristics of HIV-specific CD8+ T cells in
the lymphoid tissues of ECs.
In this study, we used a variety of methodological approaches, including polychromatic
flow cytometry and single-cell RNA sequencing (scRNAseq) analyses, to compare the
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functional and transcriptional properties of HIV-specific CD8+ T cells in the peripheral
blood and lymph nodes (LNs) of ECs and CPs. Our findings demonstrate that immune
control of viral replication is associated with the occurrence of polyfunctional HIV-specific
memory CD8+ T cells that exhibit a weak cytolytic signature and preferentially home to B
cell follicles in the LNs of ECs.

3.2 Results
CD8+ T cells actively suppress HIV replication in the LNs of ECs
To define the nature of protective CD8+ T cell responses in LNs, where HIV replicates in
vivo, we obtained tissue biopsies (cervical, iliac, inguinal, mesenteric, pelvic, or
peribronchial LNs) and fine needle aspirates (inguinal LNs) from HIV+ individuals on
antiretroviral therapy (ART) and untreated HIV+ individuals categorized as acute
seroconverters, ECs, or CPs (Table 3.1). Extremely low numbers of vRNA+ cells were
detected in the LNs of ECs compared with the LNs of CPs (p = 0.0174; Fig. 3.1A). In line
with previous findings (Boritz et al., 2016), vRNA+ cells were visualized in the B cell
follicles and the paracortical region (T cell zone) (Fig. 3.2). Total CD4+ T cell-associated
HIV DNA and RNA measurements were also lower in the LNs of ECs compared with the
LNs of CPs (p = 0.0428 and p = 0.0016, respectively; Fig. 3.1B), and CD8+ T cells from
the LNs of ECs displayed greater efficacy in a modified viral suppression assay (SaezCirion, Shin, Versmisse, Barre-Sinoussi, & Pancino, 2010) compared with CD8+ T cells
from the LNs of CPs (p = 0.0224) and CD8+ T cells from the LNs of HIV+ individuals on
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ART (p = 0.0323; Fig. 3.1C). These results suggest that CD8+ T cells maintain active
control of HIV replication in the LNs of ECs.
Table 3.1. Clinical characteristics of donors included in the study. Estimated
duration of disease was based on the date of first HIV+ test (self-reported for EC and
ART or clinically tested for CP and Acute) and the date of specimen collection. For the
CP and Acute groups, patients did not present any symptoms of an acute infection and
the status was confirmed with PCR, Western blot, and ELISA (in conjunction with clinical
status for the Acute group). Values represent median and interquartile range.
EC

ART

CP

Acute (Fiebig IV-VI)

12

14

18

7

Site

San Francisco
(USA)

San Francisco
(USA)
Philadelphia
(USA)
Mexico City
(Mexico)

Mexico
City
(Mexico)

Mexico City
(Mexico)

Age

52
(47-59)

40
(32-58)

31
(24-37)

23
(20-27)

Gender

10 Males / 1
Female / 1 Male
to Female

8 Males / 1
Female / 5 No
Info

10 Males /
1 Female
/ 7 No Info

7 Males / 0 Female

Protective
HLA Alleles
(HLAB*27/B*57)

4 Yes/ 3 No / 5
No Info

0 Yes / 7 No
/7 No Info

0 Yes /12
No / 6 No
Info

No Info

Estimated
Duration of
Disease
(months)

198
(120-321)

156
(24-140)

2
(0.6-7.7)

0.5
(0.2-0.8)

Viral Load
(copies/mL)

<40

<40

51,396
(12,845213,173)

1,996,027
(1,297,4614,421,034)

CD4 Count
(cells/μL)

903
(657-1542)

544
(359-601)

348
(175-521)

306
(238-370)

Number

87

Figure 3.1. CD8+ T cells from the LNs of ECs display superior antiviral efficacy. (A)
Representative RNAscope images of paraffin-embedded lymph node (LN) biopsies from
one EC and one CP (left) and data quantification (right). TCZ, T cell zone; BCF, B cell
follicle. Elite controllers (EC): n = 7, ART-treated individuals (ART): n = 10, chronic
progressors (CP): n = 11. (B) Quantification of cell-associated HIV DNA and RNA from
negatively-selected LN CD4+ T cells by qPCR. One data point on the DNA plot was
adjusted from 0 to 1 to display on the log scale. Error bars represent median and
interquartile range. EC: n = 5, CP: n = 8. (C) Representative flow plots from a viral
suppression assay using LN-derived CD8+ T cells co-cultured with autologous LNderived CD4+ T cells infected with HIV BAL virus in vitro (left) and data quantification
(right). Dotted lines represent median and interquartile range. EC: n = 4, ART: n = 8, CP:
n = 6. Flow cytometry data were pre-gated on single live CD8- T cells. Significance was
determined using the Kruskal-Wallis test with Dunn’s correction (A), an unpaired t-test
(B), or Welch’s ANOVA with Benjamini-Hochberg correction (C). * p < 0.05, ** p < 0.01.
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Figure 3.2. HIV RNA is present in B cell follicles and the T cell zone in LNs. (A)
Gating scheme used to sort LN-derived CD4+ T cell subsets for viral quantification.
Representative flow plots were generated from the LNs of one EC. (B) Quantification of
HIV RNA in LN-derived CD4+ T cell subsets by qPCR. The limit of detection value was
used in the absence of detectable HIV RNA (open circles). EC: n =. , ART: n = 2, CP: n
= 2. (C) Frequency distribution of vRNA+ cells in B cell follicles (BCF) and T cell zone
(TCZ). (D) Percent frequency of vRNA+ cells in B cell follicles, as determined by
RNAscope. EC: n = 7, ART: n = 10, CP: n = 11. Error bars represent mean and SEM (B)
or median and interquartile range (C). Significance was determined using a two-way
ANOVA (B) or the Kruskal-Wallis test with Dunn’s correction (C). ** p < 0.01, *** p <
0.001.
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Cytolytic CD8+ T cells are rare in LNs of ECs
In peripheral blood, the frequency of cytolytic HIV-specific CD8+ T cells, defined by
expression of perforin and granzyme B, correlates inversely with plasma viral load (pVL)
(Hersperger et al., 2010; Migueles et al., 2002; Migueles et al., 2008). We therefore
hypothesized that enhanced CD8+ T cell-mediated cytolytic activity may underlie viral
control in the LNs of ECs. However, lower frequencies of perforin+, granzyme B+, and
perforin+ granzyme B+ memory CD8+ T cells were detected in the LNs of ECs compared
with the LNs of CPs (p = 0.0001, p = 0.0025, and p = 0.0003, respectively; Fig. 3.3A and
Fig. 3.4A and B). The frequency of perforin+ granzyme B+ memory CD8+ T cells also
correlated positively with pVL (r = 0.8213, p < 0.0001; Fig. 3.3B). Importantly, perforin
and granzyme B were broadly expressed among circulating memory CD8+ T cells in
donor-matched samples from ECs, indicating that the non-cytolytic phenotype was
restricted to LNs (Fig. 3.4C). Immunohistochemical analyses confirmed that fewer
perforin+ CD8+ T cells, but not granzyme B+ CD8+ T cells, were present in the LNs of
ECs compared with the LNs of CPs (Fig. 3.3C and D).
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Figure 3.3. Cytolytic CD8+ T cells are rare in the LNs of ECs. (A) Representative
flowplots showing perforin and granzyme B expression in LN memory CD8+ T cells (left)
and data quantification (right). EC: n = 13, ART: n = 11, CP: n = 13, acutely-infected
individuals (acute): n = 7. (B) Correlation between the frequency of perforin+ granzyme
B+ LN memory CD8+ T cells and plasma viral load (pVL). Values for pVL below the limit
of detection were plotted as 40 copies/mL. Significance was determined using
Spearman’s rank correlation. (C) and (D) Representative immunohistochemistry images
of LN biopsies (left) stained for perforin (C) or granzyme B (D) and data quantification
across donor groups (right). EC: n = 5, ART: n = 9, CP: n = 14. (E) Representative flow
plots showing HIV-specific tetramer staining of LN memory CD8+ T cells (left) and data
quantification (right). Each data point represents a distinct tetramer+ population. (F)
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Representative flow plots showing HIV-specific tetramer+ cells (colored contours)
overlaid on total LN memory CD8+ T cells (grey background) gated to display perforin
and granzyme B expression (left) and data quantification (right). Each data point
represents a distinct tetramer+ population. EC: n = 25, ART: n = 6, CP: n = 8. (G)
Representative flow plots of redirected killing assays (left) and data quantification (right).
Data was pre-gated on single live TFL4+ cells. Flow cytometry data, except in (G), were
pre-gated using scheme shown in fig. S2A. Significance was determined using the
Kruskal-Wallis test with Dunn’s correction (A, C, D, E, F, H, I, and K) or a two-way
ANOVA (G). * p < 0.05, ** p < 0.01, *** p < 0.001.
We then used human leukocyte antigen (HLA) class I-matched tetramers to examine
HIV-specific CD8+ T cells. Higher frequencies of tetramer+ CD8+ T cells were present in
the LNs of ECs compared with the LNs of CPs (p = 0.04; Fig. 3.3E). However, a very
low frequency of HIV-specific CD8+ T cells expressed perforin and granzyme B,
especially in the LNs of ECs (Fig. 3.3F). In response to cognate peptide stimulation,
HIV-specific CD8+ T cells from the LNs of ECs also failed to upregulate either perforin or
granzyme B, unlike CD8+ T cells paired by donor and specificity from the peripheral
blood of ECs (Fig. 3.5A). Moreover, CD8+ T cells from the LNs of ECs did not exhibit
discernable expression of perforin or granzyme B after 3 days in culture with HIVinfected CD4+ T cells from the same LNs (Fig. 3.5B).
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Figure 3.4. Fewer CD8+ T cells from the LNs of ECs express perforin and granzyme
B. (A) Gating scheme used in flow cytometry experiments. Representative plots were
generated from the LNs of one EC. Flow cytometry data shown in this report were pregated on memory CD8+ T cells unless specified otherwise. (B) Quantification of perforin
and granzyme B expression in LN-derived CD8+ T cells across donor groups. (C)
Representative flow plots showing perforin and granzyme B expression in matched
peripheral blood and LN-derived CD8+ T cells from one EC (left) and data quantification
across donor groups (right). EC: n = 13, ART: n = 11, CP: n = 13. Significance was
determined using the Kruskal-Wallis test with Dunn’s correction (B) or the Wilcoxon
matched pairs signed rank test (C). * p < 0.05, ** p < 0.01, *** p < 0.001.
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To quantify rather than infer cytolytic activity, we performed ex vivo redirected killing
assays based on the detection of active caspase 3, which reliably identified non-viable
target cells (Fig. 3.6A and B). In contrast to circulating CD8+ T cells, donor-matched
CD8+ T cells from the LNs of ECs largely failed to kill P815 mastocytoma target cells precoated with a CD3-specific monoclonal antibody, which mimics signals delivered via the
T cell receptor (Fig. 3.3G). A similar anatomical discrepancy was observed using paired
samples from CPs (Fig. 3.3G). Moreover, no significant increases in target cell death
were observed after extended incubation (24 hours), ruling out the involvement of
temporally delayed killing mechanisms (Fig. 3.6B).
Collectively, these data suggest that cytolytic activity is unlikely the major mechanism of
protection byCD8+ T cells in the LNs of ECs.
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Figure 3.5. CD8+ T cells from the LNs of ECs do not upregulate cytolytic molecules
in response to cognate antigen exposure. (A) LNMCs were stimulated for 6 hours
with peptides representing optimal epitopes derived from HIV. Perforin and granzyme B
were quantified in HIV-specific CD8+ T cells. Colored dots in the representative flow plots
(left) depict HIV-specific CD8+ T cells defined by the expression of at least one of the
following markers: CD107a, IFNg, TNF, MIP-1b, or IL-2. Black and red numbers indicate
the frequency of HIV-specific CD8+ T cells before and after background subtraction,
respectively. Background was the unstimulated condition. EC: n = 18, ART: n = 5, CP: n
= 19. (B) Frequency of LN-derived perforin+ granzyme B+ CD8+ T cells after 3 days in
culture with HIV-infected autologous LN-derived CD4+ T cells, as shown in Fig. 1c. EC:
n = 4, CP: n = 6. Significance was determined using the Kruskal-Wallis test with Dunn’s
correction (A) or an unpaired t-test (B). * p < 0.05.
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Figure 3.6. Active caspase-3 detection captures the majority of killed target cells.
CD8+ T cells isolated from the LNs, tonsils, and peripheral blood of HIV– individuals were
incubated with anti-CD3-coated P815 cells at an target:effector ratio of 1:6 for 4 or 24
hours. (A), Representative flow plots showing the detection of killed target cells via
active caspase 3 versus LIVE/DEAD Aqua (L/D Aqua). Numbers represent frequencies
of cells in each gate before (blue) or after background subtraction (red). (B) Breakdown
of the total killing after 4 hours. Casp, active caspase-3. Each pie chart represents total
killing after background subtraction. (C) Summary plot of redirected killing assays at 4
hours and 24 hours. % target killed represents the sum of Casp–Aqua+, Casp+Aqua+, and
Casp+Aqua– after background subtraction. LN: n = 2, Tonsil: n = 4, Blood: n = 4. Error
bars represent mean and SEM. Significance was determined using a two-way ANOVA
(C). n.s., not significant.
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CD8+ T cells in LNs of ECs displayed increased follicle-homing potential
B cell follicles are thought to represent immunoprivileged sites that potentiate HIV
persistence as a consequence of limited immunosurveillance by CD8+ T cells (Connick
et al., 2014; Connick et al., 2007; Folkvord et al., 2003; Folkvord et al., 2005; Fukazawa
et al., 2015). Previous studies have also demonstrated an inverse correlation between
the frequency of follicle-homing (CXCR5+) CD8+ T cells and pVL (Li et al., 2016;
Rahman et al., 2018; Reuter et al., 2017). In line with these findings and the relative
absence of vRNA+ cells in the B cell follicles of ECs (Fig. 3.2C and D), we detected
higher frequencies of CXCR5+ memory CD8+ T cells in the LNs of ECs compared with
the LNs of CPs (p = 0.0288; Fig. 3.7A). No increased frequencies were observed for
HIV-specific CXCR5+ CD8+ T cells (p = 0.124; Fig. 3.7B). However, perforin and
granzyme B were typically expressed at higher frequencies among CXCR5– CD8+ T
cells compared with CXCR5+ CD8+ T cells, reaching significance in the ART cohort (p =
0.0026, Fig. 3.7C).
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Figure 3.7. CD8+ T cells in LNs of ECs display increased follicle-homing potential.
(A) Representative flow plots showing CXCR5 expression on LN-derived memory CD8+
T cells (left) and data quantification across donor groups (right). EC: n = 12, ART: n = 9,
CP: n = 8. (B) Quantification of CXCR5 expression on LN tetramer+ memory CD8+ T
cells. Each data point represents a distinct tetramer+ population. EC: n = 26, ART: n = 6,
CP: n = 8. (C), Representative flow plots showing perforin and granzyme B expression in
LN-derived CXCR5+ and CXCR5– memory CD8+ T cells (left) and data quantification
(right). Error bars represent median and interquartile range. EC: n = 12, ART: n = 9, CP:
n = 8. Significance was determined using the Kruskal-Wallis test with Dunn’s correction
(A, B, and C). * p < 0.05, ** p < 0.01, *** p < 0.001.

HIV-specific CD8+ T cells have a distinct transcriptional profile in the LNs of ECs
To identify potential correlates of viral control in lymphoid tissues, we analyzed the
transcriptomes of resting HIV-specific CD8+ T cells from the LNs of ECs and CPs (Fig.
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3.8A). The scRNAseq data were initially processed using an unsupervised kernel-based
algorithm to determine cellular similarity in a global manner (see Methods). Clusters of
transcriptionally distinct cells were present in each donor group (Fig. 3.8B). Importantly,
normalized expression of PRF1 and GZMB was lower in HIV-specific CD8+ T cells from
the LNs of ECs compared with HIV-specific CD8+ T cells from the LNs of CPs (Fig.
3.8C), and normalized expression of transcripts encoding other cytolytic molecules,
including GZMA, GZMH, GZMK, GZMM, FASL, and TNFSF10 (Russell & Ley, 2002;
Voskoboinik et al., 2015), was either comparable between groups or enriched in HIVspecific CD8+ T cells from the LNs of CPs compared with HIV-specific CD8+ T cells from
the LNs of ECs (Fig. 3.8C).
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Figure 3.8. Distinct transcriptomic signatures characterize HIV-specific CD8+ T
cells from the LNs of ECs and CPs. (A) Set-up of the scRNAseq experiment, including
data exclusion criteria. (B) tSNE visualization of the unsupervised kernel-based
algorithm. (C) Violin plots of cytolysis-related genes showing z-normalized expression.
(D) Average percent error of k-fold cross-validation of support vector machine (SVM)
models using subsets of the L0-norm-ranked gene list. Each cross-validation was
reiterated 100 times. (E) Heatmap showing z-normalized expression of the 200 feature
genes. (F) Gene ontology (GO) analysis of the feature gene list using topGO. The top 25
enriched terms were reported, and p-values were calculated using the classic Fisher
method. (G) tSNE feature plots showing the distribution of gene expression. tSNE
coordinates were calculated using the first 50 principal components and iterated 1,000
times. The color gradient displays relative log-normalized gene expression. Significance
was determined using scDD calculations (C and G). * p < 0.05, ** p < 0.01, *** p < 0.001.

We then applied a supervised machine-learning algorithm to determine which transcripts
best characterized HIV-specific CD8+ T cells from the LNs of ECs and HIV-specific
CD8+ T cells from the LNs of CPs (see Methods). A set of 200 genes reliably
distinguished each donor group (average error < 0.5%) (Fig. 3.8D). Hierarchical
clustering of these ‘feature’ genes clarified the key inter-group differences (Fig. 3.8E),
most of which could be assigned to immune response pathways via gene ontology (GO)
analysis (Fig. 3.8F), and t-Distributed Stochastic Neighbor Embedding (tSNE)
visualization generated two distinct clusters of HIV-specific CD8+ T cells that clearly
differentiated ECs from CPs (Fig. 3.8G). Overlaying transcript abundance of specific
‘feature’ genes onto the tSNE plot further revealed that HIV-specific CD8+ T cells from
the LNs of CPs preferentially expressed inhibitory receptors, such as TIGIT, LAG3, and
CD244, as well as the terminal differentiation marker KLRG1 and the transcription factor
EOMES, collectively indicating an exhausted phenotype (Buggert, Tauriainen, et al.,
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2014; Tauriainen et al., 2017; Wherry & Kurachi, 2015), whereas HIV-specific CD8+ T
cells from the LNs of ECs preferentially expressed IL7R, which is crucial for homeostasis
(Carrette & Surh, 2012), and several chemokines/cytokines, such as CCL5 and IL32,
collectively indicating a highly functional memory phenotype (Fig. 3.8G).
To confirm and extend these findings, we reanalyzed our scRNAseq data using the
reproducibility optimized test statistic (ROTS) (Suomi, Seyednasrollah, Jaakkola, Faux,
& Elo, 2017), a Bayesian model of differential distribution (scDD) (Korthauer et al.,
2016), and Seurat (Butler, Hoffman, Smibert, Papalexi, & Satija, 2018). A total of 2,264
differentially expressed genes achieved significance in at least two of these independent
analytical frameworks (Fig. 3.9A). These genes were enriched for immune-related
terms, such as ‘immune response’, ‘immune system process’, and ‘defense response’, in
GO analyses (Fig. S3.9B). Of particular note, ingenuity pathway analysis (IPA) further
identified a core cassette of 11 transcripts encoding predicted secreted factors that were
selectively upregulated in HIV-specific CD8+ T cells from the LNs of ECs, including TNF,
CCL5, RNASE1, and IL32, which have been shown to suppress HIV replication (Appay
& Rowland-Jones, 2001; Bedoya et al., 2006; Cocchi et al., 1995; Lane et al., 1999;
Monteleone et al., 2014; Ribeiro-Dias, Saar Gomes, de Lima Silva, Dos Santos, &
Joosten, 2017; Zapata et al., 2016) (Fig. 3.9C).
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Figure 3.9. Differential expression analysis of the scRNAseq data. (A) Venn
diagram showing the overlap of differentially expressed genes detected by each of the
three algorithms. A total of 2,264 genes achieved significance (p < 0.05) in at least two
of the three algorithms. These genes are listed in table S2. (B) The top 25 GO terms
enriched among the 2,264 differentially expressed genes. (C) List of secreted molecules
that were upregulated in ECs, as determined by IPA. Expression p-values were derived
from the scDD algorithm. Expr Log Ratio represents log fold-change values obtained
from the ROTS algorithm; positive values indicate higher expression levels in ECs
relative to CPs.
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HIV-specific CD8+ T cells are polyfunctional and translate proteins efficiently in
the LNs of ECs
To examine functionality of HIV-specific CD8+ T cells, we stimulated lymph node
mononuclear cells with HIV peptides and measured the upregulation of various
cytokines by flow cytometry. In response to cognate peptide stimulation, higher
frequencies of HIV-specific CD8+ T cells from the LNs of ECs produced TNF compared
with HIV-specific CD8+ T cells from the LNs of CPs (p = 0.0003) and HIV-specific CD8+ T
cells from the LNs of HIV+ individuals on ART (p = 0.039) (Fig. 3.10A and B). A similar
difference was observed for IFNg (p = 0.045), but the differences for MIP-1b and IL-2 did
not reach statistical significance (Fig. 3.10B). Moreover, HIV-specific CD8+ T cells from
the LNs of ECs were frequently polyfunctional, whereas HIV-specific CD8+ T cells from
the LNs of CPs were predominantly monofunctional (Fig. 3.10C and D).
To seek an explanation for these findings, we returned to our GO analysis of the 200
‘feature’ genes. In addition to immune-related terms, several protein translation-related
terms were also highlighted, including ‘SRP-dependent cotranslational protein targeting
to membrane’, ‘protein targeting to ER’, and ‘translation initiation’ (Fig. 3.10F). Most of
these genes encoded ribosomal protein subunits that were preferentially expressed in
HIV-specific CD8+ T cells from the LNs of ECs (Fig. 3.10E). Gene set enrichment
analysis (GSEA) similarly identified ‘translation’, ‘SRP-dependent cotranslational protein
targeting to membrane’, and ‘3’ UTR-mediated translation regulation’ as the most highly
enriched gene sets in the EC group (Fig. 3.10F).
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We then performed in vitro translation experiments which measure the uptake of
fluorescently labeled amino acid analog L-homopropargylglycine (HPG) in resting and
activated CD8+ T cells from the LNs of ECs, CPs, and HIV+ individuals on ART. Higher
frequencies of resting memory CD8+ T cells from the LNs of ECs incorporated HPG into
newly synthesized proteins compared with resting memory CD8+ T cells from the LNs of
CPs (p = 0.003) (Fig. 3.10G). These differences emanated primarily from the central
memory compartment (Fig. 3.10G). After stimulation with HIV-derived peptides or antiCD3, functionally responsive CD8+ T cells from the LNs of ECs also incorporated more
HPG than functionally responsive CD8+ T cells from the LNs of CPs (p = 0.008 and p =
0.01, respectively) and functionally responsive CD8+ T cells from the LNs of HIV+
individuals on ART (p = 0.04 and p = 0.004, respectively) (Fig. 3.10G). These results
suggest that efficient protein translation can explain, at least in part, the antiviral efficacy
and polyfunctional nature of HIV-specific CD8+ T cells in ECs.
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Figure 3.10. Polyfunctionality is associated with protein translation efficiency in
HIV-specific CD8+ T cells from the LNs of ECs. (A) Representative flow plots showing
the production of TNF and IL-2 by HIV-specific CD8+ T cells from the LNs of one EC and
one CP in response to cognate peptide stimulation. Plots were pre-gated on total
memory CD8+ T cells using scheme shown in fig. S2A. (B) Quantification of cytokine
production by HIV-specific CD8+ T cells from LNs. The total response for each readout
was determined by summing the corresponding frequencies after background
subtraction of all Boolean gates using permutations of CD107a, IFNg, TNF, MIP-1b, and
IL-2. Error bars represent median and interquartile range. (C) Polyfunctionality plot of
HIV-specific CD8+ T cells from LNs. Only combinations of 4 and 5 functions are shown.
Error bars represent mean and SEM. EC: n = 49, ART, n = 10, CP: n = 27. (D) Pie
charts summarizing all combinations of functions. (E) Heatmap showing z-normalized
expression of genes from the feature list identified by GO protein translation terms. (F)
Gene set enrichment analysis (GSEA) of the scRNAseq data with reference to the
Reactome Pathway Database, reporting the top 10 enriched pathways in ECs and CPs.
(G) Quantification of protein translation efficiency in LN-derived CD8+ T cells. LNMCs
were incubated with HPG in methionine-free medium for 6 hours in the presence or
absence of HIV-derived peptides or anti-CD3. Responding cells were defined using
Boolean gating for IFNg+ and/or TNF+ events. CM, central memory; EM, effector
memory. EC: n = 3, ART: n = 3, CP: n = 4. Error bars represent mean and SEM.
Significance was determined using a one-way ANOVA (D and G), or a two-way ANOVA
(B). * p < 0.05, ** p < 0.01, *** p < 0.001.

3.3 Discussion
In this study, we found that weakly cytolytic CD8+ T cells homed to B cell follicles, which
constitute a major viral reservoir in vivo (Fukazawa et al., 2015; Pantaleo et al., 1991;
Pantaleo et al., 1993; Pantaleo et al., 1994; Perreau et al., 2013), and potently
suppressed HIV replication in the lymphoid tissues of ECs. Moreover, these LN-derived
CD8+ T cells downregulated inhibitory receptors, upregulated multiple soluble factors
and cytokines, and displayed efficient protein translation. Although cause and effect
arguments can always be made in the context of human studies, these features likely
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identify a protective immune signature, because CD8+ T cells from the LNs of HIV+
individuals on ART failed to acquire the characteristics of CD8+ T cells from the LNs of
ECs even in the absence of viremia.
Ultrasensitive assays have revealed ongoing viral replication and evolution in the plasma
of ECs (Blankson et al., 2007; Mens et al., 2010; O'Connell et al., 2010). In line with the
notion of anatomically localized immune control, however, we detected very few vRNA+
cells and very little HIV DNA and RNA in the LNs of ECs. We also found that CD8+ T
cells from the LNs of ECs suppressed HIV replication in autologous CD4+ T cells far
more efficiently than CD8+ T cells from the LNs of CPs and HIV+ individuals on ART.
Depletion studies in non-human primates have shown that CD8+ T cells are required to
maintain effective control of SIV (Cartwright et al., 2016; Fukazawa et al., 2015).
Moreover, we and others have demonstrated that circulating CD8+ T cells exhibit
superior cytolytic activity in ECs (Hersperger et al., 2010; Migueles et al., 2008). It was
therefore surprising to find that very small CD8+ T cells from the LNs of ECs did not
express cytolytic molecules compared with CD8+ T cells from the LNs of CPs. This
particular finding suggests that limited immunosurveillance by cytolytic T cells is a
general phenomenon in HIV-infected lymphoid tissues (Reuter et al., 2017). Although we
cannot exclude a role for cytolytic mechanisms, especially during the early stages of
infection, our data clearly show that a potent cytolytic response is not a prerequisite for
durable immune-mediated suppression of HIV. These data are consistent with the
observation that terminally differentiated effector memory T cells, which are highly
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cytolytic, primarily circulate in the blood and patrol highly vascularized organs rather than
other tissue sites (Thome et al., 2014).
The general exclusion of cytolytic CD4+ and CD8+ T cells from lymphoid tissues is likely
a conserved feature of the immune system that has evolved to limit the destruction of
antigen-presenting cells and stromal tissues under conditions of persistent stimulation.
Non-cytolytic effector functions may therefore be necessary for effective immune control
of viruses and other pathogens that specifically target these sites. Indeed, an equivalent
scenario has been described in the liver, where hepatitis B virus-specific CD8+ T cells
eliminate the infection without killing hepatocytes via the secretion of IFNγ and TNF
(Guidotti et al., 1996). Similarly, non-cytolytic mechanisms of immune control have been
described in the context of infection with herpes simplex virus, measles virus, and
vaccinia virus (Guidotti & Chisari, 1996, 2001), as well as HIV and SIV infection (Klatt et
al., 2010; C. M. Walker et al., 1986; Wong et al., 2010). Our results add to this body of
literature and further suggest that spatial distribution and the efficient translation of
antiviral proteins are key features of a protective HIV-specific CD8+ T cell response in
lymphoid tissues.
A limitation of our study was the small sample size, which was most apparent in the
scRNAseq experiment. Ideally, we would validate signatures identified in this dataset
with an independent cohort. However, such cohorts are not easily accessible, given the
extremely low frequency of ECs (<1% of all infected individuals) and the increasingly
early initiation of ART. Several of the key gene signatures were nonetheless confirmed
in terms of functionality and protein expression, indicating that these signatures are
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generalizable. The interpretation of the scRNAseq data was potentially confounded by
antigen load since the comparison was limited to only between ECs and CPs. Technical
difficulties and the low frequency of HIV-specific CD8+ T cells in LNs of ART-treated
individuals did not permit the inclusion this group in our scRNAseq experiment. In order
to alleviate this caveat, we included the ART-treated group in most of our functional
experiments. Since CD8+ T cells from LNs of ECs were more polyfunctional, suppressed
viral replication more potently, and translated proteins more efficiently than CD8+ T cells
from LNs of both CPs and ART-treated individuals, these major signatures could not be
explained by antigen load per se.
In summary, we have shown that non-cytolytic CD8+ T cells with distinct functional,
phenotypic, and transcriptional signatures, including the upregulation of known or
predicted soluble factors, efficient protein translation, and a high ribosome biogenesis,
suppress viral replication in the LNs of ECs. These observations are highly pertinent in
light of current “kill” strategies designed to achieve a functional cure for HIV (Trautmann,
2016). Collectively, our data support a model in which viral suppression rather than viral
eradication dictates immune efficacy, without excluding a role for cytolytic mechanisms,
and provide fresh impetus in the search for novel antiviral factors that may complement
existing therapies for HIV (Levy, 2003).
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3.4 Methods
Study design
Peripheral blood samples, tissue biopsies (cervical, iliac, or inguinal LNs), and fine
needle aspirates (inguinal LNs) were obtained from HIV+ individuals on ART (n = 14) and
untreated HIV+ individuals categorized as acute seroconverters (Fiebig stage IV–VI, n =
7), ECs (n = 12), or CPs (n = 18). Donors were recruited at three different sites: INERCIENI, Mexico City, Mexico; the University of California, San Francisco, USA; and the
University of Pennsylvania, Philadelphia, USA. Clinical characteristics are summarized
in table S1. Paraffin-embedded LN slides from CPs (n = 7) for microscopy experiments
were obtained via the Pathology Core at the Hospital of the University of Pennsylvania
(Philadelphia). All donors provided informed consent in line with protocols approved by
the INER-CIENI Ethics Committee, the Federal Commission for the Protection against
Sanitary Risk (COFEPRIS), and the Institutional Review Boards of the University of
California (San Francisco) and the University of Pennsylvania (Philadelphia). Sample
sizes were not predetermined by power calculations but instead were dependent on
sample availability. Investigators were not blinded to group identity during the course of
the study. Primary data are reported in data file S1.

Sample processing and storage
Peripheral blood mononuclear cells (PBMCs) were isolated using standard density
gradient centrifugation, and LN mononuclear cells (LNMCs) were collected from whole
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biopsies via mechanical homogenization. Fine needle aspirates were processed for
immediate experimentation. PBMCs and LNMCs were cryopreserved at –140 °C.

RNAscope
Next-generation in situ hybridization was performed on LN biopsies as described
previously (Deleage, Wietgrefe, et al., 2016).

qPCR quantification of cellular HIV-1 DNA and RNA
Cell-associated DNA and RNA were purified using an AllPrep DNA/RNA Mini Kit
(Qiagen), concentrated in a SpeedVac System (Thermo Fisher Scientific), and
normalized to cell equivalents via quantitative PCR (qPCR) with reference to genomic
telomerase reverse transcriptase for DNA and expressed ribosomal protein lateral stalk
subunit P0 for RNA (Thermo Fisher Scientific). Total cell-associated HIV DNA and RNA
were quantified via qPCR using a QuantStudio 6 Flex RealTime PCR System (Applied
Biosystems) with the LTR-specific primers F522-43 (5’GCCTCAATAAAGCTTGCCTTGA-3’; HXB2 522–543) and R626-43 (5’GGGCGCCACTGCTAGAGA-3’; HXB2 626–643) and a FAM-BQ probe (5’CCAGAGTCACACAACAGACGGGCACA-3’). Cell-associated HIV DNA copy number
was determined in a final reaction volume of 20 μL incorporating 4 pmol of each primer,
4 pmol of probe, 5 μL of DNA, and 10 μL of 2x TaqMan Universal Master Mix II, with
UNG (Thermo Fisher Scientific). Thermal parameters were as follows: 50 °C for 2
minutes (1 cycle), 95 °C for 10 minutes (1 cycle), and 95 °C for 15 seconds followed by
59 °C for 1 minute (60 cycles). Cell-associated HIV RNA copy number was determined
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in a final reaction volume of 20 μL incorporating 4 pmol of each primer, 4 pmol of probe,
5 μL of RNA, 0.5 μL of reverse transcriptase, and 10 μL of 2x TaqMan RNA-to-CT 1Step (Thermo Fisher Scientific). Thermal parameters were as follows: 48 °C for 20
minutes (1 cycle), 95 °C for 10 minutes (1 cycle), and 95 °C for 15 seconds followed by
59 °C for 1 minute (60 cycles). For HIV DNA measurements, external quantification
standards were prepared from the ACH-2 cell line in a background of HIV– human
cellular DNA, calibrated against the Division of AIDS Virology Quality Assurance
Program HIV-1 DNA Quantification Standard (National Institutes of Health AIDS
Reagent Program). For HIV RNA measurements, external quantification standards were
prepared from full-length NL4-3 virion RNA, and copy number was determined using a
Real-Time HIV-1 Viral Load Assay (Abbott Molecular), calibrated against the Division of
AIDS Virology Quality Assurance Program HIV-1 RNA Quantification Standard (National
Institutes of Health AIDS Reagent Program). Copy number for all samples was
determined in triplicate by extrapolation against a seven-point standard curve (1–10,000
cps).

Peptide stimulation assay
Cryopreserved LNMCs and PBMCs were thawed and rested overnight at 37 °C in RPMI
medium supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1%
penicillin/streptomycin (R10). Cells were then washed in R10 and resuspended at 2 x
106 cells/mL. Approximately 0.5 x 106 to 1 x 106 cells were used per condition, with lower
bounds defined by cell availability in each sample. All stimulation conditions included
anti-CD28 and anti-CD49d (each at 1 µg/mL, BD Biosciences), GolgiStop (0.7 µL/mL,
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BD Biosciences), and brefeldin A (1 µg/mL, Sigma-Aldrich). Cells were stimulated for 6
hours at 37 °C with peptides previously described HLA-specific optimal HIV epitopes
(each at a final concentration of 1 µg/mL, New England Biolabs). Positive controls
incorporated staphylococcal enterotoxin B (1 µg/mL, Sigma-Aldrich). Degranulation was
detected via the addition of anti-CD107a–PE-Cy5 (eBioH4A3, eBioscience) at the start
of the assay to capture surface-mobilized events in real time (Betts et al., 2003).

Flow cytometry
LNMCs and PBMCs were stained with anti-CCR7–APC-Cy7 (G043H7, BioLegend) for
10 minutes at 37 °C. Cells were then labeled with LIVE/DEAD Fixable Aqua (Thermo
Fisher Scientific) for 10 minutes at room temperature to identify non-viable events,
stained with a cocktail of directly-conjugated monoclonal antibodies for 20 minutes at
room temperature to detect surface markers, fixed/permeabilized using a
Cytofix/Cytoperm Kit (BD Biosciences), stained with another cocktail of directlyconjugated monoclonal antibodies for 1 hour at room temperature to detect intracellular
markers, and fixed in 1% paraformaldehyde (Sigma-Aldrich). Data were acquired using
an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo software v9.9.4
(Tree Star Inc.).

Antibodies
The following directly-conjugated reagents were used in flow cytometry experiments.
Tetramer panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 (M5E2,
BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–BV711 (UCHT1,
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BioLegend), anti-CD4–PE-Cy5.5 (S3.5, Thermo Fisher Scientific), anti-CD8–BV570
(RPA-T8, BioLegend), anti-CD27– BV785 (O323, BioLegend), anti-CD45RO–BV650
(UCHL1, BioLegend), anti-CD69–PE-Cy5 (TP1.55.3, Beckman Coulter), anti-CD103–
BV605 (2E7, BioLegend), anti-CXCR5–AF488 (RF8B2, BD Biosciences), anti-perforin–
PE-Cy7 (dG9, eBioscience), anti-granzyme B–AF700 (GB11, BD Biosciences), antiTbet–PE-Dazzle (4B10, BioLegend), and anti-Eomes–AF647 (WD1928, eBioscience).
Peptide stimulation panel: anti-CD107a–PE-Cy5 (eBioH4A3, eBioscience), anti-CCR7–
APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–
BV510 (HIB19, BioLegend), anti-CD3–BV711 (UCHT1, BioLegend), anti-CD4–PE-Cy5.5
(S3.5, Thermo Fisher Scientific), anti-CD8–BV570 (RPA-T8, BioLegend), anti-CD27–
BV785 (O323, BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), anti-CXCR5–
AF647 (RF8B2, BD Biosciences), anti-IFNg–FITC (B27, BD Biosciences), anti-TNF–
BV605 (MAb11, BioLegend), anti-IL-2–APC-R700 (MQ1-17H12, BD Biosciences), antiMIP-1b–PE-Cy7 (D21-1351, BD Biosciences), anti-perforin–BV421 (B-D48, BioLegend),
anti-granzyme B–PE-TxRed (GB11, Thermo Fisher Scientific), and anti-Tbet–PE (4B10,
eBioscience). Redirected killing assay panel: anti-active caspase 3–FITC (C92-605, BD
Biosciences), anti-CD3–PE (SK7, BD Biosciences), and anti-perforin–PE-Cy7 (dG9,
eBioscience). Suppression assay panel: anti-p24–FITC (KC57, Beckman Coulter), antiCD14– BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–
BV711 (UCHT1, BioLegend), anti-CD4–PE-Cy7 (RPA-T4, BioLegend), anti-CD8–BV570
(RPA-T8, BioLegend), anti-CD25–Tricolor (CD25-3G10, Thermo Fisher Scientific), antiperforin–BV421 (B-D48, BioLegend), and anti-granzyme B–PE-TxRed (GB11, Thermo
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Fisher Scientific). Translation assay panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend),
anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19, BioLegend), antiCD3–BV711 (UCHT1, BioLegend), anti-CD4–APC (S3.5, Thermo Fisher Scientific), antiCD8–BV570 (RPA-T8, BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), azide–
AF488 (A10266, Thermo Fisher Scientific), anti-TNF–PE-Cy7 (MAb11, Thermo Fisher
Scientific), and anti-IFNg–AF700 (B27, BD Biosciences). Viral quantification panel: antiCCR7–APC-Cy7 (G043H7, BioLegend), anti-CD3–APC-R700 (UCHT1, BD
Biosciences), anti-CD4–PE-Cy7 (RPA-T4, BioLegend), anti-CD8–PE-Cy5.5 (RPA-T8,
eBiosciences), anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19,
BioLegend), anti-CD45RA–PE-CF594 (HI100, BD Biosciences), anti-CXCR5–AF647
(RF8B2, BD Biosciences), and anti-PD-1–BV421 (EH12.2H7, BioLegend).

Tetramers
HLA class I tetramers conjugated to BV421 or PE were produced as described
previously (Price et al., 2005). The following specificities were used to detect HIVspecific CD8+ T cells: A*0201-IV9 (ILKEPVHGV), A*0201-SL9 (SLYNTVATL), A*0201FK10 (FLGKIWPSHK), A*0201-TV9 (TLNAWVKVV), A*2402-RW8 (RYPLTFGW),
A*2402-KW9 (KYKLKHIVW), A*2402-RL9 (RPMTYKGAL), B*0702-GL9 (GPGHKARVL),
B*0702-HI10 (HPRVSSEVHI), B*0702-SM9 (SPAIFQSSF), B*2705-KK10
(KRWIILGLNK), B*3501-VY10 (VPLDEDFRKY), B*3501NY9 (NSSKVSQNY), B*5701KF11 (KAFSPEVIPMF), B*5701-TW10 (TSTLQEQIGW), B*5701-ISW9 (ISPRTLNAW),
and B*5701-QW9 (QASQEVKNW).
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Immunohistochemistry
LN biopsy material was cut at a thickness of 5 µm and processed as described
previously (Schuetz et al., 2014). Briefly, tissue sections were heated in 0.01% citraconic
anhydride containing 0.05% Tween-20 and incubated overnight at 4 oC with monoclonal
or polyclonal antibodies specific for perforin (1:100, 5B10/VP-P967, Vector Laboratories
Inc.) or granzyme B (1:200, HPA003418, Sigma-Aldrich). Slides were then washed in
TBS containing 0.05% Tween-20, and endogenous peroxidases were blocked using
1.5% (v/v) H2O2 in TBS, pH 7.4. Antigens were revealed using mouse Polink-1 or rabbit
Polink-2 HRP in conjunction with ImmPACT DAB (Vector Laboratories Inc.) and Warp
Red (Biocare Medical Inc.). Slides were then washed in H2O, counterstained with
haematoxylin, mounted in Permount (Thermo Fisher Scientific), and scanned at 200x
magnification using a ScanScope CS System (Aperio Technologies). Representative
regions of interest (0.4 mm2) were identified visually, and high-resolution images were
extracted from the whole-tissue scans. The percent area positive for CD4+ T cells was
quantified using CellProfiler v3.1.5 (Carpenter et al., 2006).

Single-cell RNAseq
The experimental setup was described previously in Buggert et al. (Buggert, Nguyen,
Salgado-Montes de Oca, et al., 2018). Briefly, single HIV tetramer+ cells were index
sorted directly into 96-well microtiter plates containing lysis buffer using a FACSAria II
flow cytometer (BD Biosciences). Cellular nucleic acids were recovered using an
RNEasy Plus Micro Kit (Qiagen) and RNAClean (SPRI) beads (Beckman Coulter).
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Performance was assessed using External RNA Controls Consortium (ERCC) RNA
Spike-In Mix (Ambion). Reverse transcription was performed using oligo-dT primers, and
cDNA was amplified over 22–24 PCR cycles using universal primers and Kapa HiFi
HotStart ReadyMix (Kapa Biosystems). After clean-up, amplified cDNA was barcoded
using Illumina Nextera libraries and sequenced to a depth of approximately 2 million 150
bp paired-end reads/cell on a HiSeq 4000 (Illumina). Whole transcriptome data were
obtained from 221 cells (n = 552 sorted cells).

Single-cell RNAseq analyses
Semblance, a kernel-method learning framework was used to assess the pairwise
similarity between cells and compute the distance metric that best fitted the structure of
the data (Agarwal & Zhang, 2019). Cell-to-cell similarity was learned using a rank-based,
nonparametric function, and tSNE kernelization allowed the use of data from all available
features. Dimensionality reduction was performed using kernel tSNE, wherein the
pairwise similarity between cells was computed using the Semblance kernel as a
distance measure. In determination of the cell-to-cell similarity matrix, the Gini index was
used to account for the distribution of each gene and weigh it appropriately in the kernel
calculation. The Gini index enabled the prioritization of genes with high variance as the
genes that were more likely to provide useful features for niche group detection. Single
cells were then projected onto a two-dimensional space using kernel tSNE, enabling
intuitive visualization of hidden structures within the data. The supporting code is freely
available online and can be implemented via the R Package Semblance
(https://cran.rproject.org/web/packages/Semblance/index.html).
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For support vector machine (SVM) analyses, genes were selected using a t-score cut-off
of p < 0.01. Selected genes were then ranked using L0-norm regularization. The L0norm-ranked gene lists were fed into the SVM algorithm for cross-validation (k-fold = 10)
in subsets (increment = 100 genes). The average prediction error for each crossvalidation was used to determine how well each subset of genes classified the desired
labels. All steps were performed in MATLAB (MathWorks). L0-norm regularization was
implemented using the MATLAB Feature Selection Library (MathWorks).
Differentially expressed genes were identified using three approaches: ROTS (Suomi et
al., 2017), which optimizes the t-statistics based on the inherent characteristics of the
data; scDD (Korthauer et al., 2016), which is a differential expression analysis method
that accounts for the possibility of multimodally distributed gene expression; and Seurat
(Butler et al., 2018), which uses the non-parametric Mann-Whitney U-test to assess the
null hypothesis that a randomly selected mean expression value for a given gene in one
group will have an equal chance of being less than or greater than a randomly selected
mean expression value for the same gene in a second group. As different genes in the
dataset exhibited different distribution properties, these approaches in combination
allowed us to winnow the list of differentially expressed genes, specifying a cut-off of p <
0.05 in at least two of the three outputs. The scDD p-values are reported for simplicity.
The topGO package Bioconductor v3.8 was used for GO analyses
(https://bioconductor.org/packages/release/bioc/html/topGO.html). GO terms associated
with each gene were obtained using the August 2017 ENSEMBL Database. Significance
was determined using the classic Fisher method. GSEA analyses were performed using
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software developed by the Broad Institute (Mootha et al., 2003; Subramanian et al.,
2005).

Redirected killing assay
P815 mastocytoma target cells were labeled with LIVE/DEAD Violet (Thermo Fisher
Scientific) and TFL4 (OncoImmun), washed twice in PBS, and incubated for 30 minutes
at room temperature with anti-CD3 (5μg/mL, UCHT1, BioRad). CD8+ T cells were
negatively selected from LNMCs or PBMCs using a CD8+ T Cell Enrichment Kit
(StemCell Technologies). Isolated CD8+ T cells were rested in R10 for at least 45
minutes at 37 °C and then incubated with anti-CD3-coated P815 cells at different
effector-to-target ratios in a 96-well V-bottom plate for 4 hours at 37 °C. Cells were then
stained as described above (see Antibodies section) and acquired using an LSRII flow
cytometer (BD Biosciences).
Killing capacity was calculated by subtracting the frequency of active caspase3+ TFL4+
LIVE/DEAD– P815 cells in target-only wells from the frequency of active caspase3+
TFL4+ LIVE/DEAD– P815 cells in wells containing effector cells.

Viral suppression assay
The viral suppression assay was modified from Sáez-Cirion et al. (Saez-Cirion et al.,
2010). Briefly, CD4+ T cells were positively selected from LNMCs or PBMCs using a
CD4+ T Cell Enrichment Kit (StemCell Technologies).
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Technologies) and activated using a cocktail of IL-2 (100 U/mL, Chiron), anti-CD3 (1
µg/mL, UCHT1, Bio-Rad), anti-CD28 (1 µg/mL, L293, BD Biosciences), and anti-CD49d
(1 µg/mL, L25, BD Biosciences). Concurrently, autologous CD8+ T cells were negatively
selected from LNMCs or PBMCs using a CD8+ T Cell Enrichment Kit (StemCell
Technologies) and rested in R10. After 2 days, CD4+ T cells were infected with HIV-1
BAL (UPenn CFAR Virology Core) by spinoculation and incubated with or without
autologous CD8+ T cells in the absence of exogenous IL-2. Cells were harvested after a
further 3 days, stained as described above (see Antibodies section), and acquired using
an LSRII flow cytometer (BD Biosciences).
Suppression capacity was calculated by dividing the frequency of p24+ CD4+ T cells in
wells containing autologous CD8+ T cells by the frequency of p24+ CD4+ T cells in wells
lacking autologous CD8+ T cells.

HPG translation assay
The protein translation assay was adapted from Araki et al. (Araki et al., 2017). Briefly,
LNMCs were rested overnight and incubated for 30 minutes in methionine-free R10. The
cultures were then supplemented with Click-iT HPG (100 µM, Thermo Fisher Scientific).
Cells were stimulated with PepMix HIV (GAG) Ultra (2µg/mL/peptide, JPT Peptide
Technologies), PepMix HIV (NEF) Ultra (2µg/mL/peptide, JPT Peptide Technologies), or
anti-CD3 (5μg/mL, UCHT1, BioRad) in the presence of GolgiStop (0.7 µL/mL, BD
Biosciences) and brefeldin A (1 µg/mL, Sigma-Aldrich). After 6 hours, cells were stained
as described above (see Antibodies section) and acquired using an LSRII flow cytometer
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(BD Biosciences), following the instructions in the Click-iT Plus Alexa Fluor Picolyl Azide
Toolkit (Thermo Fisher Scientific).

Statistics for non-sequencing data
Data were checked for normality using the Shapiro-Wilk normality test. Parametric tests
were used if the data passed the normality test, and non-parametric tests were used if
the data failed the normality test. Multiple corrections for two-way ANOVA were
performed using the two-stage linear step-up procedure of Benjamini, Krieger, and
Yekutieli. Specific tests are indicated in the relevant figure legends. Analyses were
performed using R Studio or Prism v7.0 (GraphPad).
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CHAPTER 4: EPILOGUE
4.1 Summary and implications
Recent studies suggest that CD8+ T cells in tissues, including LTs, have a distinct
phenotype compared to their blood counterparts. This dissertation aims to determine
whether this concept is applicable to HIV infection by defining the identity of CD8+ T cells
that are associated with effective control of HIV replication in LNs.
In chapter 2, we demonstrated that a large portion of CD8+ T cells in LN of HIV-infected
individuals are TRM and their frequency is positively linked to the effective immunemediated control of HIV in ECs. The key findings of this chapter are: (i) CD69+ CD8+ T
cells are present in high frequency in HIV-infected LNs but do not resemble recently
activated cells; (ii) instead they exhibit transcriptional and epigenetic profiles of TRM cells
that are distinct from non-resident T cells in LNs; (iii) CD69+ TRM most often dominate the
HIV-specific CD8+ T cell response in LNs; and (iv) most importantly, we found high
magnitudes of LN HIV-specific TRM in ECs. Collectively, these data extend our current
understanding of immunosurveillance in LTs and strongly suggest that ongoing CD8+ T
cell-mediated immunity against HIV in LTs is, at least in part, mediated by TRM.
In chapter 3, we defined the transcriptional and functional signatures of LN CD8+ T cells
from ECs. Specifically, we showed that (i) there is an extremely low level of viral
replication detected in LNs of ECs; (ii) LN CD8+ T cells from ECs exhibit a superior level
of viral suppression capacity; (iii) however, this suppression activity is unlikely mediated
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by cytotoxic mechanisms as LN CD8+ T cells from ECs, including HIV-specific ones,
produce a very low level of cytolytic proteins, such as perforin and granzyme B, and kill
target cells very poorly; (iv) instead these cells upregulate the transcription of noncytolytic antiviral molecules, produce multiple cytokines upon stimulation, are more
poised to traffic to BCFs, and display a high level of protein translation potential. These
data support a model where viral suppression rather than elimination is the major
mechanism of maintaining HIV control in LTs during the chronic phase of infection (Fig
4.1).

Figure 4.1 Model of effective CD8+ T cell-mediated HIV control in LTs. In this model,
HIV-specific CD8+ T cells exhibit a TRM profile to remain local to surveil LTs, the critical
reservoirs for persistent viral replication. These cells utilize non-cytolytic, rather than
cytolytic, mechanisms to control HIV replication in LTs. In addition, the suppression
activities likely occur in both TCZ and BCFs, leading to almost complete suppression of
viral replication in LTs.
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Collectively, the findings included in this dissertation substantially extend our knowledge
on CD8+ T cell responses in LTs during HIV infection. For the first time, we provided
evidence for the participation of CD8+ TRM in anti-HIV immunity in LTs. This finding
emphasizes the notion that immunity in blood does not fully recapitulate immunity in
tissues, including LTs. By definition, these TRM remain at a location for a long time
without entering circulation. Therefore, sampling the peripheral blood for immunological
studies fails to capture this population and tissue-specific immunological features.
Since their discovery, TRM have been shown to be critical in immune responses to
pathogens and cancers (Amsen et al., 2018; Rosato, Beura, & Masopust, 2017). These
cells are thought to form the front line defense that can immediately respond to a
reinfection. They can act as immediate effector cells that quickly kill infected host cells or
as immune mediators by inducing a local antiviral state and recruit other immune cells
via cytokine and chemokine secretion (Rosato et al., 2017). This concept is important for
pathogenic infection, including HIV, as most of the viral replication occurs in tissues such
as LTs (J. D. Estes et al., 2017; Pantaleo et al., 1991; Pantaleo et al., 1993). Emerging
evidence indicates that HIV reservoirs in tissues are harbored by CD4+ TRM (CanteroPerez et al., 2019). This finding further emphasizes the importance of understanding
anti-HIV immunity directly in tissues in order to better inform a cure strategy. The fact
that we detected an elevation of HIV-specific CD8+ TRM in LNs of ECs suggests that
CD8+ TRM are a novel correlate of effective immune-mediated control of HIV. Moreover,
this correlate has been extended to the gut mucosa, which is another critical site of HIV
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pathogenesis (Kiniry, Li, et al., 2018). Therefore, TRM should be a target for cure
strategies and even for prophylactic vaccines.
Learning from other infections, this approach is a promising one. Therapeutic and
prophylactic vaccines inducing CD8+ TRM in the genital mucosa have shown protection
against Herpes Simplex Virus-2 reactivation and infection, respectively, in animal models
(Shin & Iwasaki, 2012; Srivastava et al., 2017; Srivastava et al., 2019). Similarly, a
prophylactic live-attenuated influenza virus vaccine that induces lung TRM has
demonstrated protection against heterosubtypic infection in a mouse model (Zens,
Chen, & Farber, 2016). Intravenous BCG immunization inducing strong lung TRM
responses in rhesus macaques has been shown to protect 90% of animals challenged
with Mycobacterium tuberculosis (Darrah et al., 2020). An experimental prophylactic
tuberculosis vaccine using a Rhesus Cytomegalovirus (RhCMV) vector protected 41% of
rhesus macaques from Mycobacterium tuberculosis infection. This protection was
associated with strong pathogen-specific TRM responses (Hansen et al., 2018). The
same platform has been tested for SIV infection where a RhCMV/SIV vaccine protected
50% of animals intrarectally challenged with pathogenic SIVmac239 (Hansen et al., 2011;
Hansen et al., 2013). This vaccine induced strong TEM responses at sites of viral
replication such as LNs and mucosal tissues (Fukazawa et al., 2012; Hansen et al.,
2009). Though they have not been definitely shown, these responses resemble
characteristics of TRM. On the other hand, using the RhCMV platform for therapeutic
purposes has been proven to be challenging. In fact, RhCMV/SIV vaccine did not
promote significant viral reservoir clearance in SIV-infected animals that had received
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ART as early as 4-9 days post-infection (Okoye et al., 2018). This finding indicates that
the induction of TRM alone is likely not sufficient for a sterilizing cure; but it is still valid to
be explored for a functional cure.
The fact that effective responses against HIV are associated with the presence of TRM in
LTs raises a few important points for consideration. Since we were able to examine only
a few out of hundreds of LNs present in the body, it remains to be determined if the level
of viral control differs between LNs. Is it possible that there is ongoing viral replication
and evolution in some LNs but not others? And if that is the case, how is it related to
different aspects the CD8+ TRM responses? If indeed the level of viral control varies
among LNs, it will be critical to determine if there is ongoing viral evolution at some sites
but not others? What is the threshold (i.e. the number of sites where control is achieved)
for a functional cure? It is also important to determine how long these TRM stay resident
in a specific LN and whether that duration has implications for a functional cure.
In addition to the identification of HIV-specific LT CD8+ TRM, we also defined the
functional and transcriptional features associated with effective CD8+ T cell-mediated
viral control in LNs of ECs. Results in chapter 3 indicate that these features in LNs are
not exactly the same as what have been previously described in blood. CD8+ T cells in
LNs of ECs exhibit low cytolytic capacity, typified by very low expression levels of
cytolytic proteins such as perforin and granzyme B as well as low target cell-killing
activity. These levels are much lower compared to blood (Kiniry, Hunt, et al., 2018;
Reuter et al., 2017). Though these data are only cross-sectional and do not provide
definitive proof, they indicate that CD8+ T cell-mediate cytotoxicity is unlikely a major
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mechanism that maintains viral control in LTs. As described in 1.6, in blood, cytotoxicity
is one of the strongest correlates of the EC status (Hersperger et al., 2010; Migueles et
al., 2002; Migueles et al., 2008). Therefore, the absence of this signature in LNs of ECs
is unexpected and very striking. However, this finding does not invalidate the correlation
between blood cytolytic CD8+ T cells and the EC status. In fact, a robust cytolytic profile
of blood CD8+ T cells from ECs might reflect the effective elimination of infected cells in
the spleen, where cytolytic CD8+ T cells can potentially interact with infected targets.
Despite their low cytolytic capacity, LN CD8+ T cells from ECs are highly polyfunctional
and display superior viral suppression capacity, indicating that CD8+ T cells in LTs might
utilize alternative non-cytolytic mechanisms to control viral replication. This finding has
major implications for HIV cure research.
Currently, one of the most prominent HIV cure strategies is “shock and kill.” Briefly, this
is a two-steps approach in which the first step involves the reactivation of the HIV latent
reservoirs and the second step involves the utilization of cytolytic mechanisms to
eliminate infected cells (Deeks, 2012). The success of this strategy rests on the
assumption that immune cells, namely CD8+ T cells, can effectively kill infected cells at
sites of HIV reservoirs. In other words, the strategy assumes that LT CD8+ T cells are
highly cytotoxic. Nevertheless, LT CD8+ T cells, as demonstrated in this study, are
largely not cytotoxic, the prospect of the “shock and kill” strategy is now called into
question. In fact, clinical trials of the “shock and kill” strategy using histone deacetylase
inhibitors have successfully “shocked” but failed to “kill”, as no measurable reduction in
HIV reservoir size has been detected (Y. Kim, Anderson, & Lewin, 2018). This failure
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can be partially due to the negative impact of the histone deacetylase inhibitors used in
“shock and kill” on the antiviral functions of CD8+ T cells (Walker-Sperling, Pohlmeyer,
Tarwater, & Blankson, 2016). Additionally, it is well-established that CD8+ T cells fail to
accumulate in BCFs, which are major sanctuaries for persistent viral replication
(Bronnimann et al., 2018; Connick et al., 2014; Connick et al., 2007; Fukazawa et al.,
2015). Our study sheds light on an additional challenge for “shock and kill” to overcome,
which is the rarity of cytolytic CD8+ T cells in LT and the inability of these cells to quickly
upregulate them upon stimulation.
In contrast to the “shock and kill” approach, our results reignite an old avenue of HIV
cure research, which is to identify the non-cytolytic mechanisms that are capable of
suppressing viral replication in LTs. This avenue was established very early in the
pandemic. In fact, non-cytolytic response mediated by CAF was the first type of CD8+ T
cell responses observed in HIV-infected individuals, one year prior to the description of
the cytolytic response (B. D. Walker et al., 1987; C. M. Walker et al., 1986). Enhanced
CAF activities in both blood and LTs have been associated with improved disease
clinical state (Blackbourn et al., 1996; Mackewicz, Ortega, & Levy, 1991). CAF is
exclusively produced by CD8+ T cells and can be composed of one or more secreted
soluble factors (Levy, 2003; C. M. Walker & Levy, 1989). It can be active against multiple
retroviruses, including HIV-1, HIV-2, SIV, murine retroviruses, and avian retroviruses
(Copeland, McKay, & Rosenthal, 1995; Levy, 2003). Mechanistically, it blocks LTRdriven HIV transcription by interfering with RNA polymerase II accumulation (Blazek,
Teque, Mackewicz, Peterlin, & Levy, 2016; Mackewicz, Blackbourn, & Levy, 1995;
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Shridhar, Chen, & Gupta, 2014). Multiple studies have attempted to identify the exact
identity of CAF but all failed. Though multiple soluble factors, such as α-defensins, betachemokines, and TOE1, exhibit viral inhibition activities resembling of CAF, none of
them fully recapitulate CAF characteristics (Cocchi et al., 1995; Sperandio et al., 2015;
L. Zhang et al., 2002).
Independent of the exact identity of CAF, non-cytolytic control of HIV has been
demonstrated in vivo. Depletion of CD8+ T cells in rhesus macaques does not increase
the life-span of productively SIV-infected cells, indicating that direct killing is not the main
mechanism antagonizing viral replication (Klatt et al., 2010; Wong et al., 2010). In
addition, the equivalent life-span of wild-type virus-infected cells and escape-mutantinfected cells in pigtail macaques infected with a SIV-HIV chimeric virus (SHIV) suggests
that non-cytolytic viral control is at work (Balamurali et al., 2010). Our results significantly
extend these findings by demonstrating the relevance of this viral control mechanism in
LTs. We also identified potential antiviral molecules for validation including IL-32 and
RNase 1. If cure strategies inducing cytolytic elimination of HIV-infected cells is termed
“shock and kill”, strategies inducing non-cytolytic control of HIV replication can be termed
“block and lock”. Ultimately, the elimination of HIV reservoirs through “shock and kill” is
required for a sterilizing cure. However, if non-cytolytic mechanisms are indeed
responsible for the maintenance of viral suppression in ECs, who can remain aviremic
for 20 years or even longer, “block and lock” might be sufficient for a functional cure.
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4.2 Open questions and future directions
Despite the exciting potential of transferring the knowledge unveiled in this dissertation
into a functional HIV cure, many questions remained to be answered before this
potential can be realized.

Which non-cytolytic mechanisms should be induced?
It is clear through Results in chapter 3 that non-cytolytic mechanisms are contributing to
the maintenance of viral control in LNs of ECs. However, this current study fell short of
identifying the exact mechanisms that are at work. In the future, advanced technologies
such as high-throughput drug screens, CRISPR/Cas9 screens, and highly sensitive
proteomic approaches, should be utilized to identify non-cytolytic molecules that can
suppress HIV replication. Nevertheless, via transcriptional analysis, we have identified a
list of secreted molecules that can contribute to the non-cytolytic control of HIV (Fig
3.9C). Some of those molecules have been shown to exert antiviral activities, such as IL32 and RNase 1.
IL-32 is a cytokine that was discovered in 1992. Originally, it was termed NK4 transcript
and was found to be produced by NK and T cells upon activation with IL-2 or mitogens,
respectively (Dahl, Schall, He, & Cairns, 1992). However, studies have shown that IL-32
can also be produced by other cell types, including but not limited to fibroblasts,
monocytes/macrophages, epithelial cells, and fibroblasts (Ribeiro-Dias et al., 2017).
Interestingly, this cytokine has no homology with other well-studied cytokines and is not
found in rodents (Ribeiro-Dias et al., 2017). IL-32 exists in multiple isoforms including the
131

full-length γ and smaller spliced isoforms α, β, δ, θ, ε, ζ, and η. This cytokine can be
released upon necrotic death or secreted via exosomes. To date, the receptor for IL-32
still has not been identified (Ribeiro-Dias et al., 2017).
Despite many unknowns, IL-32 has been shown to be relevant for HIV immunity. In fact,
IL-32 is elevated in serum, LNs, and gut of HIV-infected individuals (Rasool et al., 2008;
A. J. Smith et al., 2011). However, conflicting reports exist on whether IL-32 has a proHIV or anti-HIV role during the infection. On one hand, IL-32 induces the production of
immunosuppressive molecules such as IDO and ILT4, which dampen immune cell
activation, reduce the production of cytotoxic molecule, and promotes HIV replication in
LTs (A. J. Smith et al., 2011). On the other hand, knocking down endogenous IL-32
results in an increase of HIV LTR activity, indicating that IL-32 can antagonize HIV
replication (Rasool et al., 2008). Exogenous addition of IL-32 can also suppress HIV
production from macrophages (Nold et al., 2008). Since IL-32 exists in multiple isoforms,
variation in biological activities between isoforms can potentially account for the
contradictory roles of this cytokine in HIV infection. IL-32γ is proinflammatory through the
induction of IL-6 and IFNγ but IL-32α is largely anti-inflammatory through the induction of
IL-10 (S. H. Kim, Han, Azam, Yoon, & Dinarello, 2005; Zaidan et al., 2019). Meanwhile,
IL-32β exerts both pro- and anti-inflammatory properties (Zaidan et al., 2019). Higher
plasma levels of IL-32γ and β but not α at an earlier clinic visit predicts disease
progression at a later visit in a cohort of slow progressors (El-Far et al., 2016).
Additionally, IL-32γ but not α and β can induce HIV production in latently infected CD8+
T cells isolated from ART-treated individuals (Zaidan et al., 2019). Our preliminary data
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have shown that the exogenous addition of IL-32α into a culture of HIV-infected CD4+ T
cells results in a 30-50% reduction in viral production (Fig 4.2A and B). In contrast, the
addition of IL-32β induces only a minimal level of viral suppression (Fig 4.2A and B).
These results indicate that IL-32α but not β can suppress HIV replication, at least in
vitro; and this cytokine is potentially involved in the non-cytolytic suppression of HIV
replication in LNs of ECs. However, this finding requires further validation. Key questions
include: Which IL-32 isoforms are predominant in LNs of ECs? What are the protein
levels? And how can the expression of this cytokine be manipulated?

Figure 4.2 IL-32α but not β can suppress HIV replication. CD4+ T cells were isolated
from HIV- donors and activated for 2 days with α-CD3/CD28 prior to infection with 5ng
with HIV BAL virus in the presence or absence of IL-32. IL-32 was added after 45
minutes of virus spinoculation. After 3 days, the culture was stained for intracellular p24
(A) Representative flow cytometry plots showing the % of p24+ cells in the culture. (B)
Quantification %p24 reduction for each condition (calculated by (%p24+ in cultures with
IL-32/%p24+ in cultures without IL-32)*100). 5ng: n =4, 50ng: n=8, 500ng: n=4. Bars
represents average ± SEM. Experiment performed by Son Nguyen.
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RNase 1, also known as RNase A, is another secreted molecule that was found to be
upregulated in HIV-specific CD8+ T cells in LNs of ECs. This RNase is one of eight
members of the protein ribonuclease A (RNase A) superfamily (Koczera, Martin, Marx, &
Schuerholz, 2016). It can induce the production of proinflammatory cytokines such as
TNF, IL-6, and IL-12 by DCs (Koczera et al., 2016; D. Yang et al., 2004). Exogenous
addition of RNase 1 into cultures of HIV-infected CD4+ T cells resulted in a decrease in
p24 level in the supernatant, demonstrating the antiviral activity of this RNase (Bedoya
et al., 2006). In addition, it has also been shown that RNase 1 is partially responsible for
the anti-HIV activity by CD8+ T cell-mediated HLA-alloantigen recognition (Pinto, Sharpe,
Cohen, & Shearer, 1998; Rugeles et al., 2003). Another study observed an anti-HIV
effect of RNase 1 extracted from human chorionic gonadotropin preparations,
suggesting its potential protective role during pregnancy (Lee-Huang et al., 1999).
RNase 4, which is closely related to RNase 1, has been implicated in the CD8+ T cellmediated suppression of X4-tropic HIV replication (Cocchi et al., 2012). These results do
support a role for RNase 1 in the non-cytolytic control of HIV. However, similar to IL-32,
further experimentation is required to confirm the contribution of RNase 1 in anti-HIV
immunity.
Though we currently do not know the exact mechanism, through this dissertation we
hope to bring to attention the relevance of non-cytolytic HIV control. It remains to be
determined whether IL-32 or RNase 1 or other molecules implicated in our study is the
CAF that the field has been searching for. However, non-cytolytic HIV control does not
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have to be dependent on just one specific molecule. Instead, it could be a combination
of multiple molecules. In addition, it does not have to be due to some unidentified
molecules but could be due to an enhancement of existing molecules. Our data on
polyfunctionality and protein translation potential support this concept. In fact, we
observed a signature of polyfunctionality that is coupled to enhanced protein translation
potential by HIV-specific CD8+ T cells in LNs of ECs. This enhanced potential, which is a
totally novel feature of effective HIV-specific CD8+ T cells, possibly poise these cells to
quickly produce proteins, including known cytokines and other non-cytolytic antiviral
molecules, upon activation. This augmented responsiveness of LN HIV-specific CD8+ T
cells in producing known soluble molecules might be sufficient to effectively control HIV
replication, even in the absence of a novel antiviral molecule. If this is true, boosting
protein translation efficiency of CD8+ T cells can be explored as a part of a cure strategy.
Ultimately, in order to turn the concept of non-cytolytic HIV control into practice, one
would need to determine a way to induce these mechanisms. Without a definite target, it
is challenging to identify a rational induction approach. Therefore, once the exact noncytolytic mechanism is identified, the design of an induction strategy is more feasible.

Can inducing cytotoxic CD8+ T cells in LTs still be used as a cure strategy?
Our results, though strongly supporting a role for non-cytolytic HIV control, do not
exclude the viability of targeting CD8+ T cell-mediated cytotoxicity as a cure strategy. As
discussed in 4.1, the ultimate sterilizing cure requires the elimination of HIV-infected
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cells. Since we observed only weak cytotoxicity in LTs of HIV-infected individuals, an
enhancement of this effector function is needed to make it viable for a cure strategy.
Chimeric antigen-receptor (CAR) T cells have been considered as a cure strategy for
over 25 years (Kuhlmann, Peterson, & Kiem, 2018; Wagner, 2018). CAR is an
engineered cell therapy approach that endows T cells with a new or enhanced specificity
to a target of interest for therapeutic purposes. For example, CAR T cells targeting
CD19, which is expressed on all B cells, have shown more than 80% efficacy in
combating pediatric acute lymphoblastic leukemia (Davila et al., 2014; D. W. Lee et al.,
2015; Maude et al., 2014). Several CAR designs have been studied for targeting HIVinfected cells, namely CD4 and/or broadly neutralizing antibodies (Wagner, 2018).
Potent anti-HIV activities mediated by CAR T cells have been in vitro and in animal
models (Ali et al., 2016; Anthony-Gonda et al., 2019; Hale et al., 2017; Leibman et al.,
2017). However, different anti-HIV CAR T cell designs have only shown limited
effectiveness in human clinical trials (Deeks et al., 2002; Mitsuyasu et al., 2000; R. E.
Walker et al., 2000). It is important to emphasize that the success of CAR T cell cure
strategies relies on the intrinsic cytotoxic capacity of the engineered cells, their ability to
traffic to LTs, and their retention in these sites. Published data in mice indicate that
during homeostasis CD8+ T cells with the strongest cytolytic potential, i.e. CX3CR1+/hi,
are constrained to the blood vasculature and do not recirculate through LTs (Bottcher et
al., 2015; Gerlach et al., 2016). In other words, cytolytic CD8+ T cells are not recruited to
LTs under homeostasis. Therefore, successful CAR T cell cure strategies must be able
to reconcile the differential LT trafficking and cytolytic capacities of effector T cells.
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Regarding strategies that boost CD8+ T cell cytotoxicity, IL-15 has been actively
investigated. It can induce cytotoxic functions of CD8+ T cells via perforin granzyme B
upregulation (Fig 4.3A) (Tamang et al., 2006; Ye, Young, & Liu, 1996; Younes et al.,
2016). In mouse tumor models, the combination of a IL-15 superagonist (N-803) and the
immune checkpoint blockade anti-PD-L1 result in an increased expression of granzyme
B by CD8+ T cells at the site of metastasis compared to monotherapy with either reagent
alone (Knudson, Hicks, Alter, Schlom, & Gameiro, 2019). This enhancement effect of a
IL-15 on CD8+ T cell cytotoxicity has been observed in other cancer models (B. Liu et al.,
2016; R. B. Liu et al., 2013). In the context of HIV/SIV infection, CD8+ T cells from ARTtreated individuals upregulate perforin expression upon IL-15 stimulation (White et al.,
2007) . The administration of a native heterodimeric IL-15 in SHIV-infected rhesus
macaques results in an increased frequency of granzyme B+ CD8+ T cells as well as a
reduced levels of viral RNA in LNs (Watson et al., 2018). In addition to enhancement of
cytotoxic functions, IL-15 superagonist can increase CD8+ T cell traffic into BCFs via the
upregulation of CXCR5 (Webb et al., 2018; Webb et al., 2020). This added benefit is
highly relevant for HIV/SIV infection as BCFs are sites of persistent viral replication that
are typically devoid of CD8+ T cells (Bronnimann et al., 2018; Connick et al., 2014;
Connick et al., 2007; Fukazawa et al., 2015). Not only impacting CD8+ T cell function, IL15 superagonist does show some latency reversal activities (R. B. Jones et al., 2016;
McBrien et al., 2020). The combinatory effect of cytotoxicity inducing, BCF trafficking
enhancing, and latency reversal makes IL-15 superagonist an attractive candidate for a
cure strategy. However, some reports have indicated that the reduction of SIV replication
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in ART-naïve rhesus macaques after IL-15 superagonist administration is only transient
as T cells become less responsive to the therapy (Ellis-Connell et al., 2018) In addition,
the latency reversal activity of IL-15 superagonist appears to be weak in vivo (McBrien et
al., 2020; Webb et al., 2020). These results call into question the sufficiency of IL-15
superagonist as a cure strategy. In reality, it is likely going to require a combination of IL15 superagonist, an immune checkpoint blockade, and a latency reversal agent to make
this approach a viable cure strategy. However, this concept remains to be tested.
Dual-affinity re-targeting antibody (DART) is another strategy that employs CD8+ T cell
cytotoxicity. This approach utilizes engineered antibodies that are bi-specific, one
specific for effector cells and one for target cells, in order to induce lysis of HIV-infected
cells by CD8+ T cells (Fabozzi, Pegu, Koup, & Petrovas, 2019; H. Yang, Wallace, &
Dorrell, 2018). A DART combining a non-neutralizing Env-specific antibody (A32 or 7B2)
and an anti-CD3 antibody has been shown to mediate ex vivo CD8+ T cell-mediated
lysis of HIV-infected CD4+ T cells (Sung et al., 2015). A different study using a DART
combining several broadly neutralizing antibodies (PGT121 and PGT145) and an antiCD3 antibody also showed killing of low Env-expressing resting CD4+ T cells by CD8+ T
cells. In the same study, the addition of two DARTs into ex vivo PBMC cultures isolated
from ART-treated individuals resulted in a reduction of viral RNA after 14 days,
suggesting that DARTs have the potential of targeting HIV latent reservoirs (Sloan et al.,
2015). Another DART construct that utilizes the broadly neutralizing antibody VRC07
has demonstrated both a latency reversal and a CD8+ T cell-mediated lysis effect on
PBMC isolated from ART-treated individuals (Pegu et al., 2015). Though these results
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are promising, it is important to emphasize that DARTs have mainly been tested ex vivo
and using blood CD8+ T cells, which are highly cytolytic. One study has gone on to test
the effect of DART using LT CD8+ T cells. This study showed that DART enhanced the
ex vivo ability to lyse HIV-infected CD4+ T cells by follicular CD8+ T cells isolated from
HIV- tonsils or HIV+ LNs (Petrovas et al., 2017). The in vivo safety and efficacy of DART
are to be determined as a phase 1 clinical trial (NCT03570918) is currently underway.
CAR T cells, IL-15, and DART all show promise as cytolytic-centric cure strategies.
However, is cytotoxicity required for a cure? And is it the most desirable strategy? For
the first question, our results indicate that the answer is likely to be no for a functional
cure. For the second question, implications from our results, other viral infections, and
autoimmunity indicate that cytolytic-centric cure strategies might not be the most
desirable ones. In chapter 3, we demonstrated that the frequency of perforin+ granzyme
B+ CD8+ T cells in LNs positively correlated with viral, indicating that the expression of
these cytolytic molecules are associated with increased inflammation. In fact, we
observed an elevated level of IL-15, which is known to induce perforin expression, in
LNs of CPs compared to ECs (Fig 4.3 B). This finding corroborated a previous finding
suggesting that IL-15 drives activation of bystander CD8+ T cells, which in turn is
associated with disease progression in untreated HIV+ individuals as well as increased
morbidity and mortality in ART-treated individuals (Younes et al., 2016). As a side note,
since viral control in ECs is linked to low levels of IL-15 in LNs , the usage of IL-15
superagonist as a cure strategy should be reassessed. On the other hand, deleterious
effects of CD8+ T cells have been observed in several parasitic and viral infections,
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including leishmaniasis, malaria, Chagas disease, Coxsackie virus, and Zika virus
infections (Ferreira et al., 2017; Henke, Huber, Stelzner, & Whitton, 1995; Jurado et al.,
2018; Nitcheu et al., 2003; Novais et al., 2017; Novais et al., 2013). In these diseases,
aberrant cytotoxicity mediated by pathogen-specific CD8+ T cells in tissues is linked to
pathology. Similarly, CD8+ T cell-mediated cytotoxicity is involved in the pathology of
autoimmune diseases such as type 1 diabetes (Coppieters et al., 2012; Coppieters &
von Herrath, 2011; Knight et al., 2013; Trivedi et al., 2016); psoriasis and vitiligo (Cheuk
et al., 2017; Cheuk et al., 2014; van den Boorn et al., 2009); and multiple sclerosis (Deb
et al., 2010; Ifergan et al., 2011; Murray et al., 1998; Zhao et al., 2018).

Figure 4.3 Elevated level of IL-15 in LNs of CPs. (A) Tonsil CD8+ T cells from HIVindividuals were pre-labeled with CFSE and stimulated for 5 days ± 10ng/mL IL-15 (left:
representative flow plots, right: data quantification). Perforin and granzyme B expression
were quantified in dividing CD8+ T cells (CFSE low). (B) Immunohistochemistry staining
of LN biopsies for IL-15 (left) and data quantification (right). Bars represent mean ±
SEM. Significance was determined using paired T-test (A) and one-way ANOVA with
Tukey test (B). * p < 0.05, ** p < 0.01. Experiment performed by Son Nguyen, Alberto
Sada-Japp, and Claire Deleage.
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Together, these insights have led us to speculate that inducing cytotoxic CD8+ T cells in
LTs as a cure strategy for HIV might have unwanted pathological effects. In fact, it is
tempting to postulate that the absence of strong cytolytic activities in LTs, or tissues in
general, is a evolutionarily conferred mechanism to protect these compartments from
chronic inflammation and HIV conveniently exploits this property to its own advantage. A
few lines of evidence exist to support this postulation. First, as mentioned earlier in this
section, cytolytic CD8+ T cells are restricted to the blood vasculature and do not traffic to
LTs under homeostasis (Bottcher et al., 2015; Gerlach et al., 2016). Second, though LN
CD8+ T cells can upregulate perforin and granzyme B during 5 days of in vitro
stimulation, these cells require at least two rounds of cell division and concurrently lose
the expression of CD69, which decreases their ability to stay resident in LTs and primes
them for tissue egress (Reuter et al., 2017). Third, human CMV-specific CD8+ T cells,
which exhibit a strong cytolytic profile in blood, express cytolytic proteins at low levels in
LNs, implying that the LT microenvironment is not conducive for cytotoxic activities
(Hertoghs et al., 2010; Remmerswaal et al., 2012).
In the light of possible deleterious effects and the natural lack of cytotoxicity in LTs, the
pursuit of a cytolytic-centric cure for HIV needs to be carefully reexamined. The success
of this approach will come with a cost, most likely in the form of tissue damage.
Currently, the molecular mechanisms that hamper cytotoxicity in LTs have not been
identified. Some questions of interest not only to the HIV cure field but also to the
general immunology community are: what is the epigenetic architecture at cytolytic loci
in LT CD8+ T cells? Are cytolytic genes in these cells regulated post-transcriptionally?
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What are the microenvironmental factors in LTs that reduce the production of cytolytic
proteins? And what do LT CD8+ T cells degranulate?. The identification of these
regulators will unveil potential points of intervention through which the cytotoxic capacity
of CD8+ T cells can be unleashed, either genetically or pharmacologically. However,
these studies should be accompanied by the search for a way to limit damage to LTs
caused by CD8+ T cell-mediated cytotoxicity. Alternatively, non-cytolytic-centric HIV cure
strategies can be explored, especially given that this mechanism occurs naturally in ECs
and likely spares LTs of cytotoxicity-mediated damages.

What happens during the acute phase of infection in ECs?
A classical question that has always been asked of studies on ECs is “Which is the
chicken and which is the egg?” In other words, are the described immunological
signatures the cause or consequences of the low viral loads in ECs? This question can
only be answered by looking at early events that happen during acute infection.
However, most of what we know about ECs have been restricted to chronic infection.
This is an intrinsic caveat of studying ECs because these individuals, by definition,
cannot be identified until their viral loads have already reached the set point. Therefore,
there is very little information on acute HIV infection in ECs.
During acute infection, ECs can experience plasma viral loads in the range of 106
copies/mL (Goujard et al., 2009). Their CD4+ T cell counts and CD4+ T cell frequencies
are both higher than non-controllers (Goujard et al., 2009). Viral control is established by
a median of 6 months and a range of 2 to 12 months after primary infection (Goujard et
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al., 2009). In a cohort of eleven HIV-infected individuals identified during peak viremia,
the strength of HIV-specific cytolytic CD4+, but not CD8+, T cell responses during acute
infection predicts chronic viral set point, suggesting that this effector mechanism is
crucial for the establishment of viral control (Soghoian et al., 2012). Some case studies
have associated robust HIV-specific CD8+ T cell responses to the establishment of
spontaneous HIV control (Moosa et al., 2018; Morley et al., 2019). In hyperacute HIVinfection, the frequencies of proliferating cytolytic CD8+ T cells and of a precocious NK
cell subset one-week post-viremia detection were elevated in future controllers (Kazer et
al., 2020). It is clear that these studies were largely anecdotal; the study size were very
small and not controlled; and the studied immunologic features were restricted to the
peripheral blood. Therefore, there is still a need to bridge our gaps in the knowledge
regarding the establishment of viral control during acute infection.
Since it is almost impossible to study the acute phase of infection in human ECs, the
rhesus macaque model provides an opportunity to study this question in a controlled and
systematic manner. It has been reported that approximately 50% of Mamu-B*08+ and
20% of Mamu-B*17+ rhesus macaques infected with SIVmac239 achieve EC status (P. A.
Mudd & Watkins, 2011). In this model, SIV-specific CD8+ T cell responses targeting
Mamu-B*08 epitopes during acute infection is responsible for the establishment of viral
control (Valentine et al., 2009). However, it is unclear what features of acute SIV-specific
CD8+ T cells, including those in LTs, mediate viral control. Therefore, future studies
should utilize this animal model in order to determine the correlates of viral control
establishment. Some questions that could be answered are: what is the early kinetic of
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SIV-specific CD8+ T cell responses in blood and tissues of EC animals and noncontroller animals? Are CD8+ T cells from EC animals primed differently during primary
infection? What effector functions of CD8+ T cells in blood and tissues are enriched in
EC animals during acute infection? And are these mechanisms different from
mechanisms that maintain viral control during chronic infection?
It is important to emphasize that the questions of viral control establishment and
maintenance are two separate but equally important questions. This dissertation, similar
to previous studies on ECs, does not address the question of establishment. However, it
does address the question of maintenance. This is essential because regardless of how
viral control is established, during chronic infection CD8+ T cells still actively maintain
viral control as their removal results in viral rebound (Fukazawa et al., 2015).
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4.3 Concluding remarks
According to the World Health Organization, as of 2018, almost 38 million peoples are
still living with HIV. Moreover, within 2018 alone, almost 2 million were newly infected
with HIV and almost 1 million people lost their lives to illnesses associated with this
infection. These numbers highlight the pressing need for a cure and vaccine for HIV,
neither of which is available in spite of over 30 years of intensive research.
The design of a HIV vaccine or cure can greatly benefit from insights on anti-HIV
immunity, especially at sites of viral reservoirs such as LTs. By studying HIV ECs, this
dissertation uncovered two novel correlates of effective anti-HIV immune responses in
LTs: increased frequency of CD8+ TRM and enhancement of non-cytolytic antiviral
activities mediated by CD8+ T cells. These findings highlight a few important concepts.
First, location matters. Because the majority of HIV-specific CD8+ T cells in LNs are TRM,
studying CD8+ T cell responses to HIV in blood does not reflect the nature of the
responses at sites of viral persistence. Furthermore, the elevation of CD8+ TRM frequency
in LNs of ECs indicates that constant local immune pressure exerted on HIV-infected
cells in LTs is key to the successful control of viral replication. Second, cell-mediated
cytotoxicity might not be the only or best path to a cure. In fact, suppressing cytotoxic
activities in LTs is likely a natural mechanism that protects these tissues from damages
caused by chronic inflammation. In addition, since non-cytolytic mechanisms mediated
by CD8+ T cells appear to be sufficient to maintain viral control in LTs, these
mechanisms should be targets for cure strategies.
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With the identification of CD8+ TRM and non-cytolytic viral suppression signatures, we
believe that future cure, and even vaccine, strategies should aim to induce these
features. The induction of CD8+ TRM can potentially be achieved by an appropriate
choice of vectors and/or immunization routes. The CMV vector has shown some
promises by inducing effector memory CD8+ T cell responses in tissues, including LTs,
that resemble TRM in rhesus macaques (Fukazawa et al., 2012; Hansen et al., 2011;
Hansen et al., 2013; Hansen et al., 2009). Intralymphatic, mucosal, and intravenous
immunization, in contrast to intradermal and intramuscular, have been shown to induce
tissue-resident CD8+ T cell responses that are effective in tumor and infection models
(Bialkowski et al., 2016; Cuburu et al., 2012; Darrah et al., 2020). On the other hand, the
induction of non-cytolytic viral suppression mechanisms in CD8+ T cells will require
significantly more works. It should begin with the identification of the exact mechanisms
involved and continue with determining optimal induction approaches. These are all
exciting directions for research. With the implications from this dissertation and results
from upcoming research, the goal of developing a functional cure for HIV will hopefully
be achievable within the foreseeable future.
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